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Abstract 
 
Background 
Healthy adipose tissue (AT) growth is critically dependent on vascular support and this 
relationship appears to be reciprocal. Optimal angiogenesis and functional vascular tone 
ensure normal supply of oxygen, insulin, and nutrients, thus preventing AT hypoxia and 
insulin resistance. Normal vascular function may also be regulated by factors derived 
from the healthy AT (adipokines). In obesity AT expansion, especially of the abdominal 
subcutaneous and omental depots (SAT and OAT respectively), contributes to the 
increased risk of metabolic and cardiovascular diseases. In addition, perivascular AT 
(PVAT) may also mediate vascular function by producing vasoactive adipokines, either 
directly or through indirect effects on components of the adjacent vessel wall. Changes 
in vascular characteristics during AT expansion in SAT, OAT and PVAT have all been 
the focus of much recent research. 
During the tenure of this project three studies, with separate but related aims, explored 
the vaso-responsiveness, angiogenic and adipokine secretory capacity of resistance 
vessels embedded within abdominal adipose tissue depots and the adipokine secretory 
capacity of PVAT.      
Aims 
The aims were to investigate in:  
Study 1: the depot- and diabetes-specific differences of noradrenaline (NA) synthesis, 
NA-mediated vasoconstriction and tissue fibrosis in abdominal SAT and OAT of 
morbidly obese patients. 
Study 2: the depot- and diabetes-specific differences of capillary density, angiogenic 
capacity and angiogenesis-related mRNA and protein expression.  
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Study 3: the adipokine production of PVAT of the saphenous vein (SV) and internal 
thoracic artery (ITA). 
Methods  
Studies 1&2: Abdominal SAT and OAT, from morbidly obese patients undergoing 
weight-reducing surgery, were used for investigating 1) vascular function (myography); 
2) adipokine secretion (explant and ELISAs); 3) adipocyte morphology and capillary 
density (histochemistry and immunohistochemistry); 4) angiogenic capacity (tissue 
culture),  and 5) vasculature-related gene and protein expression (real-time PCR and 
western blot).  
Study 3: Segments of SV and the ITA with the surrounding PVAT intact, obtained 
from patients undergoing coronary artery bypass graft surgery (CABG), was used to 
investigate: 1) PVAT morphology (histochemistry), 2) adiponectin and leptin secretion 
(immunohistochemistry). PVAT and vessels were isolated respectively for investigating 
adipokine production by ELISAs. Cultured human umbilical vein endothelial cells 
(HUVECs) and human coronary artery endothelial cells (HCAECs) used to investigate 
secretory capacity of adiponectin by the endothelium.   
National Ethical Committees approved all studies and patients gave written informed 
consent. 
Results 
Study 1: In non-diabetic subjects, the SAT vessels showed significantly greater 
sensitivity to NA-mediated vasoconstriction, compared to vessels of OAT or to vessels 
of either depot of diabetic patients. The non-diabetic SAT also exhibited lower NA 
synthesis and collagen deposition.  
Study 2: Lower capillary density, angiogenic capacity and down-regulation of 
angiogenesis-related genes was also only apparent in the SAT of non-diabetic subjects, 
compared with OAT or either depot of diabetics.  
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Study 3: In the PVAT adiponectin mRNA and protein expression was detected in the 
endothelium and in cultured human endothelial cells (ECs). 
Discussion & Conclusion  
The SAT of non-diabetics secreted less noradrenaline and exhibited lower tissue 
collagen deposition. Furthermore, the arterioles from this depot preserved their 
sensitivity to NA-mediated vasoconstriction. Conversely, elevated local NA production, 
greater collagen deposition and relative insensitivity of microvessels to NA-medaited 
vasoconstriction characterised the OAT, as well as both SAT and OAT of diabetics. NA 
also directly stimulated collagen mRNA expression. 
Greater angiogenic capacity of the OAT of non-diabetics and both SAT and OAT of 
diabetics may reflect local hypoxia, perhaps because of compromised vascular function.  
Human ECs displayed the capacity to produce adiponectin. The effect of EC-derived 
adiponectin on vasculature needs further investigation. 
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1.1 Prevalence and definition of obesity 
The prevalence of obesity has increased over the past three decades and currently 
reached epidemic proportions globally [1]. Today, more than 500 million people suffer 
from obesity and its related complications worldwide, and this number continues 
increasing each year [2]. Obesity is defined as excessive adipose tissue (AT) deposition 
that may impair health [2]. A common method used to identify obese patients is by 
measuring the body mass index (BMI, body weight in kilograms divided by the square 
of body height in metres, kg.m-2). Individuals with BMI over 30 kg.m-2 are considered 
as obese, while those with BMI over 40 kg.m-2 are defined as morbidly obese [2]. The 
morbidly obese patients are associated with high risks of developing metabolic 
disorders and cardiovascular diseases [3, 4]. In particular, obesity in abdominal area 
(central obesity) is an important risk factor of insulin resistance, Type II diabetes, 
hypertension and increased cardiovascular morbidity and mortality [5, 6].   
1.2 Metabolically healthy but obese patients (MHO) 
A unique phenotype of a sub-set of obese patients has been reviewed recently [7]. This 
sub-set of patients appears to be protected from obesity-related metabolic and 
cardiovascular complications and display favourable metabolic profiles despite their 
excessive adipose mass [7]. They are known as “metabolically healthy but obese” 
(MHO) patients. MHO individuals are characterized by their preserved insulin 
sensitivity, absence of hypertension, dyslipidemia and inflammation, and favourable 
adipokine profiles (Figure 1) [7]. Although 30 years has passed since MHO was first 
described in 1980s [8], it remains difficult to adequately standardize the identification of 
MHO patients. Several criteria have been used to characterize MHO patients, mainly 
based upon the assessment of insulin sensitivity by various methods, such as the 
hyperinsulinemic-euglycemic clamp, homeostasis model assessment (HOMA) and oral 
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glucose tolerance test (OGTT), or the levels of the metabolic risk factors such as lipid 
profiles, blood pressure, and C-reactive protein. Due to the lack of consensus in the 
definition, the reported prevalence of MHO phenotype ranges from 20 - 44% [7]. It is 
still unclear why the MHO individuals are resistant to the obesity-related complications. 
In this cohort weight reduction and AT loss after bariatric surgery achieved almost no 
metabolic benefits, even surprisingly, at least in some studies, leading to deterioration of 
insulin sensitivity in these individuals [9, 10], which suggests that the excessive AT 
may play a protective role. The molecular mechanisms that underlie this phenotype, 
especially in terms of protection from future development of diabetes or cardiovascular 
diseases, are still being investigated.   
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Figure 1 The major factors identifying MHO from metabolically abnormal obese 
 
 
 
 
 
 
                                                                                                                                [7] 
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1.3 AT structure, distribution and abdominal depot-specific differences  
1.3.1 AT structure and function 
AT is the loose connective organ mainly composed of adipocytes, as well as cells of the 
stromal vascular fraction (SVF) which includes pre-adipocytes, vascular endothelial 
cells (ECs) and macrophages. The major function of AT is to store excess energy in the 
form of triglycerides (TGs) [11], thus it was believed to be involved in body lipid and 
energy homeostasis. More recently, it has become clear that, in addition to lipid storage, 
AT is an important secretory organ associated with the production of multiple mediators 
known as adipokines [12].  These adipokines include pro-inflammatory adipokines such 
as tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and 
interleukin-6 (IL-6), and anti-inflammatory adipokines such as adiponectin and leptin. 
The dysregulation of adipokine secretion in obesity may contribute to the development 
of obesity-associated abnormalities by mechanisms including inhibition of adipogenesis, 
adipocyte hypertrophy and necrosis, immune cell infiltration and dysregulation of tissue 
metabolism [12, 13].  
1.3.2 AT distribution and depot-specific differences in the abdominal area 
Physiological expansion of AT is normal in many sites throughout the body, but only 
the abnormal AT accumulation in specific depots is associated with the adverse 
metabolic outcomes [14]. The regional AT expansion mainly includes two patterns of 
deposition, identified as android (upper body AT expansion) and gynoid pattern (lower 
body AT expansion). Obese individuals with the gynoid shape are less prone to 
metabolic disorders and cardiovascular diseases [15, 16], while those with android AT 
expansion, especially in the abdominal area, are more often associated with elevated 
risks of metabolic and cardiovascular complications such as insulin resistance, Type II 
diabetes, hypertension and atherosclerosis [17].  
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Abdominal AT mainly comprises two depots: the abdominal subcutaneous depot (AT 
under the skin, SAT) and intra-abdominal omental depot (AT of greater omentum, 
OAT). In the initial studies, the distribution of AT was assessed by anthropometric 
measurements such as skinfolds and waist-to-hip circumference ratios [18, 19] which 
were unable to distinguish SAT from OAT. Later, because of the development of 
imaging techniques, several studies clearly distinguished SAT from OAT using 
computed tomography (CT) and magnetic resonance imaging (MRI). It demonstrated 
that OAT, rather than SAT, was an important risk factor that mediates glucose 
intolerance in central obesity [20-22]. Recently, the depot-specific differences between 
SAT and OAT have been widely investigated in rodents and humans. In rodents, the 
intrinsic difference between the two depots has been shown by fat transplantation 
technique. Host mice receiving SAT into an omental depot gained less body weight and 
displayed favourable metabolic profile, but no metabolic benefit was achieved in the 
reverse situation when OAT transplanted into the subcutaneous region [23]. In addition, 
transgenic mice with elevated SAT expansion displayed improved insulin sensitivity 
and higher circulating adiponectin levels compared to their ob/ob littermates [24]. In 
human studies, individuals with higher proportions of OAT and relatively lower SAT 
were associated with insulin resistance and increased expression of inflammatory 
markers [5, 6]. Thiazolidinedione-induced AT redistribution (displayed as the 
SAT/OAT ratio elevation) showed favourable glucose, insulin and lipid profiles [25]. 
Furthermore, liposuction in SAT depots achieved no impact on circulating 
cardiovascular risk factors, other than a reduction in leptin [26]. These data implicate 
SAT as being a weaker risk factor during the development of morbidly obesity or even 
having a protective effect. 
1.3.3 “Spillover” hypothesis 
  28
SAT is commonly considered the “good” depot in the context of obesity-related 
complications. This AT accounts for approximately 80% of the total body AT in human 
[27], which includes abdominal, gluteal, and femoral SAT (Figure 2) [28]. In healthy 
lean individuals, SAT provides the buffering action to maintain the energy homeostasis 
after excess calorie intake. This function is thought to be mediated by the  “fatty acid 
trapping” pathway (systemic TG is the source of AT fatty acid) [29],  thus SAT 
becomes the primary depot for lipid accumulation. However, when the buffering action 
is insufficient to maintain the “fatty acid trapping”, elevated fatty acid starts to be 
deposited ectopically, leading to the AT expansion in OAT and AT infiltration into 
insulin sensitive organs such as liver, skeletal muscle and heart. When adipocytes 
enlarged (hypertrophied) by fatty acid intake, their efficiency to buffer excess fatty acid 
decreases [29] and both lipid synthesis and lipolysis within the bigger adipocytes 
became more active [30]. Consequently, the elevated transmembrane fatty acids may 
flow into the circulation and cause the ectopic AT accumulation.  
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(Extract from http://dietdatabase.com/obesity-facts-and-statistics) 
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Figure 2 Body fat distribution: normal (left) vs obese (right). 
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1.4 AT morphology and oxygenation 
1.4.1 AT expansion and adipocyte size  
AT stores excess energy in the form of TGs. This function makes AT perhaps the only 
tissue with the capacity to increase and decrease its size dramatically under normal 
physiological conditions [31]. AT expandability and plasticity are determinants of 
obesity-related risk of metabolic diseases [14]. In situations of positive energy balance 
(energy intake exceeds energy expenditure), AT expands by generating new small 
adipocytes (AT hyperplasia) or increasing the volume of pre-existing adipocytes (AT 
hypotrophy) or both [32]. There is a negative correlation between subcutaneous 
adipocyte size and insulin sensitivity in non-diabetic subjects in vitro. Hypertrophic 
adipocytes are associated with insulin resistance, while small adipocytes may contribute 
to the preserved insulin sensitivity of AT [33]. Small adipocytes are also associated with 
increased secretion of adiponectin, which is widely accepted as an anti-inflammatory 
adipokine that protects against insulin resistance and cardiovascular risk [34]. In 
contrast, large adipocytes secrete more pro-inflammatory adipokines including MCP-1, 
IL-6, and TNF-α, which are associated with chronic inflammation and metabolic 
disorders [34]. Paradoxically, adipocyte size, examined in different depots measured by 
X-ray and CT, were significantly smaller in OAT than SAT [35]. Interestingly, 
adipocyte hypertrophy and hyperplasia in OAT are associated with hypertriglyceridemia, 
independent of body composition [36]. Compared with SAT, OAT adipocytes appear to 
exhibit greater hypoxia- and inflammation-related gene expression, which suggests a 
more toxic microenvironment in this depot [37]. However, this may be due to 
inflammatory cells trapped in the adipocyte fraction.  
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1.4.2 AT oxygenation in obesity 
Sufficient oxygen supply is an important determinant of normal AT function [38]. Local 
tissue hypoxia may occur at the early stages of AT growth and limit healthy AT 
expansion [39]. In obesity vascular oxygen supply may be compromised by rapid AT 
expansion.  
Much evidence from animal studies suggest AT hypoxia in obesity [40]. Hypoxia-
related genes, including hypoxia inducible factor-α (HIF-α) and glucose transporter-1 
(GLUT-1), were more highly expressed in AT of obese mice compared with lean mice, 
hypoxic AT was also associated with increased inflammatory gene expression. 
Moreover, pimonidazole staining showed a larger hypoxic area in obese mice compared 
with the lean littermates. Last but not least, AT oxygen tension (PO2), which is a direct 
reflection of the local oxygen supply, was lower in AT of obese mice [40].  
However, data from human studies are not consistent with the rodent results. To date, 
there are mainly two studies investigating the local oxygenation in SAT of obese versus 
lean individuals. One showed that PO2 was significantly lower in overweight/obese 
patients, accompanied with local inflammation, compared with lean individuals [41], 
but the other study pointed to local PO2 being elevated in obese patients due to the low 
oxygen consumption [38]. Interestingly, although the human data of AT oxygenation is 
debatable, both studies found that obesity is associated with decreased AT angiogenesis 
and capillary rarefaction (low capillary density), which suggests the importance of AT 
vasculature in maintaining AT normal function.  
1.5 AT vasculature: angiogenesis and vasoreactivity  
Sufficient vascular support is a key factor maintaining AT growth and functions. 
Effective vascular network includes optimum angiogenesis, adequate capillary density, 
and normal vascular function. Vasculature modulates AT in many ways. Firstly, it is an 
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important source of nutrients, oxygen, and insulin. Adequate blood supply prevents 
tissue hypoxia and insulin resistance. Secondly, systemic blood is enriched with growth 
factors and progenitor cells derived from bone marrow and other tissues. This facilitates 
the cell differentiation into pre-adipocytes or ECs and ensures the capacity of AT 
expansion. Finally, the vascular network may also enhance the transportation and 
infiltration of immune cells such as macrophage cells, which may amplify AT 
inflammation [42].  
1.5.1 Interplay between angiogenesis and adipogenesis 
In mice, there is a close interplay between angiogenesis and adipogenesis [43]. The 
initial AT development is characterized by the appearance of fat cell clusters, which is 
known as “primitive fat organ” [44]. In humans pre-adipocytes and ECs expressed αvβ3 
integrin and plasminogen activator inhibitor-1(PAI-1), which are involved in the 
regulation of pre-adipocyte and EC migration [45]. This finding suggests that the 
formation of the primitive fat organ may be due to the pre-adipocyte migration towards 
developing capillary ECs. Furthermore, AT-derived SVF in vitro differentiated into not 
only the ECs but also adipocytes [45]. In addition, both SVF and mature adipocytes can 
induce neovascularization and vessel structure formation [46]. Very recent data also 
demonstrated that Zfp423, a gene controlling pre-adipocyte determination, was 
expressed in capillary ECs, which suggests that they may share the same progenitor [47].  
1.5.2 Regulation of AT angiogenesis 
Normal angiogenesis in AT is through the recruitment and interplay of both adipogenic 
and angiogenic precursor cells, which leads to an optimum AT expansion. However, 
angiogenesis in pathological AT expansion may be triggered by hypoxia. In response to 
AT overexpansion, angiogenesis plays a rate-limiting role constraining AT growth, this 
may cause tissue hypoxia, immune cell infiltration and chronic inflammation (Figure 3) 
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[39]. Angiogenesis in AT is regulated by multiple factors including classic angiogenic 
pathway, such as vascular endothelial growth factor (VEGF) and neuropilin-1 (NRP-1), 
as well as the  adipokines released from AT. 
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The normal AT growth is through the preadipocyte recruitment and the interplay 
between adipocyte expansion and concomitant angiogenic support (A); However, 
pathological AT expansion lead to adipocyte hypotrophy and hypoxia, also 
angiogenesis is limited (B) [39]. 
 
 
 
 
 
Figure 3  Healthy and unhealthy AT expansion. 
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1.5.2.1 VEGF 
In mammals, there are five structurally related VEGF ligands (A, B, C, D and placenta 
growth factor), which are highly involved in the regulation of EC survival, proliferation 
and vascular permeability [48]. VEGFB was also shown to mediate fatty acid transport 
and insulin sensitivity [49]. As a major angiogenic inducer, VEGFA has been widely 
investigated in previous studies. It is not only required during the initial EC 
development in angiogenesis but also plays a key role in EC survival in the healthy 
tissue [48]. The expression of VEGFA is dependent on its sensitivity to hypoxia and 
HIF is a potent regulator of VEGF levels [50]. In mice, VEGF overexpression is 
associated with greater number and size of vessels. It also contributes to improved 
insulin sensitivity and glucose tolerance, which suggests a protective role of VEGF-
induced vascular growth in high fat diet-induced obesity and insulin resistance [51]. In 
humans, VEGF levels in AT were positively correlated with insulin sensitivity [52], 
while the failure to trigger VEGF-induced angiogenesis is an important cause of AT 
capillary rarefaction (low capillary density), hypoxia and inflammation in SAT [41]. 
However, the protective effect of VEGF-induced angiogenesis is still debatable. In 
rodents, VEGF protein secretion and gene expression were the highest in OAT 
compared to other depots [53]. Human adipocyte derived from OAT showed 
significantly higher VEGF mRNA expression, in contrast to SAT [37]. However, 
despite greater expression of VEGF, adipocytes in OAT still exhibited more 
inflammatory and hypoxic characteristics [37]. 
1.5.2.2 NRP-1 
NRPs are transmembrane glycoproteins with multiple functions in neuronal and 
cardiovascular developments [54].  There are two known homologues of NRP, NRP-1 
and NRP-2, which are both involved in tissue angiogenesis. During tissue growth, NRP-
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1 is preferentially localized in the arteries while NRP-2 is more expressed in the veins 
[55]. NRPs are important receptors for VEGF ligands. NRP-1 especially is the co-
receptor for VEGF receptor 1 and 2 [56]. In ECs, NRP-1 primarily interacts with 
VEGFR2, enhancing proliferation, survival, migration, and permeability (Figure 4) [57]. 
NRP-1 knockout mouse embryos displayed a series of vascular defects, suggesting the 
critical role of NRP-1 in mediating neovasculature formation [58]. Therefore, normal 
NRP-1 expression is essential for angiogenesis in addition to VEGF expression.  
The role of NRP-1 in AT angiogenesis is unclear. In rat white AT, NRP-1 was found 
mainly in vascular smooth muscle cells (VSMCs) and ECs of arteries. Adipocytes also 
showed NRP-1 expression [59]. In human fatty bone marrow, higher NRP-1 expression 
was detected in adipocytes in contrast to hematopoietic and stromal cells [60]. These 
data suggest a possible NRP-1 involvement in AT angiogenesis.  
1.5.2.3 Adipokines 
The AT is increasingly being recognised as a crucial endocrine organ, associated with 
the synthesis and secretion of several hormone-like molecules, adipokines. Among them, 
the most prominent ones are leptin and adiponectin [12].  
Leptin is an adipokine involved in the regulation of appetite and energy expenditure in 
the central nervous system (CNS). Peripherally, it also plays a role in inducing 
angiogenesis. In mice, leptin induced angiogenesis synergistically with VEGF, but 
failed to do so in ob/ob mice [61]. In humans, leptin showed angiogenic effects by 
binding to its functional EC receptors and stimulating the EC tube formation [62]. In 
response to AT hypoxia, both leptin mRNA expression and protein secretion were 
elevated, and the elevation was dependent on oxygen concentration [63].   
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Figure 4 VEGF signalling via NRP-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
                                                                 [57] 
VEGF-A165 promotes complex formation by binding to NRP-1. Carboxy-terminal PDZ 
domain binding motif of NRP-1 associates with PDZ protein synectin, which is 
considered as an important factor mediating NRP-1 effect in VEGFA signalling 
pathway via VEGFR2. VEGFR2/NRP-1 complex formation is highly involved in 
signalling mediated by p38 kinase, ERKs1/2, and Pyk2 pathway, which lead to p130Cas 
tyrosine phosphorylation and consequently EC migration, guidance and vessel 
morphogenesis.   
 
CUB (a) domain 
Factor V/VII domain (b) domain 
MAM (c) domain
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Tyrosine kinase domain 
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Adiponectin, as a protective anti-inflammatory adipokine, is also involved in AT 
angiogenesis. In lean healthy individuals, adiponectin is one of the most abundant 
proteins in the circulation. However, these levels are reduced significantly in obesity, 
perhaps due to the AT hypoxia [63, 64]. The angiogenic effect of adiponectin is still 
under investigation. In a mouse tumour model, adiponectin showed an anti-angiogenic 
effect by inducing endothelial cell apoptosis [65]. In human coronary arteries, 
adiponectin suppressed the VEGF-induced endothelial cell migration by increasing 
cellular cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) 
activity, thus protecting vessels from atherosclerosis [66]. However, adiponectin also 
exhibits pro-angiogenic effects in mouse mammary tumour growth [67]. Furthermore, 
in human umbilical veins adiponectin promoted EC migration and differentiation into 
capillary-like structures [68].   
1.5.2.4 Depot-specific difference in angiogenesis 
Very few studies have directly compared the angiogenic capacity of SAT and OAT. 
Also the data from the four currently reported studies all appear contradictory. One 
rodent study and one human study demonstrated greater angiogenesis in OAT by 
showing that there was higher VEGF mRNA expression and protein secretion from this 
depot [37, 53]. However, in another human study, SAT explants incubated in Matrigel 
showed more capillary sprouts compared to OAT even after normalization to the SAT 
initial capillary density [69]. Moreover, the later study demonstrated that there was no 
significant angiogenic difference between the two depots after normalizing the vessel 
number to the number of adipocytes [70].  
However, the hypoxic and inflammatory environment in OAT cannot be explained by 
its normal or even higher angiogenic capacity. It is interesting to see that not only 
adipocytes but also ECs from OAT were more hypoxic and inflammatory [37], thus it is 
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doubtful whether the function of neovasculature formed by those inflammatory ECs is 
preserved. 
1.5.3 AT vasoreactivity  
1.5.3.1 AT microcirculation: definition and function 
The microcirculation is defined as “all those arterial vessels that respond to increasing 
pressure by a myogenic reduction in the lumen diameter”, which also include the 
capillaries and venules [71]. The major function of the microcirculation is to supply 
nutrients and oxygen for tissue growth and repair. In addition, it also plays an important 
role in stabilizing the hydrostatic pressure and determining the peripheral resistance [72]. 
The in vivo microvascular function in lean healthy individuals and obese patients has 
been examined in a few studies [73]. In the basal state and during physiological 
systemic hyperinsulinemia, obese patients displayed higher systolic blood pressure 
(SBP), impaired insulin sensitivity and capillary recruitment compared to lean 
individuals, Thus, the alteration of microvascular function in obesity may not only 
contribute to the increased peripheral resistance, but also affect glucose and insulin 
metabolism [73].   
1.5.3.2 Regulation of vasoreactivity in AT 
Ion channels, endothelium-derived vasoactive molecules, and neuronal transmitters 
regulate vasoreactivity. In addition, the microvasculature embedded in AT is also 
directly regulated by adipokines released from adipocyte, as well as the perivascular 
adipose tissue (PVAT) [74]. Thus alterations of AT cellular and hormonal components 
and vascular structure may be associated with the compromised vascular function in 
obese patients.   
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Potassium and calcium channels (K+ and Ca2+ channels) 
The interplay between K+ and Ca2+ channel is an important determinant of vascular tone 
[75]. K+ channels are critical regulators of VSMC membrane potential. The activation 
of K+ channel increases the efflux of K+, causing cell membrane hyperpolarisation, 
closure of Ca2+ channel, decrease of intracellular Ca2+ and vasodilatation. In contrast, 
the inhibition of K+ channel causes cell membrane depolarisation, the voltage-activated 
Ca2+ channel opening, elevated intracellular Ca2+ concentration and vasoconstriction 
(Figure 5) [75]. Accumulative evidence suggests vascular K+ channel alteration is 
involved in major cardiovascular diseases, such as hypertension and diabetes [75], 
which are highly prevalent in obese patients.  
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Figure 5 Vascular tone regulated by K+ channel activation and inhibition  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                               [75] 
Left: opening of a K+ channel (grey) in the cell membrane causes an efflux of 
intracellular K+ and cell membrane hyperpolarisation, which consequently inhibits 
voltage-activated Ca2+ channels (white) and decreases intracellular Ca2+ levels, resulting 
in vasodilatation.  
Right: Reversely, closure of a K+ channel decreases an efflux of intracellular K+, 
leading to cell membrane depolarization and opening of Ca2+ channels. Influx of Ca2+ 
increases intracellular Ca2+ levels, resulting in vasoconstriction. 
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Endothelium 
The endothelium is not only the monolayer covering the internal lumen of vessels, but 
also a key factor regulating vascular homeostasis [76]. In healthy ECs, a delicate 
balance between EC-derived vasodilators [nitric oxide (NO), prostacyclin (PGI2) and 
endothelial-derived hyperpolarizing factor (EDHF)] and EC-derived vasoconstrictors 
[endothelin-1(ET-1), angiotensin II (Ang II) and thromboxane A2 (TXA2)] maintains the 
normal vasoreactivity and vascular permeability [77].  
As the most important EC-derived vasodilator, NO is synthesized from L-Arginine 
catalysed by a family of NO synthases (NOS), NO mediates vasodilatation by activating 
guanylate cyclase to increase intracellular cyclic guanosine monophosphate (cGMP) 
levels. Because of the short half-life of NO, it cannot be synthesized and stored in 
advance, therefore, production of NO highly relies on the activity of endothelial NO 
synthase (eNOS) [77]. 
ET-1, as the counterpart of NO, plays an important role in regulating vasoconstriction. 
ET-1 induces vasoconstriction by binding its G-protein-coupled receptors (GPCR, ETA 
and ETB) on VSMCs and ECs. ETA is involved in the recruitment of phospholipase C 
(PLC), which leads to the intracellular Ca2+ increase and vasoconstriction [78], while 
ETB was also shown to be involved in pulmonary angiogenesis through modulating 
vascular monocyte adhesion [79].      
Obesity is closely associated with endothelial dysfunction, which is characterized by the 
impaired endothelium-dependent vasodilatation [80]. Impaired vascular relaxation in 
AT may also compromise insulin-mediated capillary recruitment, therefore leading to 
insulin resistance [73].  
Insulin 
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To maintain the homeostasis of microvascular system, insulin regulates both 
vasodilatation and vasoconstriction (Figure 6). Insulin mediates vasodilatation by 
activating eNOS via insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3-kinase 
(PI3-kinase) and protein kinase B (Akt) pathway [81]. In contrast, insulin induces 
vasoconstriction by stimulating ET-1 production. ET-1-induced vasoconstriction is 
elevated following the infusion of insulin [82].  
In the postprandial state, insulin mediates microvascular blood flow redistribution from 
non-nutritive to nutritive vessels, thus enhancing insulin and substrates supply to insulin 
sensitive organ (capillary recruitment) [83]. In healthy individuals, there is a subtle 
balance between insulin-mediated vasoconstriction and vasodilatation, so the net effect 
on vascular tone is negligible [77]. However, obesity-related vascular dysfunction is 
associated with an alteration of this balance with upregulation of ET-1 and impaired NO 
bioavailability and bioactivity [84].  
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Figure 6 Pathways involved in the insulin-induced vascular tone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                       [77] 
Left: insulin binds and activates insulin receptor, consequently activating insulin 
receptor substrate-1. Downstream from that, PI3-kinase phosphorylates PDK-1 and Akt, 
leading to eNOS phosphorylation and NO production.  
Right:  insulin also regulates synthesis and secretion of ET-1 via mitogen-activated 
protein kinase (MAPK) branch. Signalling includes tyrosine phosphorylated SHC 
binding to SH2 domain of growth factor receptor-bound protein 2 (GRB2), activation of 
the pre-associated guanine nucleotide exchange factor (SOS), removal of GDP from Ras 
and initiation of a kinase phosphorylation cascade including Raf-1, MAPK/extracellular 
signal-regulated kinases (MEK), and MAPK.  
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Adipokines 
AT is an important endocrine organ associated with the production of pro-and anti-
inflammatory adipokines. These adipokines not only regulate AT metabolism and 
functions, but also are involved in the regulation of vascular tone [12, 85].  
Leptin is a crucial adipokine, which regulates appetite and energy metabolism. It also 
shows vasoactive effects mediating both vasodilatation and vasoconstriction [86, 87]. 
Leptin at physiological concentrations mediates vasodilatation through AMP-activated 
Akt signalling pathway, leading to eNOS activation via Ser1177 phosphorylation [88]. 
However, elevated leptin levels have been shown in obesity [89], and hyperleptinemia 
is considered as a key factor contributing to the vascular tone dysregulation and 
hypertension. Centrally, the vasocontractile effect of leptin is through activation of the 
sympathetic nervous system [90]. Peripherally, leptin increased both ET-1 secretion and 
ETA expression, which are tightly associated with EC dysfunction, NO depletion and 
reactive oxygen species (ROS) elevation [91, 92]. Furthermore, leptin stimulates the 
secretion of pro-inflammatory adipokines from macrophages, which may further 
increase vasoconstriction and blood pressure [93].  
Adiponectin is a cardioprotective adipokine [94]. The vasodilatory effect of adiponectin 
has been shown both in vivo and in vitro. In rats, adiponectin is involved in both NO- 
and K+ channel-mediated vasodilatation [95, 96]. In humans, adiponectin activates 
eNOS and increases NO production by binding to adiponectin type 2 receptor or T-
cadherin on EC surface [74] , and adiponectin levels in circulation positively correlated 
with endothelium-dependent vasodilatation [97].  
Both IL-6 mRNA expression and protein levels are elevated in AT of obese patients 
[98]. The vasoactive effect of IL-6 is time dependent. Acute exposure to IL-6 in vitro 
leads to the aorta relaxation by elevating the production of prostacyclin in VSMCs [99], 
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while  the long-term chronic increase of plasma IL-6 impaired endothelial function by 
stimulating Ang II-mediated ROS synthesis and reducing eNOS gene expression [100]. 
TNF-α is associated with chronic inflammation in obesity. Macrophage infiltration into 
the AT in obesity leads to elevated TNF-α mRNA expression, observed both in rodents 
and human [89]. It has been reported that TNF-α mediates endothelium-dependent 
relaxation in cerebral arterioles by elevating iNOS expression [101], it is also involved 
in the regulation of endothelium-independent vasodilatation via phospholipase A2 
activation and ceramide generation.   
PVAT 
PVAT is defined as a layer of AT surrounding almost all blood vessels (except cerebral 
vessels), which is comprised of  adipocytes, SVF, macrophages and neuronal networks 
(Figure 7) [102]. There is no anatomic facia to separate this fat depot from vascular 
adventitia, which facilitates the direct access of the factors secreted from PVAT into the 
vascular system [103]. Recent data suggest that PVAT shows an anti-contractile effect 
in both rodent and human vessels. Several studies have demonstrated that PVAT 
secreted soluble relaxing factors leading to K+ channel-mediated vasodilatation [104, 
105]. The identity of adipocyte-derived relaxing factor (ADRF) is still under 
investigation. Adipokines including adiponectin and Ang 1-7 have been considered as 
potential candidates of ADRF because of their vasodilatory effect [96, 104]. In human 
arterioles, adiponectin mediates vascular relaxation by improving NO bioavailability, 
while blockade of adiponectin binding to its type 1 receptor completely abolished the 
anti-contractile effect of PVAT [74]. Ang 1-7 induced vasodilatation via the 
endothelium-dependent pathway stimulating NO release, as well as endothelium-
independent pathway involving H2O2-mediated activation of soluble guanylate cyclase 
[106].  
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Figure 7 Interaction between PVAT and vasculature 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                      [102] 
PVAT interacts with vascular endothelium, smooth muscle, and immune cells and the 
mediators are involved.  
ADRF adipocyte-derived relaxing factor; Ang II angiotensin II; IL-8 interleukin-8; 
MCP-1 monocyte chemoattractant protein 1; ROS reactive oxygen species 
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Like other AT depots PVAT also expands during the development of obesity and 
becomes more inflammatory [107]. Significant macrophage infiltration has been 
observed in PVAT of obese animals accompanied by the decrease of anti-inflammatory 
adipokines, such as adiponectin [102]. Evidence suggests that local inflammation 
abolished anti-contractile properties of PVAT in obese patients [74] and the altered 
paracrine effect of PVAT may be an important risk factor associated with vascular 
dysfunction and insulin resistance [108].  
Prostanoids 
Prostanoids are synthesized from the substrate arachidonic acid catalysed by 
cyclooxygenase 1 and 2 (COX-1/COX-2). The endothelium-derived prostanoids include 
vasoconstrictors (TXA2) and vasodilators [prostaglandin E2 (PGE2) and prostacyclin 
(PGI2)]. Rat and human adipocytes are also capable of synthesizing prostanoids, which 
suggest that prostanoids may play a role in regulation of the vasculature in AT [109].  
Increased production of TXA2 was found in the aorta and carotid arteries of obese mice 
[110]. This response was fully blocked by non-selective COX inhibitors but not COX-2 
selective inhibitors, which suggests that COX-1-dependent vasoconstrictor synthesis 
may contribute to the enhanced vasoconstriction in obesity [110, 111]. Also evidence 
suggests that obesity-linked hyperinsulinemia may inhibit the stimulatory effect of 
adrenergic agonists on the synthesis of PGE2 and PGI2, thus contributing to the 
increased peripheral resistance and hypertension in obesity [112]. 
Neuronal transmitters 
Noradrenaline (NA) is a classic neuronal molecule synthesized and released from 
sympathetic neurons and peripheral tissues. A series of enzymes are involved in NA 
synthesis, the most important ones are tyrosine hydroxylase (TH, catalysing the first 
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step of the reactions), L-aromatic amino acid decarboxylase and dopamine-ß-
hydroxylase (DBH).    
In obese individuals, the adrenergic effect on AT metabolism mainly includes the 
stimulation of lipolysis and glucose uptake [113]. Additionally, ß-adrenergic agonists 
induced IL-6 and inhibited leptin release from AT both in vitro and in vivo [114]. 
However, the adrenergic regulation on AT microvasculature is less clear. The effect of 
NA on vascular tone is achieved by binding to its functional adrenoceptors ɑ and ß. 
Stimulation of ɑ1-adrenoceptors activates the PLC and inositol 1, 4, 5-trisphosphate 
(IP3) pathway, causing Ca2+ mobilization from organelles into cytoplasm and VSMC 
contraction. In contrast, stimulation of ß-adrenoceptors increases intracellular cAMP by 
activating adenylate cyclase (AC), leading to the activation of PKA, elevation of K+ 
influx and vasodilatation [115].    
Obese patients have increased sympathetic activity. Compared with lean healthy 
individuals, obese patients showed higher renal NA spillover [116]. Greater systemic 
NA levels were observed in hypertensive obese patients compared to normotensive 
patients, which implicated a pathological role of NA elevation in obesity-associated 
hypertension [117]. Recent data points to AT as a new source of NA. Both NA and NA 
synthetic enzymes were found in rodent adipocytes [118]. Microvasculature embedded 
in the AT may be directly regulated by NA released from adipocytes, but the adrenergic 
effect on microvascular tone within AT between different depots is still to be 
investigated.  
Neuropeptide Y (NPY) is a 36-amino acid peptide derived from the brain and 
sympathetic nerves [119]. In the central nervous system, it participates in the regulation 
of energy homeostasis by increasing food intake and decreasing physical activity [120]. 
Peripherally, NPY is stored and released along with NA from sympathetic nerve 
terminals [121]. Both human and animal studies confirmed the cooperation between 
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NPY and NA in the regulation of vascular tone [122]. NPY potentiated NA-induced 
vasoconstriction particularly via sensitizing ɑ1 adrenergic vasoconstriction [123]. 
Elevated activities of NPY and its receptors have been observed in experimental obesity 
[124]. However, its effect on the AT vascular tone is not known.    
Collagen deposition 
The AT expansion in obesity is accompanied by considerable tissue remodelling, which 
is characterized by increased macrophage infiltration, tissue fibrosis and increased 
extracellular matrix (ECM) components [125]. The accumulation of ECM in AT may be 
a consequence of chronic inflammation and hypoxia. ECM synthesis was enhanced in 
adipocyte precursors after treatment with conditioned media with secretions from 
macrophages [126], while inhibition of HIF-1α expression significantly prevented AT 
fibrotic response [127].    
Elevated ECM protein and gene expression have been observed in AT in obesity [128]. 
Particularly, collagen type VI is elevated in SAT and associated with insulin resistance 
[129, 130]. Fibrosis may also affect the vasculature in AT. Abundant collagen staining 
was seen around vessels in OAT, and collagen gene expression was elevated in SVF 
compared to adipocytes [128]. These data implicate the deposition of collagen in AT as 
altering vascular structure and function. Collagen type I and type III are predominant in 
cross-banded fibrils of vessel wall, which provide tensile strength [131].  In obese 
patients, both of them were increased in AT [128]. Increased collagen deposition in the 
vascular wall directly causes vascular fibrosis and arterial stiffening and contributes to 
atherosclerosis and hypertension [132].  
Data from rodents suggest NA may be a potent regulator of ECM in liver and lung [133, 
134]. NA induced hepatic fibrosis in mice by modulating the leptin action, while 72 hrs 
of NA infusion significantly induced pulmonary fibrosis and vascular hypertrophy 
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detected in lung histology [134].  However, whether NA shows similar fibrotic effects 
in AT and AT vasculature is unknown.  
1.5.3.3 Depot- and diabetes- specific differences in vasoreactivity  
In previous studies, structure and function of large- and medium-size vessels have been 
widely investigated in obese patients. The pathological alterations include increased 
vascular stiffness [135], decreased compliance and distensability [136], and endothelial 
dysfunction [137]. However, the microvasculature in AT is less well studied. One study 
compared microvascular structure and function in obese patients with healthy lean 
individuals using arterioles from SAT. Increased media thickness, vessel stiffness and 
impaired endothelium-dependent vasodilatation were found in the obese compared with 
lean group [138].  
OAT, compared with SAT, is more associated with increased risks of metabolic and 
cardiovascular diseases in obesity [17, 139], the direct comparison between SAT and 
OAT in obesity is helpful to understand the intrinsic depot difference and to what extent 
these two depots contribute to obesity-related complications. Two studies have been 
reported, mainly focused on the endothelium-dependent vasodilatation [140, 141]. Both 
studies suggest the vasodilatory impairment in OAT caused by the endothelial 
dysfunction. In addition, even SAT NO-mediated vasodilatation was compromised in 
obese patients with Type II diabetes [141].  
However, vasoconstriction, as a counterpart of vasodilatation, is also involved in AT 
metabolism and remodelling [142]. Very few studies that compare the depot difference 
in AT microvascular contractile function have been reported. Only one study 
investigated the NA-mediated vasoconstriction in SAT, and concluded that NA-
mediated vasoconstriction in SAT was enhanced in obese patients with and without 
Type II diabetes compared to the lean controls [141].      
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1.6 Aims of the thesis 
The aims of this thesis were to investigate in:  
Study 1: the depot- and diabetes-specific differences of noradrenaline (NA) synthesis, 
NA-mediated vasoconstriction and tissue fibrosis in abdominal SAT and OAT of 
morbidly obese patients. 
Study 2: the depot- and diabetes-specific differences of capillary density, angiogenic 
capacity and angiogenesis-related mRNA and protein expression.  
Study 3: the adipokine production of PVAT of the saphenous vein (SV) and internal 
thoracic artery (ITA). 
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Methods and Materials 
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2.1 Study population  
2.1.1 Patient recruitment 
Morbidly obese patients undergoing laparoscopic bariatric surgery (gastric bypass, 
gastric sleeve, or gastric band) were recruited from the pre-operative clinic (North 
London Obesity Surgery Service, Whittington Hospital, London, UK). Morbid obesity 
was define as BMI ≥ 40 kg.m-2 or BMI ≥ 35 kg.m-2 with significant co-morbidities 
[143]. Patients with coronary artery disease, uncontrolled hypertension, malignancy or 
terminal illness, connective tissue disease or other inflammatory conditions likely to 
affect cytokine levels, immuno-compromised subjects and those with substance abuse 
or other causes for poor compliance were excluded. The study was approved by the 
National Ethics Committees and written informed consent was obtained from all 
participants. 
2.1.2 Demographic and anthropometric data 
Weight (kg) and height (m) were measured in pre-clinic assessment and BMI was 
calculated. Blood pressure and pulse were measured using digital monitor (Datex-
Ohmeda Patients Monitor, GE Healthcare, UK). Patient information including 
demographic data (date of birth, gender, ethnicity), surgery type (gastric bypass, gastric 
band, gastric sleeve), co-morbidities, current medication, weight loss history, smoking 
habits and alcohol consumption were recorded from hospital notes. 
2.1.3 Blood and AT sample collection 
Blood samples, following an overnight fast, were drawn from an ante-cubital vein on 
the day of the operation immediately after anaesthesia. After centrifugation (3000 rpm, 
15 minutes, 25oC), the plasma or serum was collected and stored at -80 oC until analysis.  
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AT from the abdominal subcutaneous and intra-abdominal greater omental depots was 
obtained during the surgery (~5g each) and quickly transported in serum-free medium 
(Cellgro, Mediatech Manassas, VA) to the laboratory. 
2.2 Adipokine study  
2.2.1 AT organ and EC culture 
0.05 g AT from each depot was dissected and incubated in 500 μl Cellgro serum-free 
media (Mediatech Manassas, VA) with 5% penicillin-streptomycin overnight ( 37 oC, 
95% O2 / 5% CO2). Following incubation the medium was collected and stored at -80oC 
until later assessment of adipokines secretion.  
HUVECs and HCAECs, obtained from TCS Cell Works (Buckingham, UK), were 
cultured in endothelial basal medium (EBM; Lonza, Nottingham, UK) supplemented 
with gentamycin-ampicillin, epidermal growth factor and bovine brain extract 
(Singlequots; Lonza) and 10% (v/v) foetal bovine serum (FBS) (complete EBM). Cells 
were harvested when they reached 80-90% confluence, and then stored in -80oC for 
subsequent total RNA extraction. 
2.2.2 Insulin and adipokine ELISAs 
Serum insulin level was measured by specific insulin ELISA (Mercodia, Sweeden). 
Insulin sensitivity was determined by the Homeostasis Model Assessment Index-Insulin 
Resistance (HOMA-IR). HOMA-IR was calculated from the fasting glucose (mmol/l) 
and insulin levels (mU/L) using the equation HOMA-IR=(insulin *glucose)/22.5 [144]. 
Adipokine levels in serum and tissue culture supernatant including total adiponectin, 
leptin and MCP-1 were measured by commercially available two-site ELISAs (R&D 
Systems, UK). Briefly, standards and samples were pipetted into the 96 wells of 
microplates pre-coated with antibody against the target protein. After incubation, target 
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protein was bound to the antibody pre-coated on the bottom of the well. The unbound 
substance was then washed away, followed by adding a detecting enzyme-linked 
antibody specific for the target protein. After washing, to remove the unbound antibody-
enzyme reagent, the substrate was added and colour development in proportion to the 
amount of target protein bound was observed. Colour development was stopped at set 
times as per manufacturer’s instructions and the intensity of the colour measured by the 
microplate reader (Opsys MR, Dynex, UK), as absorbance at 450 nm, with correction at 
540 nm. 
2.3 Histochemistry and immunohistochemistry  
2.3.1 Estimation of adipocyte number, size and capillary density  
0.3 g tissue from each depot was fixed in 10% formalin for 24 hours at room 
temperature and then transferred to 50% ethanol at +4 oC prior to being embedded in 
paraffin. 3 μm sections were deparaffinised and dehydrated in Xylene (Sigma-Aldrich, 
UK) for 20 min, followed by 100, 90, 80, 70, and 60% ethanol. The sections were 
incubated for 30 minutes in a dark moist container with the staining solution containing 
lectin fluorescein isothiocyanate (FITC) conjugate (from Griffonia simplicifolia [GS], 
25 μg/ml, Sigma-Aldrich), lectin tetramethylrhodamine isothiocyanate conjugate (from 
Ulex europaeus [UEA], 10 μg/ml, Sigma-Aldrich), and 4’,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI, 0.3 μg/ml, Sigma-Aldrich). The GS lectin stains the 
plasmalemma, UEA stains the capillaries [145], and DAPI stains nuclei [146]. Sections 
were rinsed with 0.1M sodium phosphate buffer (PBS, pH 7.4) for 40 min and then 
mounted on glass slides with water-soluble mounting medium (Cardinal Health, Dublin). 
Images of the stained sections were captured with a Zeiss Axioplan 2 upright 
microscope (Intelligent Imaging Innovations, Denver, USA) using a Photometrics 
CoolSnap HQ CCD camera and a Sutter Lambda LS 175W Xenon arc lamp. 
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Images were then analyzed by ImageJ software (National Institutes of Health, USA). 
Adipocyte number per section was counted by numbering all the adipocytes on the 
picture (Figure 8A). Damaged or incompletely displayed adipocytes were excluded. 
Adipocyte size was measured by tracing the pixel area (Figure 8B). For tracing the 
pixel area, “Free Hand” function was selected in ImageJ and the border of each 
adipocyte was traced manually. Capillaries shown as orange spots or lines were also 
counted and expressed as capillary number per section (Figure 8C).  
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A: All adipocytes on each section were counted and numbered.  
B: Area of each adipocyte was measured by tracing the border manually. 
C: Capillaries were labelled by UEA staining, and then counted manually.   
 
 
 
 
A B 
C 
Figure 8 Calculation of adipocyte number (A), area (B) and capillary number (C) 
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2.3.2 Macrophage staining  
Slides were washed in Tris buffered saline for 2 min and blocked at room temperature 
for 5 minutes in DAKO peroxidase blocking solution and 10% horse serum. CD68 
affinity purified rabbit anti-human polyclonal antibody (Sigma-Aldrich, UK), as a 
macrophage marker, was added and incubated for 60 minutes at room temperature and 
secondary antibody (1:1000 dilution of anti-rabbit IgG peroxidase conjugated antibody, 
Sigma-Aldrich, UK) for 45 minutes. Detection was by standard Avidin Biotin Complex 
(ABC)/DAB method. 
2.3.3 Estimation of endothelial markers and catecholamine synthetic enzyme  
AT sections were immunostained for EC markers, CD31 and CD34, as well as for TH 
(marker of catecholaminergic fibres). Slices were washed in 0.1M PBS for 30 minutes 
and permeabilized and blocked with 0.1% Triton in 10% FBS for 60 minutes. Tissue 
was then incubated overnight at 4oC in anti-CD34 antibody, or anti-CD31 antibody or 
sheep anti-TH antisera (1:250, Abcam, UK). Sections were washed and subsequently 
incubated in 488 Alexa Fluor rabbit anti-sheep (1:1000) for 1 hour. Slices were cover-
slipped with Vectashield HardSet mounting medium (Vector Laboratories, USA) with 
DAPI. Images were captured and analysed using ImageJ software. TH stained area was 
selected using threshold function to filter the DAPI staining (Figure 9A&B), and then 
images were transformed into 8 bit (Figure 9C). TH-immunoreactive fibre density was 
estimated by measuring grey density of TH stained areas with the gel analysis function, 
the grey density was shown as the area under the curve (Figure 9D) and calculated by 
“Wand tool” function. The data was expressed as number of bits per section. 
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A: TH was immunostained by TH antibody shown as green and nucleus was stained by 
DAPI shown as blue. 
B: Nucleus staining area was filtered by Image J “threshold” function. 
C: Image was transformed into 8-bit format. 
D: The grey density of TH staining area was measured by gel analysis function shown 
as the area under the curve.   
 
 
 
A B 
C 
Figure 9 Analysis of TH immunoreactive fibre densities 
D 
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2.3.4 Estimation of collagen deposition  
Sections were deparaffinized and hydrated to distilled water, followed by incubating in 
Verhoeff’s hematoxylin for 30 minutes. After washing, sections were differentiated in 2% 
ferric chloride solution for elastic fibre staining. Then slides were rinsed and iodine was 
removed. Finally sections were counterstained in Van Gieson's for 5 minutes and then 
dehydrated and coverslipped. For collagen deposition analysis, as elastic fibre staining 
(black) was filtered using ImageJ threshold function (Figure 10A&B) and the collagen 
staining area (pink) was transformed into 8 bit format (Figure 10C), the staining area 
was calculated using “Analyse Particles” function . The data was expressed as the pixel 
area of the collage deposition.  
2.3.5 Adiponectin and leptin derived from PVAT  
 For immunohistochemical identification of leptin and adiponectin, frozen transverse 
sections of vessels with intact PVAT were prepared as previously described [147]. 
Solvent that would dissolve the fat was avoided. 15 μm transverse sections were thaw-
mounted, post-fixed for 10 min in 4% formal saline and stored at -80oC until use. 
Standard immunohistochemistry was performed using the Vectastain ABC-AP kit 
(Vector Labs, Burlingame, CA, USA). Leptin was identified using a polyclonal anti-
rabbit antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) and  adiponectin 
using a polyclonal anti-rabbit antibody, (Aviva Systems Biology, UK), at  dilutions 1:25 
to 1:100 in PBS and processed following the manufacturer’s instructions. Negative 
controls were prepared in the absence of primary antibody. In some cases CD31 (1:100 
in PBS; DAKO labs, Glostrup, Denmark) immunostaining of paraffin sections was 
performed for the identification of ECs. Vector red substrate was used to develop the 
colour, sections were counterstained with haematoxylin, viewed under an Olympus BX 
50 microscope and representative photographs taken. 
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A: Collagen deposition in AT was stained by EVG staining, collagen was shown as 
pink and elastin was shown as black. 
B: Elastin staining area was filtered by Image J “threshold” function and collagen 
staining area was isolated. 
C: Collagen staining area was transformed into 8-bit format for further particle 
measurements. 
 
 
 
A B 
C 
Figure 10 Analysis of AT collagen deposition 
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2.4 AT gene expression 
2.4.1 Whole tissue and cell RNA extraction 
~0.15 g AT was ground in liquid nitrogen using a pestle and mortar. Tissue powder or 
cells were collected and homogenized in TRIzol reagent (Invitrogen, Life Technologies, 
UK). Then chloroform was added and mixed thoroughly (0.2 ml chloroform per 1ml 
TRIzol). After centrifugation (3200 rpm, 15 minutes, 4 oC), the mixture was separated 
into a lower red phenol-chloroform phase, an interphase, and a colourless upper aqueous 
phase, the upper phase containing total RNA was transported into a new eppendorf. 
Equal volume of 100% isopropanol was added and mixed gently. The sample was then 
incubated at -20oC for 1.5 hour. After another round of centrifugation (3200 rpm, 15 
minutes, 4oC), the RNA pellet was formed on the bottom of the eppendorf. The pellet 
was washed twice in 75% ethanol [ethanol for molecule biology (Sigma-Aldrich, UK); 
nuclease-free water (Invitrogen, Life Technologies, UK)] and dissolved in 40 μl 
nuclease-free water [148].  
The purity and yield of total RNA were determined spectrophotometrically (NanoDrop-
1000 Spectrophotometer, Thermo Scientific, USA). The concentration of RNA was 
measured as absorbance at 260 nm. The purity was determined by the ratios between 
260 nm and 280 nm (260/280) and between 260 nm and 230 nm (260/230). 260/280 and 
260/230 ratios within 1.7-2.0 were accepted purity for RNA.    
2.4.2 cDNA synthesis  
For first strand cDNA synthesis 500 ng of total RNA was added into reverse 
transcription reaction mixture containing MultiScribe Reverse Transcriptase (1.25 
Unit/μl), dNTP (ATP, CTP, GTP, UTP, 500 μM each), Oligod(T)16 (which ensures the 
transcription of only mRNA but not rRNA or tRNA, 2.5 μM), RNase inhibitor (0.4 
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Unit/μl), MgCl2 (5.5 mM) and reaction buffer (Taqman Reverse Transcription Reagents, 
Roche, New Jersey, USA). The sample was then incubated in the thermal cycler 
(Genius, Techne, UK) for 60 minutes at 42oC, 15 minutes at 72 oC and holding at 4oC. 
After the incubation, cDNA was stored at -20 oC until use.  
2.4.3 Real-Time Polymerase Chain Reaction (Real-Time PCR) 
Target gene transcription was measure by Taqman Real-Time PCR. Primers of β-actin 
(housekeeping gene), collagens type 1α1, NRP-1, adiponectin and leptin were 
purchased from Qiagen Company, UK. Reaction was carried out in triplicate in 284-
well microtitre plates using 5 μl total volume per well from 25 μl mixture [12.5 μl 
SYBR-green solution, 2.5 μl primer, 10 μl cDNA (25 ng) with nuclease-free water]. 
PCR cycle was 50 oC for 2 minutes, 95 oC for 15 minutes, followed by 40 cycles of 94 
oC for 15 seconds, 56 oC for 30 seconds and 76oC for 30 seconds in ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, UK). 
Cycle threshold value (the number of cycles required for the fluorescent signal to cross 
the threshold, Ct value) was used to quantify the gene expression. Data was expressed 
as the Ct ratio of β-actin / target gene. 
2.5 AT protein expression 
2.5.1 Protein extraction and quantification 
Protein lysate was prepared by using ~150 mg AT homogenized in 500 μl RIPA buffer 
(Sigma-Aldrich, UK). The total protein concentration was estimated using bicinchoninic 
acid (BCA) protein Assay (Novagen, EMD Chemicals, CA, USA). Briefly, the standard 
curve was built by using diluted bovine serum albumin as the standard (Sigma-Aldrich, 
UK, concentration: 0, 25, 125, 250, 500, and 1000 μg/ml). 25μl standards and samples 
were loaded into a 96-well plate followed by 200μl BCA working reagent (1 portion of 
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4% Cupric Sulfate plus 50 portions of BCA solution). The plate was incubated at 37 oC 
for 30 minutes. Cu2+ was reduced to Cu1+ by protein in alkaline solution and then 
reacted with BCA producing a purple colour with absorbance at 562 nm [149] in 
proportion to the protein concentration.  
2.5.2 Western blot 
2.5.2.1 Sample preparation and electrophresis  
Sample was prepared by mixing AT protein extracts with NuPAGE LDS Sample Buffer 
and NuPAGE Sample Reducing Agent (Invitrogen, UK). Each 10μl sample mixture 
contained 5 mg total protein, 2.5 μl LDS Sample Buffer and 1 μl Sample Reducing 
Agent. Then sample mixture was heated at 70oC for 3 minutes to denature the protein 
and break protein complexes.  
10μl samples and protein ladder (Spectra Multicolor Broad Range Protein Ladder, 
Thermo Science, UK) were loaded into the pre-cast polyacrylamide gels (NuPAGE, 
Novex 4-12% Bis-Tris Gels, 1.0 mm, 15 well, Invitrogen, UK). Gel was run at 200 Volt 
in a running buffer (NuPAGE MOPS SDS Running Buffer, Invitrogen, UK, 20x diluted 
in distilled water to 1x,) until the bromophenol blue dye front has reached the bottom.  
2.5.2.2 Transfer 
The gel was removed from the cassette and placed in the transfer buffer ( NuPAGE 
Transfer Buffer, Invitrogen, UK, 50 ml 20x stock diluted with 850 ml distilled water 
and 100 ml methanol) to equilibrate. Two filter papers (from PVDF/Filter Paper 
Sandwich, 0.45 µm pore size, 8.5 cm x 13.5 cm, Invitrogen, UK) were placed in transfer 
buffer and the PVDF membrane soaked in methanol. When saturated, it was rinsed in 
water and then soaked in the transfer buffer. Six sponges were saturated with transfer 
buffer for later use. The transfer “sandwich” was assembled by three sponges, first filter 
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paper, gel, PDVF membrane, second filter paper and the other three sponges. The 
electrophoretic gel transfer was carried out in the transfer blotting module (XCell II Blot 
Module, Invitrogen, UK) at a constant voltage of 35 Volt for 1.5 hour. The membrane 
was subsequently blocked in 20 ml blocking solution (5% marvel non-fat milk in PBS 
with 0.1% Tween 20) for 1 hour at room temperature.  
2.5.2.3 Antibody incubations and chemiluminescence 
The membrane containing the transferred proteins was incubated in 5 ml of primary 
antibody (diluted in blocking solution, 1:1000 dilution) at 4oC overnight, followed by 
washing and secondary antibody incubation (horseradish peroxidase conjugated, 
1:10000 dilution) at room temperature for 1 hour. Following further washes, the 
membrane was incubated with Amersham ECL western blotting detection reagent 
( 75μl reagent A plus 3ml reagent B, GE Healthcare, UK), which generates a 
chemifluorescence signal. The membrane was then exposed to an autoradiography film 
(Amersham Hyperfilm ECL, GE Healthcare, UK) for variable periods depending on 
results. The grey density of the blots was analysed by ImageJ gel function and data was 
expressed as the grey density ratio of target protein / β-actin. 
2.6 Determination of vascular reactivity   
2.6.1 Vascular tissue distinction and dissection 
The first step of vessel preparation was to distinguish artery from vein. There were 3 
major differences between artery and vein in human AT: (1). the branch of the artery is 
seen as “V shaped: while the branch of the vein was “U-shaped”; (2) the lumen size of 
artery is apparently smaller compared to the vein; (3) the blood flow was faster in artery 
versus vein (Figure 11). For ensuring the vessel luminal diameter within the range of 
200-400 μm, normally the second to third branch of artery was dissected. After 
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carefully dissecting the surrounding AT, arterioles were isolated under a dissecting 
microscope and cut into segments (~2 mm long). 
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The Lumen of arteriole is smaller with a “V-shaped” branch while venule has larger 
lumen size with a “U-shape” branch.  
 
 
 
Arteriole 
Venule 
V-shaped 
U-shaped 
Figure 11 The major differences between artery and vein 
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2.6.2 Vessel mounting 
They were then mounted on wires (40 μm diameter) in an auto dual wire myograph 
system (510 A; JP Trading, Aarhus, Denmark) containing normal physiological salt 
solution (NPSS). The NPSS contained (in mM) 112 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 
25 NaHCO3, 0.5 KH2PO3, 0.5 NaH2PO3, and 10 glucose (gassed with 95% O2/5% CO2 
to pH 7.4). During the mounting procedure, further dissection was carried out to clean 
the connective tissue surrounding the vessels which may restrict the vessel relaxation. 
Figure 12 showed how the arteriole was mounted onto the wire attached on jaws. 
Firstly, the luminal entrance of the vessel was opened by gently squeezing the vessel 
wall, normally lumen was opened by the blood spilling out, the first wire was then 
threaded through the whole segment, the arteriole performed as its own guide being 
pulled along the wire and fixed on the wire between the two jaws (Figure 12A&B). 
After that, the second wire was threaded through the artery very slowly and carefully 
avoiding any scratching on the inner layer of the vessel, this ensured the intactness of 
endothelium (Figure 12C). Finally, the second wire was attached onto the right jaw 
(force transducer). In preparation for the next step of normalization, the two wires were 
then slightly separated to make them just barely touching each other to finish the 
mounting procedure (Figure 12D). 
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A: Place the first wire between the jaws, then screw the jaws together to clamp the wire. 
B: A segment of vessel was mounted onto the first wire. 
C: The second wire was threaded through the lumen carefully. 
D: Vessel was mounted on two wires and ready for normalization.   
 
 
 
 
 
Figure 12 Vessel mounting in myography  
Wires (40µm) 
Arteriole 
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2.6.3 Vessel normalization  
The vessels were continuously aerated at 37 °C followed by the normalization. The aim 
of the normalization procedure is to stretch the segment to achieve the normalized 
internal circumference, which was defined as the internal circumference when vessel 
fully relaxed with a specified transmural pressure. For human arterioles the transmural 
pressure was typically 100 mm Hg (13.3 kPa). The lumen diameter of each segment 
was calculated by the myograph system automatically. An equilibration period of at 
least 1 h was allowed during which time tissues were contracted with KCl (100 mM) to 
optimize tissue response. 
2.6.4 Vasoconstriction measurement 
Following equilibration, vasoconstriction was assessed by constructing cumulative 
concentration-response curves for NA (10–9–10–5.5 M), and TXA2 analogue U46619 
(10–9–10–6 M). Where possible, two dose–response curves were obtained in the same 
preparation separated by a washout period of 30–60 min. With this protocol, there was 
no apparent time-dependent change in the response to any of the vasoconstrictors. 
Myography data were recorded and analysed using Myodaq and Myodata (Danish. 
Myotech, Aarhus, Denmark). Under each dose, peak value of vessel tension was 
collected; tension increase was calculated by peak value for each dose minus basal 
vessel tension (mN), and then adjusted by lumen diameter (mN/μm). 
2.7 Assays 
Plasma glucose concentration was assayed with glucose hexokinase reagent (Roche, CA, 
USA). Serum specific insulin levels were determined by ELISA (Mercodia, UK). 
Serum triglycerides, total, low density lipoprotein (LDL-) and high density lipoprotein 
(HDL-) cholesterol were assayed with commercial reagents (total-cholesterol: 
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Boehringer-Mannhein, Sussex, UK and triglycerides: Roche Diagnostics, Herts, UK). 
LDL-cholesterol was calculated using the Friedwald formula [150]. All lipid assays 
were performed by Dr David Wickens (Chemical Pathology, Whittington Hospital, 
London, UK). Insulin resistance was calculated using the HOMA where HOMA = 
(glucose in mmol/L x insulin in mIU/L)/22.5 [144]. 
2.8 Statistical Analysis 
Data were analysed using SPSS version 14 for Windows (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK). Normality of distributions was tested 
with the Kolmogorov-Smirnov test. Data are shown as mean (SD), or for non-normally 
distributed data as median (interquartile range), in text and in tables. Comparison of 
depots was by paired t-tests or by Wilcoxon test. Pearson or Spearman rank correlations 
were used for the bivariate analysis. Significance was defined as p≤0.05. 
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Chapter 3  
NA Synthesis, NA-mediated vasoconstriction and 
collagen deposition in abdominal AT 
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3.1 Introduction 
3.1.1 Sympathetic nerve activation in abdominal obesity and diabetes  
Abdominal obesity is associated with increased sympathetic nerve activity [151, 152]. 
The AT over-expansion in abdominal area includes SAT and OAT depots, consequently 
leading to subcutaneous and visceral obesity. However, the two obesity phenotypes may 
not be similar in their association with the sympathetic nerve activation. Compared to 
non-obese individuals, subcutaneous obese patients showed no significant elevation in 
muscle sympathetic nerve activity [153], while obese patients with high proportions of 
OAT showed higher muscle nerve burst compared with those with less OAT 
accumulation [151].  Moreover, in obese patients with Type II diabetes, the sympathetic 
nerve dysfunction was further exaggerated, shown as higher sympathetic nerve burst, 
decreased plasma NA clearance, and lower neuronal reuptake [152].  
3.1.2 Local NA synthesis by AT 
The major measurements of adrenergic activity in obesity are by testing the muscle 
sympathetic nerve burst or systemic NA level [151, 152]. However, the local NA 
synthesis is less investigated. AT, as an endocrine organ, is innervated by sympathetic 
nerves [154] and adrenergic regulation is highly involved in AT metabolism and 
adipokine secretion  [114, 154]. Data from rodents also show that adipocytes per se may 
be a new source of NA synthesis [118], which points to local adrenergic regulation of 
AT and its vasculature via autocrine and paracrine pathways.  
3.1.3 Adrenergic regulation on vascular tone  
The adrenergic system is an important regulator of vascular function via activation of α 
and β adrenoceptors. As a part of GPCRs, adrenoceptors mediate the functional effect of 
NA. Adrenergic dysfunction has been observed in obesity, which could be due to AT 
  75
expansion, hyperleptinemia, and hyperinsulinemia, [155]. However, the adrenergic 
effect on local vascular function within AT is less investigated. Microvasculature 
embedded in AT directly mediates tissue growth, remodelling, metabolism and 
oxygenation [42]. It is also involved in the regulation of peripheral resistance. In obesity, 
due to the sympathetic nerve overreaction, there are a series of pathological alterations 
in vascular structure including tissue fibrosis, narrowed lumen diameter and increased 
wall  thickness (reviewed in [156]). Whether the vascular function is also compromised 
is still being investigated. Previous data have reported endothelium-dependent 
vasodilatation while NA-mediated vasoconstriction is less studied [73, 138].     
3.1.4 Adrenergic effect on tissue fibrosis 
NA is a potent regulator of ECM deposition, inducing both tissue and vessel fibrosis in 
liver and lung in rodents [133, 134]. In humans, there is greater AT fibrosis in obese 
patients compared with lean individuals, and more collagen deposition surrounding 
vessels in OAT than SAT [128]. While it is probable that the vascular tone was altered 
by the accumulation of collagens around the vessels, direct evidence for this in human 
adipose microvessels is not currently available.   
3.1.5 Aims 
The aims of this study were to investigate, in human SAT and OAT: 
1. The depot- and diabetes-specific difference in NA production,  
2. NA-mediated vasoconstriction, and 
3. NA-induced collagen gene expression.   
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3.2 Methods 
Morbidly obese patients were recruited and characterised as described in Section 2.1. 
Adipocyte size and macrophage infiltration were estimated using the methods described 
in Section 2.3.1 and 2.3.2. 
NA synthetic enzyme-TH was investigated using immunohistochemistry. The staining 
and analysis have been described in Section 2.3.3  
Tissue explants and protein lysates were prepared as described in Section 2.2.1 and 
2.5.1.  
Local NA concentration in AT explant and protein lysate was measured using NA 
ELISA (Labor Diagnostika Nord, Germany). Briefly, NA in samples was extracted 
using a cis-diol-specific affinity gel, acylated to N-acyladrenaline and then converted 
enzymatically. Antigen is pre-coated to the solid phase of the microtiter plate. Acylated 
catecholamine from the sample and solid phase-bound catecholamine compete for a 
fixed number of antiserum binding sites. When the system is in equilibrium, free 
antigen and free antigen-antiserum complexes were removed by washing. The antibody 
bound to the solid phase was detected by anti-rabbit IgG-peroxidase conjugate using 
TMB as a substrate. 
Vascular tone mediated by NA and TXA2 analogue U46619 was investigated using dual 
wire myography system. Details were described in Section 2.6. 
Tissue collagen deposition was studied by EVG staining. The staining protocol and 
analysis were described in Section 2.3.4.  
For testing whether NA can induce AT collagen mRNA expression, 0.05 g of AT was 
minced and incubated for 6 hours in 500 μl serum-free medium (Cell-gro, Mediatech, 
VA, USA) with or without 1μM NA. The tissue was then stored in -80 oC for later total 
RNA extraction and real-time PCR. 
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Collagen type1α1 gene expression was investigated using total RNA extracted from 
whole AT and real-time PCR technique described in Section 2.4. 
Data were analysed using SPSS version 14 for Windows (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK). Normality of distributions was tested 
with the Kolmogorov-Smirnov test. Data are shown as mean (SD), or for non-normally 
distributed data as median (interquartile range), in text and in tables. Comparison of 
depots was by paired t-tests or by Wilcoxon test. Pearson or Spearman rank correlations 
were used for the bivariate analysis. Significance was defined as p≤0.05. 
 3.3 Results 
3.3.1 Patients’ characteristics 
 Patient characteristics are shown in Table 1 (n=44, 85% female). Compared to the non-
diabetic group, diabetic patients were older. The majority of the non-diabetic obese 
patients studied were normoglycaemic, but at the expense of hyperinsulinaemia. A sub-
set remained normoinsulinaemic and were excluded from these studies (n=3). 
 Medication regimen: None of the 44 patients were treated with ß-blockers. In the non-
diabetic group only 5 out of the 28 patients were taking any medication 
(thiazolidinedione n=1; statins n=3 and Ang converting enzyme inhibitors n=1). In the 
16 diabetic patients the main hypoglycaemic therapy was metformin (n=11) and one 
was on diet alone. 2 patients were on insulin and 2 on thiazolidinediones. Additional 
medication included statins (n=6), Ang converting enzyme inhibitors (n=5) and Ang-2 
receptor antagonists (n=2).  
Despite treatment the diabetic patients had higher fasting plasma glucose, but, lower 
insulin concentrations. Levels of HOMA-IR, serum lipids and blood pressure were all 
comparable between the two groups.  
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Table 1 Patients’ characteristics. 
Data shown as mean (SD) or median (interquartile range); BMI: body mass index, SBP, 
systolic blood pressure, DBP, diastolic blood pressure; MABP: mean arterial blood 
pressure; FPG, fasting plasma glucose, HOMA-IR, homeostasis model assessment of 
insulin resistance; TG: triglycerides; Total-, LDL-, HDL-chol, Total-, LDL-, HDL-
cholesterol 
 
 
 
Variables Non-diabetic(N=28) Diabetic(N=16) p value 
Age (year) 39.9(12.3) 48.4(8.4) 0.01 
BMI (kg.m-2) 47.7(8.9) 45.0(7.8) 0.41 
SBP (mmHg) 131.4(16.3) 136.4(20.1) 0.54 
DBP (mmHg) 79.2(9.1) 76.4(11.8) 0.59 
MABP (mmHg) 96.6(10.1) 96.4(13.6) 0.76 
FPG (mmol/L) 5.1(1.0) 7.7(3.2) <0.01 
Insulin (mIU/L) 11.3(8.1-16.1) 7.1(5.7-14.4) 0.04 
HOMA-IR 2.5(1.7-3.9) 2.7(1.3-5.5) 0.66 
TG (mmol/L) 1.8(1.2-2.3) 1.1(0.8-2.4) 0.12 
Total-chol (mmol/L) 4.2(1.2) 3.8(1.1) 0.35 
LDL-chol (mmol/L) 2.6(1.3) 2.2(1.0) 0.16 
HDL-chol (mmol/L) 0.9(0.2) 1.0(0.2) 0.10 
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3.3.2 Tissue NA synthesis 
In order to test the hypothesis that chronically elevated locally synthesized NA in the 
OAT and in diabetic patients may lead to vessel insensitivity to the catecholamine, the 
expression of the rate-limiting NA synthetic enzyme, TH, as well as tissue and explant 
levels of NA were determined.  
TH immunoreactivity was associated with the adipocytes as well as with the vasculature 
(Figure 13A&B). Lower TH density was apparent in SAT compared to that of the OAT 
depot in non-diabetic group (SAT non-diabetic: 98904 [79403-128929] arbitrary unit 
[AU], N=14 versus OAT non-diabetic: 117088 [100115-139084] AU, N=13, p= 0.04, 
Figure 13C). However, no such depot-specific difference of TH staining was found in 
the diabetic tissue (SAT diabetic: N=6, 154348.5 [125651.5-167425.25] AU; OAT 
diabetic: N=6, 171109 [153441-197658.75] AU, p=0.17).  
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TH positive staining (green) was apparent around the adipocytes of both SAT (A) and 
OAT (B). In tissue from non-diabetic subjects TH staining was significantly less in SAT 
than OAT (C, p=0.03). Within the diabetic group there were no significant differences 
in TH staining between the depots (p=0.17). 
 
A B 
C 
Figure 13 Depot- and diabetes-specific differences in TH density 
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Tissue NA levels were significantly lower in SAT compared to OAT in all patients 
(SAT versus OAT: 19.4[1.1-500.4] versus 335.6 [4.3-1921.5] pg/mg total protein, N=12, 
p=0.01).  
As shown in Figure 14, it was only in the non-diabetic group that this depot-specific 
difference was apparent (SAT versus OAT: 6.1 [0.8-563.6] versus OAT: 534.8 [2.2-
2819.2] pg/mg total protein; N=6, p=0.03), perhaps explaining the greater sensitivity of 
the vessels from this depot to its vasoconstrictive effect. In diabetic patients, the tissue 
NA was comparable in the two depots. (SAT: 194.7 [1.4-529.7] versus OAT: 335.6 
[6.4-3457.7] pg/mg total protein; N=6, p=0.17).     
Very low concentrations of NA were detected in explant medium of both SAT and OAT 
(<1.0 pg/ml), suggesting a mainly autocrine/paracrine, rather than endocrine, effect.       
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Local NA levels was significantly higher in OAT compared to SAT in non-diabetic 
while no depot-specific difference was found in diabetes.  
Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
 
 
 
 
Figure 14 Depot- and diabetes-specific difference in tissue NA concentration 
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3.3.3 NA- and TXA2 (U44419) - mediated vasoconstriction 
In all subjects the vasocontractile function of arterioles with comparable lumen sizes 
were investigated (non-diabetic: SAT 306.9 [215.9-440.0] μm and OAT 335.1 [233.4-
430.4] μm, NSAT=14, NOAT=16, p=0.73; diabetics: SAT 278.8 [179.4-442.5] μm and 
OAT 330.8 [181.1-592.8] μm, NSAT=8, NOAT=8, p=0.72).  
In the non-diabetic patients, there was a significant depot-specific difference in both the 
sensitivity to NA-mediated vasoconstriction and the maximal contractile response 
(Figure 15A&C). The arterioles from the SAT showed vasoconstriction at lower, near 
physiological doses of NA (at dose 10-8 M, p=0.01; dose 10-7.5 M, p=0.02; Log EC50: 
SAT versus OAT, -7.3[0.6] versus -6.2[0.6]). However, the maximal contractile 
response of the OAT vessels was higher compared to those from SAT (OAT: 0.021 
[0.011-0.039] mN/μm versus SAT: 0.013 [0.004-0.022] mN/μm, p=0.05).  
No depot specific differences in the sensitivity or vessel tension were seen in the 
diabetic patients (Figure 15B&D, Log EC50: SAT versus OAT, -6.4[0.7] versus -
6.4[0.8], SAT versus OAT maximal vessel tension, p=0.83).   
Furthermore, the SAT arterioles from non-diabetic patients showed greater sensitivity to 
NA at physiological doses compared to those from the diabetic patients (10-8 to10-7.5 M, 
p=0.01 and 0.03 respectively).  
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A&B: Images captured from the representative myography trace in single experiment of 
one non-diabetic and one diabetic obese patient. Vessel NA sensitivity was only 
apparent in SAT of non-diabetic group, while abolished in OAT and diabetes. 
C&D: Overall analysis of vasoconstriction in non-diabetic and diabetic obese patients, 
it confirmed the depot- and diabetes-specific difference in NA-mediated 
vasoconstriction. Data was expressed as mean and mean of standard error.  
Non-DM: non-diabetic obese patients; DM: diabetic obese patients.    
C. Non-DM D. DM 
Figure 15 Depot- and diabetes-specific differences in NA-mediated vasoconstriction (I) 
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Data was also expressed as median and interquartile range (Figure 16), it confirmed 
that SAT in non-diabetic group is the only depot showing greater sensitivity to NA-
mediated vasoconstriction within the physiological range (10-8-10-7.5, p<0.05).  
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Data was expressed as median and interquartile range, which confirmed the depot- and disease-specific difference in NA-induced vasoconstriction, 
significant increase in vessel tension was only observed in SAT of non-diabetic group from 10-8-10-7.5 M compared to OAT of non-diabetic group and 
both depots of diabetic group. 
Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
Figure 16  Depot- and diabetes-specific difference in NA-mediated vasoconstriction (II) 
  87
To examine if other vasoconstrictor also elicits a similar depot-specific difference in 
response, U46619, a TXA2 mimic and a powerful vasoconstrictor, was tested in 
arterioles from tissue from the non-diabetic group. No difference in sensitivity to 
U46619 mediated vasoconstriction was apparent between SAT and OAT derived 
arterioles (Log EC50: SAT versus OAT, -6.3[1.0] versus -6.8[0.7], p=0.29, Figure 
17A). However, at supra-pharmacological doses OAT arterioles exhibited greater 
vasoconstriction (10-6-10-5.5M, p=0.02).      
Furthermore, in the comparison between U46619- and NA-mediated vasoconstriction in 
non-diabetic group, the vasoconstriction mediated by U46619 were significantly lower 
compared with those mediated by NA in SAT (10-8 M to 10-6.5 M, p<0.05, Figure 17B), 
while there were no such differences detected in OAT, which suggests an NA-specific 
vessel sensitivity in SAT of non-diabetics.                          
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A: No significant sensitivity difference was shown in U46619-mediated 
vasoconstriction between SAT and OAT, while maximal vessel tension was 
significantly higher in OAT compared with SAT in non-diabetic group (p=0.02). 
B: NA mediated vasoconstriction was significantly higher compared to that mediated by 
U46619 in SAT of non-diabetic group (10-8 M to 10-6.5 M, p<0.05). 
 
Figure 17 Vasoconstriction mediated by TXA2 mimic U46619 and comparison of 
vasoconstriction mediated by U46619 and NA in SAT of non-diabetics 
A 
B 
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3.3.4 Collagen deposition and gene expression 
In SAT of the non-diabetic group, low levels of collagen deposition were observed both 
surrounding the vessels and dispersed within the rest of the tissue (Figure 18Ai&ii), 
while OAT showed significantly higher collagen staining which was mostly near the 
vessels but also throughout the tissue (Figure 18Aiii&iv). Greater tissue fibrosis was 
observed in diabetic tissues. In SAT, collagen staining was observed around the vessels 
and widely dispersed within the tissue, which suggests tissue fibrosis and consequent 
vessel stiffness (Figure 18Av&vi). Similar results were also found in OAT of this 
group (Figure 18Avii&viii). This finding was confirmed by collagen pixel area analysis 
and gene expression data. SAT of non-diabetic subjects displayed the lowest collagen 
deposition compared to OAT of non-diabetic group and both depots of diabetic group 
(p<0.05, Figure 18B).  
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Collagen was stained as pink and elastin was stained as black. Representative images were selected to show the collagen deposition surrounding the 
vessels and within the rest area of the tissue. In non-diabetic group, SAT showed very low levels of collagen staining both within the vessel area(Ai) 
and the other part (Aii), while abundant collagen deposition was shown in OAT wrapping the vessels(Aiii) and in the rest part of the tissue (Aiv).  
More collagen deposition was observed in the diabetic compared to non-diabetic group. In SAT, it was not only around the vessels (Av) but also 
widely dispersed within the tissue (Avi). OAT showed the similar collagen distribution and comparable collagen quantity (Avii&viii). Collagen 
staining analysis showed the least collagen deposition in SAT of non-diabetic patients compared to OAT of non-diabetics and both depots in diabetes 
(B). Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
B 
Figure 18 Depot- and diabetes-specific difference in collagen deposition 
A B 
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Collagen gene type Iα1 expression also showed the same trend, with SAT of non-
diabetic patients having the lowest mRNA gene expression compared to OAT in non-
diabetic group and both depots in the diabetic group (Figure 19A).  
Significant elevation of collagen type Iα1 mRNA expression was observed in AT 
incubated with 1μM NA compared with the control [NA: 0.67(0.64-0.68) versus 
Control:  0.62(0.61-0.65), n=6, p=0.03, Figure 19B], which implicates a direct fibrotic 
effect of NA on AT.  
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Figure 19 Depot- and diabetes-specific differences of collagen mRNA expression and collagen 
gene up-regulated by NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collagen type 1α1 mRNA was less expressed in SAT of non-diabetic group compared 
to OAT and both depots in diabetics (A). Furthermore, AT collagen gene type Iα1 was 
upregulated by 1µM NE incubation (B) 
 Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
 
A 
B 
1µM NA 
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3.3.5 Adipocyte size and macrophage infiltration 
Adipocyte area was assessed by manually tracing the pixel area (Figure 20). Smaller 
adipocytes were observed in OAT compared to SAT in both groups, while adipocyte in 
SAT were bigger in diabetic than non-diabetic patients. Moreover, SAT and OAT of 
diabetic patients displayed larger adipocytes compared to those in non-diabetic patients 
(upon the dotted line), which suggests tissue hypertrophy 
In the non-diabetic subjects, OAT, compared to SAT, showed significantly smaller 
adipocytes (SAT: N=260, 2.7[1.8-3.9] x104 pixel2, OAT: N= 286, 2.1[1.5-3.1] x104 
pixel2, p<0.001).  
The SAT depot of diabetic patients had larger adipocytes compared to that of non-
diabetic patients (diabetic SAT: 3.1 [2.0-4.5] x104 pixel2 versus non-diabetic SAT: 
2.7[1.8-3.9] x104 pixel2, p=0.04). However, in the OAT these differences were not 
significant (diabetic OAT: 2.2 [1.3-3.2] x104 pixel2 versus non-diabetic OAT: 2.1[1.5-
3.1] x104 pixel2, p=0.9).   
Low levels of AT macrophage infiltration were observed in both SAT and OAT and 
there was no significant difference between the depots and groups (data not shown).    
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More smaller adipocytes were observed in OAT compared to SAT in both groups, while 
adipocytes in SAT were larger in diabetic than non-diabetic patients. Moreover, SAT 
and OAT of diabetic patients displayed more large adipocytes compared to those in 
non-diabetic (upon the dotted line), which suggest tissue hypertrophy.  
Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
 
 
 
Figure 20 Depot- and diabetes-specific difference in adipocyte number and size. 
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3.4 Discussion 
3.4.1 Local NA synthesis in AT 
In this study, the depot- and diabetes-specific differences in AT NA synthesis, NA-
mediated micro-vasoconstriction, collagen gene expression and deposition and 
adipocyte morphology were investigated. 
Adipocytes from rodents were recently shown to synthesize catecholamine [118].  In 
this study, TH, a key enzyme involved in NA synthesis, was found in the human AT, 
and specifically located surrounding the adipocytes, which suggested the capability of 
human AT to synthesize NA. It was still not clear whether the TH was derived from 
adipocytes, peripheral sympathetic nerves, macrophages or other components within the 
tissue. No significant depot-specific difference in macrophage infiltration, examined by 
CD68 staining, was seen between SAT and OAT in the non-diabetic group and TH 
density was analyzed by measuring the whole staining area. Thus the depot-specific 
difference of TH density may be not caused by a sole component difference within the 
tissue. Furthermore, NA was detectable in protein extracts from whole tissue but not in 
explant medium, these data suggest AT-derived NA is synthesized and stored within the 
tissue instead of being directly released into the circulation.  Thus, NA from AT may 
achieve its effect through autocrine/paracrine, rather than endocrine, mechanisms and 
microvasculature embedded in the AT might be directly affected by AT-derived NA. 
3.4.2 NA-mediated vasoconstriction 
In the non-diabetic group, there was a depot-specific difference in NA-mediated 
arteriolar vasoconstriction displayed as a more sensitive response in SAT compared to 
OAT at lower NA concentrations, however this difference was absent in diabetic obese 
patients. Meanwhile, TH density and local NA concentration were significantly lower in 
SAT than OAT in non-diabetics but were elevated and comparable in the depots in 
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Type II diabetes. These data imply that the vessel sensitivity to NA-mediated 
vasoconstriction was preserved only in SAT of non-diabetic patients, perhaps due to the 
low level of tissue NA content and synthesis, whereas the arterioles in the OAT of non-
diabetics and both depots of diabetic group were desensitized by long-term exposure to 
local chronic elevated NA concentration, which has been shown in other studies [157, 
158]. In addition, this phenomenon was only apparent in NA-mediated vasoconstriction, 
TXA2 is a potent vasoconstrictor synthesized by EC and adipocyte, in response to 
physiological concentration of TXA2 mimic U46619, no significant difference was 
observed between SAT and OAT in non-diabetic group, both depots showed weak but 
comparable vasoconstriction, which suggests that the sensitivity difference to NA 
between depots is specific.  A recent study demonstrated that arteriolar vasodilatation 
was impaired in AT of morbidly obese patient, while the current study showed that the 
vasoconstriction was also compromised. Both vasodilatation and vasoconstriction are 
involved in functional microcirculation, which is critical for maintaining the 
homeostasis of blood pressure and transporting oxygen to prevent tissue hypoxia. This 
finding has also been supported by the very recent study of AT blood flow [113]. After 
intravenous adrenaline infusion, there was a significant increase in microvascular 
volume of SAT in non-diabetic group while this response was abolished in diabetes, 
which could also be explained by the NA desensitization in SAT arterioles of diabetic 
patients.    
Insulin mediated capillary recruitment required functional vasoconstriction and 
vasodilatation to transport insulin from insulin-insensitive to insulin-sensitive organs. 
Evidence showed glucose-mediated vasodilatation was abolished via beta-adrenergic 
mechanisms [159]. Current data suggests that obese patients with diabetes also showed 
resistance to NA-mediated vasoconstriction. Thus, the abortion of microvascular tone 
may be an important risk factor of tissue hypoxia and insulin resistance. 
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3.4.3 AT collagen deposition and its effect on vasoreactivity and adipocyte 
morphology  
Tissue fibrosis could be another consequence of local NA elevation. Following NA 
increase in OAT of non-diabetic group and both depots of diabetic group, there was 
accordant increase of collagen deposition within these depots. This could be a 
consequence of local NA elevation, since evidence showed fibrotic response was up-
regulated by NA in several organs and vessels [133, 134]. Current data also suggests 
that collagen mRNA expression was elevated by NA incubation.  
In addition, AT hypoxia may also contribute to collagen deposition. AT incubated in 
HIF-1α displayed significant increase of collagen synthesis (reviewed in [39]). Thus, 
collagen deposition could be a hallmark of AT hypoxia and dysfunction. It is 
noteworthy that SAT in non-diabetics showed the lowest extent of fibrosis while OAT 
in non-diabetics and both depots of diabetic patients had elevated and comparable 
collagen deposition. This implies that SAT in non-diabetics may preserve its function 
and oxygenation, perhaps explained by its vascular sensitivity to NA. Higher collagen 
deposition surrounding adipocytes in OAT and diabetes may increase the mechanic 
stress and lead to adipocyte necrosis and inflammation. 
Transforming growth factor-β (TGF- β) could be another factor involved in vessel 
fibrosis. TGF- β is a multifunctional regulator involved in cell division, differentiation, 
migration, adhesion, organization and promoting ECM production [160]. There are 
three different TGF- β isoforms, TGF- β1, TGF- β 2 and TGF- β 3, among which TGF- 
β1 plays an important role in cardiovascular system. It has been found  in ECs, VSMCs, 
macrophages, myofibroblasts and other hematopoietic cells [161]. In ECs, VSMCs and 
fibroblasts, TGF- β enhances α-smooth muscle actin and collagen type I expression via 
mediating ED-A fibronectin expression. In addition, TGF- β decreases collagenase 
production and stimulates the expression of tissue inhibitor of metalloproteinases 
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(TIMP), further exaggerates tissue fibrosis [162] . Previous study in mice showed, in 
response to high-fat diet, there was an up-regulation of TGF- β protein expression in 
both aorta and AT, which was associated with increased vessel stiffness [163]. Human 
TGF- β expression and secretion levels were higher in AT of morbidly obese patients 
compared with lean control [164]. Further study is required to identify the depot- and 
diabetes-specific difference in AT TGF- β levels as well as its effect on local collagen 
deposition. 
The abundant collagen surrounding the vessels in the tissue might restrict the 
vasoreactivity. In addition, collagen type 1α1 was highly expressed in OAT of non-
diabetic patients and in diabetes. Collagen type 1 was the major component of vessel 
wall by synthesizing cross-banded fibrils, which provided tensile strength [131]. 
Increased collagen in vessel wall may greatly increase vessel stiffness and decrease 
vessel sensitivity, but it may also explain why there was a maximal tension difference 
between SAT and OAT in non-diabetic group.    
3.4.4  Conclusion  
Thus SAT in non-diabetic obese patients preserved its adrenergic sensitivity to NA-
mediated vasoconstriction due to low levels of local NA synthesis, meanwhile the lower 
collagen deposition also meant the vascular structure is less restricted. However, the 
high levels of NA in OAT and diabetes may lead to a vessel desensitization and 
elevated collagen deposition. 
 3.4.5 Study limitations. 
During this study, AT was collected from morbidly obese patients under variety of 
treatments. While all the medication has been documented (mentioned in the text), the 
experimental interference could not be excluded.  Also most of the patients were female, 
the gender effect on the results still needs to be investigated.  
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Chapter 4  
Depot- and diabetes-specific differences in abdominal 
AT angiogenesis 
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4.1 Introduction 
4.1.1 The importance of AT angiogenesis.  
Angiogenesis is crucial to AT growth and remodelling. The adipose plasticity is 
dependent on constant alterations of numbers and functions of microvasculature to 
support and regulate AT metabolism [31]. Sufficient and functional vascular network 
ensures the delivery of oxygen, insulin and other nutrients to the tissue, thus 
maintaining AT normoxia and functions. In morbidly obese patients, capillary 
rarefaction (low capillary density) has been reported to be associated with AT hypoxia 
and insulin resistance [38].  
4.1.2 Depot-specific difference of AT angiogenesis 
Central obesity is the abdominal AT expansion including SAT and OAT. The depot-
specific difference of angiogenesis between SAT and OAT may directly determine the 
abdominal fat distribution. The angiogenic difference between SAT and OAT has been 
investigated mainly in three studies, but the results were conflicting. A human AT 
endothelium study showed that angiogenesis-related genes were more highly expressed 
in ECs in OAT compared to SAT [37]. However, AT angiogenesis study in vitro 
showed different results. The SAT explant incubated in Matrigel displayed higher 
capillary density and angiogenic capacity than OAT [69]. In addition, the third study 
concluded that there was no significant difference of capillary density between SAT and 
OAT after normalizing the capillary number to the adipocyte number [70].     
4.1.3 Regulation of AT angiogenesis   
AT angiogenesis is regulated by a series of factors, among which NRP-1 plays an 
important role as a co-receptor for VEGF receptors. In rat white AT, NRP-1 was found 
mainly in VSMC and ECs of arteries, but adipocytes also showed to be NRP-1 positive 
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[59]. This finding was confirmed in the human fatty bone marrow. Higher NRP-1 
expression was detected in adipocytes in contrast to hematopoietic and stromal cells 
[60]. However, the expression of NRP-1 in human AT depots and in diabetes has not 
been reported.  
4.1.4 Aims 
This study aimed to investigate the depot- and diabetes-specific differences of 
angiogenesis and angiogenesis-related gene expression between SAT and OAT in non-
diabetic and diabetic obese patients.  
 
4.2 Methods 
Morbidly obese patients were recruited and characterised as described in Section 2.1. 
SAT was dissected from abdominal area using forceps and scissors, OAT was dissected 
from intra-abdominal greater omentum using endoscopic linear cutter.    
Capillaries were stained by lectin tetramethylrhodamine isothiocyanate conjugate (from 
Ulex europaeus [UAE], Sigma-Aldrich) then the capillary density was calculated 
(described in Section 2.3.1).  
Sections were immunostained for EC markers, CD31 and CD34 (method described in 
Section 2.3.3). 
Angiogenic capacity was estimated by AT explant incubated in Matrigel. Briefly, SAT 
and OAT was cut into ≈ 1 mm3 pieces and embedded into individual wells of 96-well 
plates with 50 μl growth factor reduced Matrigel (BD Bioscience, UK). Each well was 
filled with 200μl EGM2-MV medium (Lonza, UK), and half of the medium was 
replaced every other day [69]. Incubation ended at day 10 and photographs were 
captured at 40x magnification using Nikon TMS microscope and ProgResC14 software 
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(resolution 1300x1030). For each sample, pictures were captured with five sections 
(whole tissue, up, down, left and right). Image information was then analysed using 
ImageJ. The pixel area covered by neovasculature was traced manually and adjusted by 
AT area (RV/A). Data was also analysed by particle measurement. Background of image 
was filtered and capillaries were isolated by ImageJ threshold function. Then capillary 
quantity was estimated by particle measurement function.  
Angiogenic gene regulation was performed using the commercially available RT2 
Profiler PCR array for human angiogenesis (PAHS-024; Qiagen, UK). Total RNA 
isolated from SAT and OAT of non-diabetic and diabetic patients (n=8) were used in 
these studies (total RNA extraction was described in Section 2.4.1). Briefly, 400ng total 
RNA was mixed with Genomic DNA Elimination Mixture first to avoid the 
contamination from any residual genomic DNA contamination in RNA samples before 
it can be amplified into secondary products that would otherwise cause false positive 
signals (400ng total RNA / 10μl mixture, incubate at 42oC for 5 minutes, then on ice for 
at least 1 minute). Reverse transcription was carried out by mixing 10μl decontaminated 
sample with 10μl  reverse transcription mixture (each 10μl contains 4μl Reverse 
Transcription Buffer, 1μl Primer and External Control Mix, 2μl Reverse Transcriptase 
Mix and 3μl RNase-free water, incubate at 42°C for exactly 15 min. Then immediately 
stop the reaction by incubating at 95°C for 5 min). Finally, samples were diluted in 
RNase-free water, mixed with RT2 SYBR Green Mastermix prior to proceeding with 
real-time PCR. The 384-well microarray plate (96x4) contains 4 replicate primer assays 
for each of 84 pathway- or disease-focused genes and 4 replicate primer assays for each 
of 5 housekeeping genes. In addition, 4 wells contain genomic DNA controls, 12 wells 
contain reverse-transcription controls, and 12 wells contain positive PCR controls. 
Finally, data was formatted and analysed using web-based analysis software of Qiagen 
(www.SABiosciences.com/pcarraydataanalysis.php). Adjusted data was expressed as 
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the fold changes of mRNA expression between target group and control group as 
specified.    
 The mRNA expressions of NRP-1 were determined by real-time RT-PCR. β-actin was 
chosen as the house-keeping gene. Data was expressed as the ratio of NRP-1 Ct/β-actin 
Ct (described in Section 2.4). NRP-1 protein levels were investigated using western blot, 
the method and analysis was described in Section 2.5. Data was expressed as the ratio 
of NRP-1 / β-actin grey density. 
Plasma glucose concentration, serum insulin levels, serum triglycerides, total, low 
density lipoprotein (LDL-) and high density lipoprotein (HDL-) cholesterol were 
assayed as described in Section 2.7. Insulin resistance was calculated using the HOMA 
where HOMA = (glucose in mmol/L × insulin in mIU/L)/22.5 [144]. 
Data were analysed using SPSS version 14 for Windows (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK). Normality of distributions was tested 
with the Kolmogorov-Smirnov test. Data are shown as mean (±SD), or for non-normally 
distributed data as median (interquartile range), in text and in tables. Comparison of 
depots was by paired t-tests or by Wilcoxon test. Pearson or Spearman rank correlations 
were used for the bivariate analysis. Significance was defined as p≤0.05. 
4.3 Results 
4.3.1 Patients’characteristics 
Patient characteristics are shown in Table 2 (n=60, 85% female). No significant 
differences were found between the two groups for most parameters except that in 
diabetic group fasting plasma glucose level is significantly higher (p<0.001) despite 
treatment (thiazolidinediones: 3/20; metformin: 14/20). The other medications were 
shown on Table 3. 
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Table 2 Patients' characteristics 
Data shown as mean (SD) or median (interquartile range); BMI: boday mass index, SBP, 
systolic blood pressure, DBP, diastolic blood pressure;  MABP: mean arterial blood 
pressure; FPG, fasting flasma glucose, Total-, LDL-, HDL-chol, Total-, LDL-, HDL-
cholesterol; TG: triglycerides; HOMA-IR, homeostasis model assessment of insulin 
resistance; Se.adipo, serum adiponectin; Se.IL-6, serum interleukin-6, Se.MCP-1, serum 
monocyte chemoattractant protein-1. 
Variables  Non-diabetic(n=40) Diabetic(n=20) P value 
Age 47.1±8.9 48.9±7.9 0.24 
BMI (kg.m-2) 46.2±8.3 45.0±6.8 0.84 
SBP (mmHg) 138.4±23.1 132.8±19.0 0.50 
DBP(mmHg) 77.4±12.2 77.2±10.7 0.77 
MABP (mmHg) 97.7±14.0 95.7±11.9 0.73 
Total-chol (mmol/L) 4.3±1.4 3.7±1.1 0.10 
LDL-chol (mmol/L) 2.5±1.3 2.0±1.0 0.12 
HDL-chol (mmol/L) 1.0±0.2 1.0±0.2 0.52 
TG(mmol/L) 1.5(1.2-2.4) 1.1(0.9-2.3) 0.09 
FPG (mmol/L) 5.2±1.1 7.7±3.2 <0.001 
Insulin (mIU/L) 8.6(6.0-20.3) 7.1(4.9-19.0) 0.61 
HOMA 1.8(1.5-4.5) 2.4(1.3-5.9) 0.61 
Se.adipo (g/ml) 4.2(2.5-7.2) 5.5(3.7-9.6) 0.06 
Se.MCP-1 (pg/ml) 272.3(178.0-424.7) 252.3(176.4-336.0) 0.59 
Se.IL-6 (pg/ml) 2.4(1.5-4.2) 1.9((1.3-3.0) 0.08 
Se.Leptin (ng/ml) 40.2(25.2-51.7) 33.8(23.8-58.7) 0.83 
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Table 3 Medication regimen in non-diabetic and diabetic group. 
Medication Non-diabetic group 
(n=40) 
Diabetic group 
(n=20) 
Statins 3/40 8/20 
Angiotensin converting enzyme 5/40 7/20 
Angiotensin-2 receptor antagonists 0/40 2/20 
Aspirin 1/40 3/20 
Selective serotonin reuptake inhibitor 8/40 4/20 
Tricyclic antidepressant 5/40 1/20 
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4.3.2 Capillary and EC density  
In the non-diabetic group, SAT showed significantly less capillary numbers compared 
to OAT (p=0.01, Figure 21Ai&ii), while in the diabetic patients, no significant depot-
specific difference in capillary numbers was observed (Figure 21Aiii&iv). Furthermore, 
there was an elevation in capillary numbers in SAT in diabetics compared to non-
diabetics (p=0.05, Figure 21Ai&iii).  
The finding was confirmed by manually counting the capillary numbers in each section, 
result shown in Figure 21B.   
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Capillary density is significantly lower in SAT (Ai) than OAT (Aii) in non-diabetic 
group, while no significant depot-specific difference was observed in diabetic group, 
SAT (Aiii) and OAT (Aiv) showed elevated but comparable numbers of capillaries. 
Nonparametric comparison showed SAT in non-diabetic group has the lowest numbers 
of capillaries compared to OAT and diabetics (B).   
Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
i.  ii
iii iv 
A
B 
Figure 21 Depot- and diabetes-specific difference in capillary density 
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Endothelial immunostaining with CD31/CD34 confirmed there was greater number of 
ECs in the OAT compared with SAT in non-diabetic patients (CD31, Figure 22 A&B; 
CD34, Figure 22 C&D). Furthermore, in non-diabetic group, capillary numbers also 
correlated significantly with both serum adiponectin (SAT: r=0.38, p=0.002; OAT: 
r=0.44, p=0.008) and serum MCP-1 concentrations (SAT: r=0.51, p=0.002; OAT: 
r=0.53, p=0.001). These adipokines have previously been shown to induce angiogenesis 
[165, 166].  
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The depot-specific difference was confirmed by CD31/CD34 staining. In non-diabetic 
group, SAT (A&C) showed less EC staining compared with OAT (B&D). 
 
 
 
 
 
D. CD34 
A. CD31 B. CD31 
C. CD34 
Figure 22 Depot- specific difference in EC quantity by CD31/CD34 staining 
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4.3.3 Angiogenic capacity 
In the non-diabetic group, significant depot difference of RV/A was found between SAT 
and OAT. More capillaries were observed in OAT compared to SAT (SAT: 8.5(8.0-9.5) 
versus OAT: 12.9(8.4-18.9), p=0.03, Figure 23Ai&ii, B). Furthermore, diabetic 
patients displayed higher RV/A in SAT compared to non-diabetics (Non-diabetic SAT: 
8.5(8.0-9.5) versus diabetic SAT: 11.5(10.8-11.4), p=0.004, Figure 23Ai&iii, B). 
However, no significant depot difference was found in the diabetic group.  
Capillary quantification by particle measurement confirmed the diabetes-specific 
difference in SAT, which also exhibited the higher capillary quantity in SAT of diabetic 
group than non-diabetic group.  
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Figure 23 Depot- and diabetes-specific difference in angiogenic capacity 
 
 
 
 
 
 
 
 
 
 
 
In non-diabetic group, SAT (Ai) incubated in matrigel showed less neovasculature expansion compared to OAT (Aii), while no significant depot-
specific difference was observed in comparison between SAT (Aiii) and OAT (Aiv) in diabetic group. Furthermore, SAT in diabetic group showed 
significantly higher angiogenic capacity compared to that in non-diabetic group. This finding was confirmed by nonparametric test that SAT in non-
diabetic group showed the lowest angiogenesis compared to OAT and diabetics (B). Non-DM: non-diabetic obese patients; DM: diabetic obese patients. 
i. Non-DM 
SAT 
iii. DM 
SAT 
ii. Non-DM 
OAT 
iv. DM 
OAT 
A B 
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4.3.4 Depot- and diabetes-specific expression of genes regulating angiogenesis  
The association between the observed depot- and diabetes-specific differences in 
capillary density and the expression of genes considered essential to angiogenesis were 
investigated.  
A comparison of the two depots revealed that, in the non-diabetics, among the 84 genes 
tested, 11, mainly angiogenic genes, were significantly up-regulated while 5 were 
down-regulated by > 2-fold in OAT compared to SAT. However, in the diabetic patients, 
only 7 out of the 11 genes were up-regulated and 9 were down-regulated in the OAT 
compared to SAT (Fugure 24A). 
Assessment of the effect of diabetes on gene expression in the two depots showed 
greater number of genes upregulated in the SAT of diabetic, compared to the non-
diabetic tissue (Figure 24B), especially those of epidermal growth factor (EGF) and 
NRP-1. However, in the OAT only 4 genes that were mainly chemokines/cytokines 
were upregulated in the diabetic compared to the non-diabetic tissue, while 3 others 
were lower in the OAT of diabetics compared to the non-diabetics (Figure 24C).  
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A: In non-diabetic group, most of angiogenic genes were up-regulated in OAT (n=11) 
compared to SAT (n=5), while diabetic patients showed comparable numbers of gene 
expression in SAT (n=9) and OAT (n=7).  
A 
B C 
Figure 24 Depot- and diabetes-specific differences in AT angiogenesis-related gene expression 
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B: in the comparison between non-diabetic and diabetic group, all gene expression was 
up-regulated in SAT in diabetes, while no significant diabetes-specific difference was 
found in OAT.  
Non-DM: non-diabetic obese patients; DM: diabetic obese patients; VEGFC: vascular 
endothelial growth factor C;  TIMP: TIMP metallopeptidase inhibitor; PTGS1: 
prostaglandin-endoperoxide synthase 1; PLG: plasminogen; MMP9: matrix 
metallopeptidase 9; IFNA1: interferon, alpha 1; HAND2: heart and neural crest 
derivatives expressed 2; FGFR3: fibroblast growth factor receptor 3; FGF1: fibroblast 
growth factor 1 (acidic); EFNA3: ephrin-A3; TYMP: thymidine phosphorylase; CXCL: 
chemokine (C-X-C motif) ligand; CCL: chemokine (C-C motif) ligand; ANPEP: alanyl 
(membrane) aminopeptidase; TNFAIP2: tumor necrosis factor, alpha-induced protein 2; 
TGFB1: transforming growth factor, beta 1; PF4: platelet factor 4; PECAM1: 
platelet/endothelial cell adhesion molecule; LECT1: leukocyte cell derived chemotaxin 
1; IFNG: interferon, gamma; IFNB1: interferon, beta 1, fibroblast; IFNA1: interferon, 
alpha 1; FIGF: C-fos induced growth factor (vascular endothelial growth factor D); 
EGF: epidermal growth factor; COL4A3: collagen, type IV, alpha 3; NOTCH4: notch 4; 
ANGPIL3: angiopoietin-like 3. 
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4.3.5 NRP protein levels in AT 
Because NRP-1, a potent mediator of angiogenesis, showed the greatest alteration 
amongst the genes modulated by diabetes in the SAT, this was further investigated at 
the protein level. 
In this study, two isoforms of NRP-1 were found in human AT. The expression of 
primary bands (~130 kDa) was relatively lower compared with the secondary ones 
(>200 kDa), but it was interesting to see that, in the non-diabetic group, more primary 
bands were observed in OAT (n=5) than SAT (n=1). Furthermore, the protein 
expression of the primary band was elevated in both SAT and OAT in diabetic patients 
versus non-diabetics. The secondary band, with a molecular weight of >200 kDa 
showed to be more highly expressed in OAT than SAT in both non-diabetic and 
diabetic groups. (Figure 25).     
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Western blot showed 2 isoforms of NRP-1, larger bands with higher molecular weight 
(>200kDa) were more highly expressed in OAT compared to SAT in both non-diabetic 
and diabetic group, while smaller bands with lower molecular weight (~130 kDa) were 
up-regulated in diabetic compared to non-diabetic group (A). Data was analysed by 
Image J and expressed as grey density ratio between NRP-1 and β-actin (B). 
Non-DM: non-diabetic obese patients; DM: diabetic obese patients; HMW: high 
molecular weight.  
 
Figure 25 NRP-1 protein levels between depots and in diabetes. 
A 
B 
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4.4 Discussion 
4.4.1 Paradox between high angiogenesis and inflammation in OAT  
This study investigated the depot- and diabetes-specific differences in human AT 
capillary density, angiogenic capacity and angiogenesis-related gene expression. AT 
angiogenesis has been shown to be beneficial in rodent samples, sufficient angiogenesis 
may prevent tissue hypoxia and reverse insulin resistance [51]. In this study, non-
diabetic obese patients showed greater capillary numbers and angiogenic capacity in 
OAT than SAT. Meanwhile, most of angiogenic genes were upregulated in OAT versus 
SAT. However, paradoxically OAT still displayed more inflammatory and hypoxic 
micro-environment [37], which perhaps indicates that increased capillary numbers and 
angiogenesis are not efficient to counter the local AT hypoxia. This could be attributed 
to the vascular tone dysfunction, since convincing data demonstrated that the 
vasodilation was impaired in OAT but preserved in SAT [140]. In addition, data in 
Chapter 3 suggests vasoconstriction was also compromised due to the NA 
desensitization. Vascular tone dysfunction may directly restrict local AT blood flow and 
contribute to the local hypoxic environment.   
4.4.2 Angiogenesis was upregulated in obese patients with Type II diabetes  
There was also elevation of capillary number and angiogenic capacity in SAT of 
diabetic compared to non-diabetic subjects. The effect of hyperglycemia and diabetes on 
angiogenesis is conflicting. In retinopathy, nephropathy, and antherosclerotic plaque, 
there was excessive angiogenesis, while the neovascularisation was decreased in wound 
healing and myocardial perfusion [167]. In this study, SAT vessels in the diabetic group 
was more angiogenic compared to that of non-diabetics, and the microarray data 
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suggests this increase could be caused by the elevation of a series of angiogenic factors, 
including VEGF and NRP-1.  
The investigation of NRP-1 protein expression in AT showed a new high molecular 
weight isoform of this molecule. This could be the NRP-1extracellular domain modified 
by addition of chondroitin sulfate-glycosaminoglycan (CS-GAG) moiety at Ser612 in the 
protein backbone. CS-GAG-linked NRP-1 has been found in HCASMC and some 
tumour cells [54], while its effect in AT needs further investigation.  
Full-length non-GAG NRP-1 was found to be up-regulated in both depots in diabetics 
compared to the non-diabetics. Data from human epithelial ovarian carcinoma cells 
showed absence of NRP-1 after 48hr incubation in glucose free medium, suggesting 
NRP-1 protein expression is glucose dependent [168]. The elevation of NRP-1 in 
diabetes could be a consequence of hyperglycemia. Also, increased NRP-1 protein 
expression may, at least partly, explain the higher angiogenic capacity and capillary 
density in OAT and diabetes.   
4.4.3 Technical limitations  
In neovasculature measurement, two different methods were used to identify the 
capillary quantity in each depot. Both of them showed a significant difference in SAT 
between non-diabetic and diabetic individuals, but only area measurement showed a 
depot-specific difference. This could be due to the limitation of the threshold function, 
which may exclude part of the vessels along with the background and loss of sensitivity 
to detect the depot difference. Furthermore, this chapter displayed two types of 
capillaries, one is the pre-existing capillary within AT stained by UEA, the other is the 
neovasculature sprout from AT. However, the maturation of vasculature includes the 
EC tube structure formation and VSMC recruitment, current data can not identify the 
association between these two types of vessels, future study needs to focus on the 
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vascular morphogenesis, also EC and SMC markers may be required to fully identify 
the components of neovasculature.      
The microarray was used for the identification of depot- and diabetes-specific difference 
in AT angiogenesis-related gene expression. It showed a series of mRNA expression 
involved in AT angiogenesis, and the sensitivity is reliable, which has been confirmed 
by western blot. However, the expense of the microarray plates and related reagents 
may restrict its utilization in studies with larger sample sizes.    
NRP-1 was selected to validate the microarray and two isoforms were observed. 
Although previous study proved that the high molecular weight band is a glycosylated 
form of NRP-1, we did not confirm that in AT due to the technical limitations. Future 
study is required to fully investigate the different isoforms of NRP-1 as well as how to 
inhibit the glycosylation of NRP-1 in AT.       
4.4.4 Conclusions 
Adipose capillary density and angiogenic capacity are lower in SAT in non-diabetic 
obese patients compared with OAT and diabetics, but AT function is preserved in these 
vessels as seen by its normal vascular tone (described in Chapter 3). The 
overexpression of a series of angiogenesis-related genes may explain the higher 
angiogenesis in OAT and in diabetes, perhaps a consequence of local inflammation and 
hypoxia.    
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Chapter 5  
The protective effect of PVAT and endothelium-
derived adiponectin 
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5.1 Introduction 
Blood vessels comprise three distinct layers, the intima, media and the outermost layer, 
the adventitia, that within medium to large vessels, are surrounded by a cushion of 
PVAT. PVAT comprises discrete adipocytes containing a network of capillaries and 
nerve fibres as well as a variety of other cell types. Leptin and adiponectin, as two of the 
most abundant adipokines in the circulation, are critical in the development of metabolic 
disorders and cardiovascular diseases. High levels of leptin and low levels of 
adiponectin are associated with adverse cardiovascular events [169]. Recent studies 
have described the endothelium-dependent vasodilatory effects of adiponectin and 
leptin [88, 170]. PVAT is considered a major source of vasoactive adipokines and, since 
no fascia separates this fat depot from the vessel adventitia, it facilitates the access of 
PVAT-derived adipokines to the vessel wall [103]. Recently, adiponectin has been 
shown to be expressed and secreted by human renal tubular epithelial cells [171], 
suggesting that adiponectin may not be produced by adipocytes solely. In addition, 
significant levels of adiponectin have been found in injured vascular walls [172], 
implicating a vascular source of adiponectin production. Apart from PVAT-derived 
adiponectin, vascular and endothelial sources have not been fully investigated.  
To test the hypothesize that human vasculature and endothelium are associated with 
adipokine production independent of PVAT both adiponectin and leptin levels were 
measured in:  
1) Saphenous vein (SV) and the internal thoracic artery (ITA) dissected free of 
surrounding PVAT.  
2) Isolated PVAT removed from SV and ITA.   
3) Local subcutaneous adipose depots (SAT, SV=calf/thigh; ITA = sternum). 
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Adiponectin and leptin mRNA expression was also determined in cultured human 
coronary artery endothelial cells (HCAECs) and umbilical vein endothelial cells 
(HUVECs). 
5.2 Methods 
Patients undergoing CABG were recruited from Orebro University Hospital, Sweeden. 
SV and ITA samples (n=6) were obtained at surgery with PVAT being isolated from 
graft material. In addition, ‘local’ subcutaneous fat (SV=calf/thigh; ITA = sternum) was 
collected (~0.05g). A separate segment of vessel with PVAT intact was also removed 
for subsequent immunohistochemistry. All samples were then transferred to UK and 
stored at -80oC until use. The study was approved by local ethical committee and 
patients gave written informed consent. 
Total protein was extracted from vessels, PVAT, and SAT, and the total protein 
concentration was estimated using BCA protein Assay (described in Section 2.5.1). 
Adiponectin and leptin levels were measured by commercially available two-site 
ELISAs (described in Section 2.2.2). Final adipokine concentration was adjusted for 
total protein concentration.  
Total RNA was extracted from HUVECs and HCAECs (cell culture described in 
Section 2.2.1). The mRNA expressions of adiponectin and leptin were determined by 
real-time PCR (described in Section 2.4). β-actin was selected as house-keeping gene. 
Data was expressed as a ratio of target gene Ct / β-actin Ct. 
Data were analysed using SPSS version 14 for Windows (Statistical Package for the 
Social Sciences, SPSS UK Ltd, Chertsey, UK). Data are shown as mean (SEM), or for 
mRNA expression data as median (interquartile range), in text and in figures. 
Comparison of mRNA expression data was by Mann-Whitney test. Significance was 
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defined as p≤0.05. 
5.3 Results 
5.3.1 Tissue levels of adiponectin and leptin 
As shown in Figure 26, Leptin (A) and adiponectin (B) levels measured by ELISA in 
isolated vessels (V); perivascular adipose tissue (PVAT) and subcutaneous adipose 
tissue (SAT) of SV (vein) and ITA (artery). 
 In the ITA, there were low levels of leptin both in the vessels and the surrounding 
PVAT when compared to the local SAT (vessel: 0.08(0.02), PVAT: 0.13(0.04) versus 
local SAT 0.59(0.23), pg/μg total protein). Isolated SV samples showed similar low 
leptin levels with detectable concentrations in the surrounding PVAT (vessel: 019(0.15), 
PVAT: 0.27(0.09) versus local SAT 0.72(0.25), pg/μg total protein, Figure 26A).  
Interestingly, while the vessel and PVAT adiponectin levels were similar, both were 
higher when compared to SAT (ITA vessel: 0.36(0.14) versus local SAT: 0.31 (0.15); 
SV vessel: 0.29(0.04) versus local SAT: 0.20(0.07), ng/ μg total protein, Figure 26B). 
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Leptin (A) and adiponectin (B) levels measured by ELISA in isolated vessels (V); 
perivascular adipose tissue (PVAT) and subcutaneous adipose tissue (SAT) of SV and 
ITA. Significant differences are apparent for the SAT compared to either V or PVAT 
for leptin. No significant differences between V, PVAT or SAT was seen for 
adiponectin. 
A 
B 
Figure 26 Adipokine levels of vessels, PVAT and SAT 
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5.3.2 Adiponectin and leptin in PVAT and endothelium 
A more pronounced cushion of PVAT was observed surrounding the SV than the ITA. 
Apart from adipocytes the ITA was encapsulated in connective tissue, muscle and 
brown adipose tissue. (Figure 27).  
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Transverse, H&E-stained sections of SV and ITA at low (left) and high (right) 
magnification, * indicates the region of left panels shown at higher magnification on the 
right. Scale bar = 2mm for left and 0.5 mm for right panels. 
 
 
 
 
Figure 27 Vessel and PVAT morphology. 
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Furthermore, both adiponectin and leptin staining was abundant surrounding adipocyte 
in PVAT from SV and ITA (Figure 28A&B), which again suggests a protective, anti-
contractile effect of PVAT in maintenance of normal vascular function as described in 
previous study [173]. 
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A: PVAT adiponectin staining;  
B: PVAT leptin staining;  
C: Negative control. 
 
 
 
 
A: Adiponectin B: Leptin 
C: Negative control 
Figure 28 Adiponectin and leptin staining in PVAT 
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Although there was no adiponectin immunostaining in either vessel wall, discrete 
staining was associated with endothelial cells lining the lumen of both the artery and the 
vein as well as those of the vasa vasorum and capillaries embedded in PVAT (Figure 
29A&B), while no evidence of leptin staining was found associated with endothelial 
cells lining the vessel lumen (Figure 29C), the vasa vasorum or capillaries (not shown). 
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A: SV endothelial adiponectin staining;  
B: Endothelium identified using CD31;  
C: No endothelial leptin staining;  
D: Negative control. 
 
 
 
 
C: Leptin D: Negative control 
A: Adiponectin B: CD31 
Figure 29 Adiponectin and leptin staining in SV endothelium 
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5.3.3 Adiponectin and leptin mRNA expression in ECs  
Adiponectin mRNA expression is abundant in both HCAECs and HUVECs, while no 
leptin mRNA expression was detectable. Furthermore, the adiponectin expression is 
significantly higher in HCAECs than HUVECs (Ct ratio, artery: 0.59(0.59-0.60) versus 
vein 0.54(0.53-0.55), p=0.03, Figure 30).  
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Adiponectin mRNA expression is abundant in both HCAECs and HUVECs, and it is 
more highly expressed in artery compared to the vein (p<0.05). Data expressed as Ct 
ration  between β-actin and adiponectin.  
 
 
 
 
 
Figure 30 Artery/vein difference of adiponectin mRNA expression in ECs 
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5.4 Discussion 
The main finding of this chapter is the first identification of endothelial adiponectin 
expression in human vessels used as bypass grafts in patients undergoing CABG. This 
source of adiponectin expression and production is independent of PVAT.  
The interplay between AT and the vasculature has been the focus of a number of studies. 
Both AT-derived SVF and adipocytes can induce angiogenesis and alterations in vessel 
structure, suggesting adipocytes and vascular cells may share the same progenitor [46]. 
Furthermore, a preadipocyte marker has been detected in ECs, implicating the 
endothelial origin of certain adipocytes [47]. This data suggests that ECs may 
differentiate from adipocyte progenitors and display a similar secretory ability to 
adipocytes in terms of adiponectin production, while the leptin secretion was 
diminished, a finding supported by the recent study showing adiponectin expression in 
mouse aortic endothelial cells [174].  
The mechanisms associated with adiponectin production from the endothelium are 
unclear, although data showing that EC adiponectin mRNA expression is elevated in 
cells exposed to supra-physiological levels of insulin was obtained (data not shown). 
Since circulating adiponectin levels show a positive correlation with insulin sensitivity 
[175], this data implies that adiponectin production in the endothelium may be also 
influenced by the metabolic status of the patients.  
Although the effects of endothelium-derived adiponectin are unknown, adiponectin is 
generally accepted as a protective molecule with anti-inflammatory, anti-diabetic and 
anti-atherogenic effects [176]. In addition, adiponectin is a vasodilator inducing 
vasorelaxation by elevating eNOS bioavailability and enhancing NO production [74]. 
Abundant adiponectin was shown in the endothelium and PVAT in this study. In 
conventional CABG preparations the SV graft is stripped of PVAT, leading to a loss of 
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PVAT-derived adiponectin as well as a potential reduction of endothelial sources. It has 
been reported that SVs harvested by the ‘no-touch’ technique, with intact PVAT and 
endothelium, provide superior grafts compared with those prepared by conventional 
CABG [177]. This improvement may be, at least in part, due to the protective effects of 
adiponectin in the intact PVAT and endothelium. Moreover, the higher adiponectin 
mRNA expression in the HCAECs may explain the arterial superiority as a bypass graft 
[178].  
Although the current study did not reveal the functional importance of endothelium-
derived adiponectin, previous data from rabbits demonstrated that local adiponectin 
elevation in intima significantly suppressed mRNA expression of atherosclerotic 
adhesion molecules and reduced atherosclerotic plaque area in vivo. Furthermore, 
adiponectin transferred from adventitia showed a similar effect, which implicates 
luminal (endothelium-derived) and exogenous (PVAT-derived) adiponectin may 
equally contribute to preventing atherosclerosis in cardiovascular system [179]. Future 
investigation is required to determine whether endothelial adiponectin concentrations 
can be up-regulated and contribute to either the atheroprotective and/or vasodilatory 
capacities of grafted vessels.  
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Chapter. 6  
Discussion and conclusion 
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6.1 Heterogeneity of the patients 
The initial aim of this thesis was to identify the AT metabolic and secretory features of 
MHO individuals, thus individuals recruited in this thesis were all morbidly obese with 
significant AT expansion. Previous studies compared obese with lean individuals and 
showed a series of obesity-related dysfunctions due to the excess AT deposition [180-
183]. However, there are no significant metabolic differences between MHO and lean 
healthy individuals, which cannot be explained by the AT expansion. Thus, AT 
dysfunction, rather than fat mass per se, may contribute to metabolic disorders in 
obesity. Comparison between different subtypes of morbidly obese patients may be 
more important to reveal the mechanisms behind MHO individuals, rather than 
comparing obese and lean phenotypes. Additionally, the advantage of this patient cohort 
is a good homogeneity in most other parameters between the two groups, which 
facilitates the investigation of the AT- and diabetes- specific differences between groups.  
Nevertheless, the limitation of this patient cohort is the lack of healthy, insulin-sensitive, 
control individuals. Although data showed SAT in non-diabetic obese patients has 
greater NA sensitivity, lower levels of NA synthesis, collagen deposition and 
angiogenesis compared to OAT and diabetes, it is still not clear whether healthy 
individuals display similar vascular features.  
6.2 Adrenergic effect on AT glucose/lip metabolism and blood flow   
In Chapter 3, the adrenergic effect on AT vasoconstriction was investigated. The major 
finding is the vessel desensitization in OAT and diabetes caused by local chronic NA 
elevation. Sympathetic nerves innervate AT and the nerve ending reaches the adipocyte 
and vasculature [154, 184]. Thus, the local NA synthesis and release in AT facilitate a 
direct adrenergic regulation of AT metabolism and vasculature via paracrine and 
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autocrine, rather than endocrine signals. Furthermore, under adrenergic regulation, there 
is close interplay between glucose/lipid metabolism, vascular tone and AT blood flow 
(ATBF), which is discussed below. 
6.2.1 Glucose and lipid 
In lean, insulin sensitive individuals, in response to oral glucose ingestion, there was 
catecholamine elevation concomitant with vasodilatation and elevated ATBF [185]. 
This effect was abolished by β-adrenoceptor antagonist [159], which implicates the 
adrenergic regulation in glucose-mediated AT vasodilatation. However, glucose-
mediated vasodilatation was impaired in glucose-intolerant individuals even at the very 
early stages [186]. Additionally, an in vivo human study showed that AT glucose uptake 
in non-diabetic obese individuals was elevated after the stimulation of α1 adrenoceptor, 
independent of insulin, while this effect was also abolished in obese patients with 
insulin resistance [187, 188]. Thus, vascular tone regulated by NA may play a role in 
AT glucose metabolism, while compromised vasodilatation and desensitized 
vasoconstriction may be important factors leading to hyperglycaemia.    
The lipolytic effect of the sympathetic nervous system in AT has been extensively 
investigated (reviewed in [154] ). Catecholamine-mediated AT lipolysis is dependent on 
the balance between lipolysis stimulated by the β2 adrenoceptor activation and anti-
lipolytic effect of α2 adrenoceptor activation [189].  A recent study compared SAT 
lipolysis induced by NA in overweight non-diabetic and diabetic individuals. NA 
infusion significantly increased non-esterified fatty acid (NEFA) output in both groups, 
but the elevation was delayed in the diabetic group. The non-diabetic subjects also 
showed lower NEFA levels in post-NA infusion compared with pre-NA infusion stage, 
while that in diabetic individuals post-NA NEFA remained higher than the pre-infusion 
values [113]. These data demonstrated that the adrenergic dysregulation may be 
associated with increased lipolysis but decreased NEFA clearance, which could 
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contribute to the elevation of circulating NEFA and increase the risk of ectopic AT 
accumulation. Interestingly, the adrenergic effect on vascular tone is coordinated with 
AT lipolysis. Thus, α2 adrenoceptor stimulation leads to vasoconstriction and 
suppression of  lipolysis, while β2 adrenoceptor stimulation promotes vasodilatation as 
well as lipolysis [190]. Therefore, the delayed excess release of NEFA could be, at least 
partly, due to the impaired vasoconstriction leading to suppression of lipolysis.  
Nevertheless, in this thesis, SAT α adrenoceptor mRNA expression was found to be 
higher in diabetic compared to non-diabetic group (β-actin/α-adrenoceptor Ct ratio, 
Non-diabetic versus Diabetic: α1: 0.60[0.57-0.63] versus 0.63[0.60-0.69], p=0.04; α2: 
0.71[0.69-0.73] versus 0.77[0.72-0.80], p=0.01), which cannot explain why the NA 
sensitivity is abolished in diabetes. Further studies are required to show the vascular 
adrenoceptor expression at the protein levels.  
6.2.2 Vascular tone and ATBF 
Most of previous studies focused on the NA spillover from heart and kidney, while AT 
per se is less investigated. Furthermore, studies have mainly focused on the 
endothelium-dependent vasodilatation and the effect of weight reduction on vascular 
function [138, 141, 191]. There is only one study investigating the NA-mediated 
vasoconstriction in SAT comparing non-diabetic and diabetic obese individuals [141]. 
This study reported higher vasoconstriction in the diabetic compared to non-diabetic 
group but failed to show the increased SAT NA sensitivity of the non-diabetic vessels 
within the physiological range. In Chapter 3, local NA synthesis in AT and adrenergic 
regulation on vascular tone was demonstrated, and reporting for the first time, the 
difference in depot- and diabetes-specific NA sensitivity. These data suggest that even 
in the context of obesity-related hyperinsulinemia and sympathetic activation, SAT in 
non-diabetic individuals retain normal vascular function by preserving local NA 
sensitivity (the potential mechanism is further discussed in Section 6.3&6.4). However, 
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due to the technical limitations, we could not fully clarify the cellular source of NA. A 
recent rodent study showed NA production from adipocytes [118], but here it cannot be 
excluded that NA may also be derived from adrenergic fibres and macrophages.  
Adequate blood flow is a direct reflection of normal vascular function. It has been 
reported that fasting blood flow is lower in insulin-resistant/obese patients compared to 
lean healthy individuals [192].  Furthermore, there is a regional difference shown as 
higher basal ATBF in abdominal area compared with femoral depot [193]. However, up 
to date, there is no direct comparison of ATBF between SAT and OAT. A recent human 
study showed that physiological levels of NA infusion in abdominal SAT significantly 
increased the microvascular volume and stimulated the capillary recruitment in non-
diabetic overweight individuals but no changes were observed in diabetics  [113]. This 
could be partly explained by the impaired vasodilatation in SAT of diabetic individuals 
[141]. However, the mechanism as to why microvascular volume was not changed in 
SAT in diabetics is still unclear. Our data suggest that SAT microvasculature of non-
diabetic obese individuals is more responsive to physiological concentrations of NA; the 
coordination between vasoconstriction and vasodilatation may generate a “pumping” 
effect to regulate the re-distribution of ATBF, whereas this effect is abolished in OAT 
and diabetes due to the impairment of both vasoconstriction and, the previously reported 
vasodilatation.           
6.3 The potential mechanism of sympathetic nervous activation in obesity   
6.3.1 AT expansion, depot-specific difference 
One potential drive of sympathetic activation is elevated adipose mass. Increased 
abdominal AT is associated with sympathetic nerve activation. Especially, the OAT 
expansion, compared with SAT, is more correlated with sympathetic nerve 
overreactivity [151].  A study in humans showed that there was no significant 
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sympathetic nerve activation in subcutaneous obesity [153], which could be also 
attributed to the low levels of local NA synthesis and preserved NA sensitivity in this 
depot. In contrast, multiple factors may be involved in OAT-induced sympathetic nerve 
activation, which includes elevated non-esterified fatty acid, leptin, macrophages and 
other inflammatory cells [155].  
6.3.2 Hyperinsulinemia  
As described in Chapter 3, the non-diabetic obese group maintained normoglycemia by 
hyperinsulinemia. The hyperinsulinemia-mediated NA spillover has been investigated 
in several studies. Under acute exposure to hyperinsulinemia, there is an elevated 
plasma concentration of NA, mainly from muscle and AT [194, 195]. Interestingly, this 
is contradictory to that seen in nonobese individuals experiencing modest weight gain, 
which is associated with increased sympathetic nervous activity but no changes in 
insulin concentration [196]. Therefore, it cannot be concluded that sympathetic nervous 
activation is only triggered by hyperinsulinemia. Furthermore, NA spillover mediated 
by acute elevation of insulin may not represent the physiological condition in vivo, 
while our data focused more on the chronic elevation of NA in OAT and diabetes, as 
well as its effect on vascular tone and collagen deposition. It suggests that vascular 
function may be compromised due to the long-term exposure to elevated local NA 
rather than the acute stimulation.  
6.4 The potential mechanism of vessel desensitization to NA 
The phenomenon of vessel desensitization by NA was firstly described thirty years ago 
[157]. Rat aortic ring incubated in Krebs solution was exposed to 800 ng∙kg-1∙min-1 NA. 
The vessel desensitization was exhibited as a significant elevation of EC50. Furthermore, 
the desensitization was abolished when the vessel NA uptake was blocked, implicating 
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the desensitization of adrenoceptors caused by the accumulation of intracellular NA. 
Furthermore, blockade of catchol-O-methyltransferase (an enzyme degrading NA) 
significantly enhanced desensitisation, which suggests that the desensitization is 
induced by NA rather than its metabolite.   
Although the mechanism of vessel desensitization in AT is still unclear, in cirrhotic 
patients vascular hypocontractility was induced by the desensitization of GPCRs [197].  
GPCRs are a large family of integral membrane receptors transducing information from 
extracellular stimuli into intracellular secondary messenger via G-protein and its 
downstream regulation [198]. One of the best characterised GPCRs is α adrenoceptor. 
Normally NA activation of its functional α1 adrenoceptor disassociates G-protein α 
subunit from the β/γ subunits and subsequently regulates intracellular Ca2+ and 
vasoconstriction. As a negative feedback, activation of GPCRs also recruits β-arrestin-2 
protein mediated by G-protein-coupled receptor kinase 2 (GRK-2), thereby hindering 
the intracellular vasocontractile pathway. However, due to the high-intensity or long-
term exposure to stimuli, there is an elevation of either GRK-2 or β-arrestin-2 protein, 
leading to the vessel desensitization [197]. The vessel desensitization observed in OAT 
and diabetes perhaps shares a similar mechanism, which is worth further investigation.    
6.5 AT fibrosis mediated by sympathetic nervous activation  
Multiple factors may contribute to tissue fibrosis. Previous studies mainly investigated 
the inflammation- and hypoxia-mediated AT fibrosis, HIF-1α was suggested as a major 
initiating factor for fibrosis induction (reviewed in [39]). Interestingly, chronic hypoxia 
is associated with sympathetic excitation, which has been shown in individuals with 
obstructive sleep apnoea (OSA) and chronic obstructive pulmonary disease [199]. 
However, direct adrenergic regulation of collagen deposition is less documented. 
Accumulating data demonstrate that catecholamine modulates tissue remodelling by 
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elevating collagen gene/protein expression [134, 200], and the local adrenergic effect on 
fibrosis was mainly investigated in heart and kidney [201, 202]. Our data suggest AT-
derived NA may also mediate local fibrotic response in AT via autocrine or paracrine 
signals. Although current data is not adequate to identify the specific subtypes of 
collagen in AT, abundant collagen gene type Iα1 was detected in AT, which was also 
up-regulated by NA incubation. In both rat and human studies, the imbalance between 
collagen type I deposition and degradation is associated with myocardial fibrosis and 
essential hypertension [203, 204]. It has been reported that human collagen type I 
production in VSMCs was stimulated by Ang II via mitogen-activated protein kinase 
/ER kinase pathway [205, 206]. Future studies should focus on the pathway involved in 
the AT collagen deposition induced by NA.  
It is noteworthy that increased TGF- β levels were observed in morbidly obese patients 
compared to the lean individuals [164]. TGF- β/Smad3 pathway is highly involved in 
pathological alterations in obesity and type II diabetes. It is demonstrated that   TGF- 
β/Smad3 regulates insulin gene transcription in β-cells in pancreatic islets [207], while 
Smad3 knockout mouse display resistance to high-fat diet-induced obesity, also these 
mice showed improved glucose tolerance, insulin sensitivity and β-oxidation [208].  
However, TGF- β-mediated fibrosis in AT is less concerned.  It has been showed that, 
in diseased vessels, TGF-β type 1 receptor expression was enhanced, leading to a 
stimulation of ECM production [209], further study should focus on the investigation of   
TGF-β and its receptor gene and protein expression in AT between depots and disease. 
Additionally, microarray data in Chapter 4 showed a significant up-regulation of TGF-
β in SAT in diabetic compared to non-diabetic group, it could be explained by the 
hyperglycemia in diabetics, which has been proved to enhance TGF-β mediated fibrotic 
effect by elevating TGF-β receptor gene expression [210]. Also up-regulation of TGF-β 
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in SAT in diabetics may, at least partly, explain the higher collagen deposition in this 
group.     
6.6 Interplay between AT fibrosis and angiogenesis 
Current data demonstrate the elevated collagen deposition in OAT and diabetics is 
concomitant with excessive angiogenic response. One popular hypothesis predicts that 
adipocyte overexpansion results in insufficient angiogenesis, tissue hypoxia, adipocyte 
necrosis, inflammation and fibrosis [41, 211]. During this process, the accumulation of 
collagen may make the tissue stiffer and inhibit angiogenesis [125]. This hypothesis was 
supported by the evidence that overexpression of HIF-1α in AT of genetic mice failed to 
trigger an angiogenic response, but unexpectedly stimulated tissue fibrosis [212]. 
However, current data suggest both fibrotic and angiogenic responses are stimulated by 
local inflammation and hypoxia. Furthermore, vascular tone, rather than angiogenesis, 
may be affected by local collagen accumulation. Although the mechanism is still 
unclear, a recent study showed that adipocyte-derived endothrophin, a cleavage product 
of the collagen type VI, induced angiogenesis in mammary tumor growth via recruiting 
endothelial precursor cells while also contributing to tissue fibrosis [213].  
6.7 Adipocyte morphology   
In Chapter 3, the adipocyte area was measured by manually tracing the cell boundary. 
The result was also confirmed by measuring the adipocyte length, though these data 
were too preliminary to include. However, the current measurements for adipocyte size 
may still not be accurate enough to show the actual value in vivo. Unlike some other 
types of cell, the adipocyte is ball-shaped and lipid engorged. The shape could be 
altered by depletion of the cellular lipid (squeezing) or stretching during the paraffin 
process or be affected by the angle of dissection. Therefore, in this study, we focused on 
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the relative size difference between depots rather than the physiological values. 
Furthermore, adipocyte morphology may be also affected by collagen deposition, thus 
adipocytes isolated by collagenase digest may not reflect the condition in vivo. In future 
study, the development of a 3D model may be required for detailed investigation of AT 
structure and morphology.   
6.8 The paradox between AT angiogenesis and hypoxia 
The close interplay between adipogenesis and angiogenesis has been widely reported. 
During optimal tissue growth, there is recruitment of both adipocytes and vascular cells, 
which was displayed as adipocyte migration towards neovasculature [43]. However, the 
angiogenesis in AT of obese patients may be an adaptive response triggered by local 
hypoxia. Although animal models have shown that elevated angiogenic response 
induced by VEGFA has a protective effect in obesity, this has not been confirmed in 
human studies. Evidence suggests oxygen tension is lower in SAT of obese patients 
compared to lean individuals, but at levels not low enough to activate the VEGF 
signalling pathway [41]. In addition, OAT showed elevated angiogenesis-related gene 
expression, VEGF protein levels and higher capillary density compared to SAT, despite 
a more inflammatory and hypoxic microenvironment compared to SAT [37, 53]. It is 
noteworthy that, under hypoxia, although angiogenesis is stimulated, arteriogenesis is 
less affected [214]. Arteriogenesis describes the process of small pre-existing arterioles 
developing into functional arteries [215]. It is doubtful whether the neovasculature is 
mature enough to be functioning; thus vascular function, as well as its regulation of AT 
blood flow may be more critical in the regulation of AT functions. We presume SAT in 
non-diabetic obese individuals may be protected from hypoxia by its functional 
vasoreactivity, despite concomitant capillary rarefaction, which may explain why the 
VEGF pathway is not triggered in this depot [41]. Moreover, preserved vascular 
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function may also ensure sufficient blood supply of oxygen and maintain the local 
oxygen tension, which has been observed in a previous study investigating similar 
hyperinsulinemic non-diabetic obese individuals [38].  
6.9 Diabetic effect on AT angiogenesis  
Previous data showed higher angiogenic capacity in SAT of obese patients than OAT 
[69]. However, we found SAT showed lower capillary number and angiogenic capacity 
in non-diabetic versus diabetic obese individuals. This difference may be caused by 
most of previous work having been done using a mixed obese group with both diabetic 
and non-diabetic patients; and also data analysis was based on mean and mean of 
standard error, which was unable to show the true significance when comparing data 
with high variability. In our group, a strict clinical criteria was used to classify obese 
patients into MHO (plasma insulin level<6.5mU/l with plasma glucose <6.0 mmol/ml, 
excluding hypertension and dyslipidemia), PO (pathological obese, insulin>7.0 mU/l 
with glucose <6.0 mmol/ml) and the diabetic group. Further work should investigate the 
angiogenic difference between the non-diabetic sub-groups - PO and MHO. The data 
obtained from the angiogenesis array also needs to be extended to the samples from 
MHO patients, as here only the non-diabetic PO were compared to the diabetics.  
6.10 AT vasculature, new target for treating obesity 
Sufficient vascular supply enriched with oxygen and insulin may protect tissue from 
hypoxia and insulin resistance, but may also facilitate growth factor transport and 
accelerate AT growth. Therefore, it is tempting to suggest that inhibiting AT 
vasculature and consequently reducing AT growth as a reasonable treatment for obese 
patients. Current data suggests even though capillary density is sufficient in OAT and 
diabetes the AT may still be associated with tissue hypoxia, pro-inflammatory 
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adipokine secretion and insulin resistance. Thus, excessive angiogenesis may not 
contribute to metabolic benefits but only facilitate the rapid ‘unhealthy’ AT growth. 
Data from rodents demonstrates that systemic VEGF repression in various tissues 
showed a protective effect against high-fat diet-induced obesity by producing a 
browning AT phenotype [216]. However, it has been reported that anti-angiogenic 
therapy may also be associated with elevated risks of endothelium dysfunction and 
other vascular diseases [217]. In addition, rapid reduction of adipose mass in MHO 
patients may cause negative metabolic consequences. It should be noted that lower 
capillary density and larger adipocytes were observed in SAT of non-diabetic patients in 
this study, but SAT still appeared to be less deleterious compared with OAT. This could 
be a consequence of its relatively normal vascular tone and reactivity, which ensures 
sufficient blood supply even with less capillary numbers and angiogenesis. Therefore, 
the improvement of vascular function may be a better way to improve or reverse the 
hypoxia and insulin resistance in AT. 
6.11 PVAT-derived Adiponectin 
The major finding in Chapter 5 is the demonstration of endothelium-derived 
adiponectin. Moreover, the adiponectin mRNA expression was significantly different 
between HCAEC and HUVEC. The heterogeneity of ECs between different vascular 
beds has been investigated in previous studies (reviewed in [218]&[219]). The major 
differences were summarised in Figure 31. Interestingly, besides the structural, 
morphological and genetic differences, HCAEC and HUVEC also displayed different 
response to inflammatory stimulation. Compared with HUVEC, there were lower levels 
of adhesion molecules expression in HCAEC by 4-hr treatment. However, prolonged 
24-hr exposure to inflammatory stimuli elevated adhesion molecules expression in both 
artery and vein [220]. This suggests that endothelium-derived adiponectin could play a 
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protective role in response to inflammation and the consequent inflammatory 
molecule/cell adhesion, an initial step in atherosclerosis. Future studies may need to 
investigate whether there are intracellular adiponectin receptors, as well as the pathways 
involved in the endothelial adiponectin synthesis and regulation.   
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Figure. 31 Major differences in structure and ECs between artery and vein 
 
                                                                                                                           
 
                                                                                                                            [219] 
          Shown are mayor EC structural and marker differences between arteries, veins, postcapillary venules, and capillaries.                                                                
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6.12 Limitation 
A major limitation in this thesis is the lack of lean control patients. At an initial stage of 
this study lean patients undergoing cholecystectomy and hernia repair surgery were 
recruited as controls. Although they were relatively insulin sensitive and metabolically 
healthy compared to the obese patients, levels of pro-inflammatory adipokines such as 
IL-6 were found to be high in the AT explant in these patients, which suggests they 
were also associated with chronic local inflammation.  
Furthermore, no animal work was undertaken to supplement the current study. Dietary-
induced obese mice model is widely utilized to investigate AT structure and function in 
obesity. However, weight gain in obese mice is more often a short-term process; it may 
be not representative of human obesity, in which the AT expansion may take many 
years. In addition, due to the anatomic difference in mice, SAT and OAT may not be 
precisely distinguished and also truly analogous to human abdominal depots.  
   
6.13 Future study 
6.13.1 Vasoconstriction induced by NPY and ET-1 
The current study displayed the depot- and diabetes- specific difference in 
vasoconstriction mediated by NA. Interestingly, data from rats showed that the NA-
mediated vasoconstriction could be amplified by the infusion of NPY [221]. However, 
the effect of NPY on microvessels embedded within AT is not clear. Preliminary data in 
our group suggested NPY showed vasocontractile effect on both SAT and OAT. This 
vasoconstriction was transient and could not be reproduced. However, the 
vasoconstriction was much higher in both depots of those obese patients with 
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hypertension or OSA. When this condition was simulated experimentally (vessel 
incubated with 10-7M NA) in vessels from non-hypertensive, non-OSA obese patients 
this led to a much stronger vasoconstriction mediated by NPY, which was not observed 
by applying NPY alone. Thus, future investigation needs to be performed to clarify the 
vasoactive effects of NPY, in the presence and absence of differing levels of NA, both 
in vivo and in vitro. 
 
6.13.2 Vasodilatation induced by Ach, leptin, adiponectin 
Acetylcholine (Ach)-induced vasodilatation of microvessels from AT was investigated 
between SAT and OAT in a previous study [140] and no significant difference was 
reported between diabetics and non-diabetics. Furthermore, arterioles in OAT showed 
barely any response to Ach. However, in that study, 10-6 M ET-1 was applied to build 
the pre-constriction, which was far beyond the normal range for vessel to contract. In 
our group, a lower dose of ET-1 (10-8M) was used and vasodilatation was shown in 
OAT.  
Our data also suggest a significant depot difference between SAT and OAT in leptin 
secretion. The higher level of leptin released from SAT raised the question whether 
there is leptin resistance in this depot and how this might affect vasoreactivity. 
Preliminary evidence showed leptin induced incomplete vasodilatation in SAT by using 
relatively high doses of leptin (8μg/ml) while OAT relaxed more quickly and 
completely under a much lower dose (2μg/ml).  
PVAT-derived adiponectin may have a protective anti-contractile function by increasing 
the bioavailability of NO [74], but whether it has similar effects on the microvessels 
with PVAT dissected is still unknown. Therefore, vasodilator differences between the 
depots also should be investigated in future studies. 
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6.13.3 Electron microscopic study: endothelial junction and mitochondria 
The cell to cell junction is a structure formed by transmembrane adhesion molecules 
linked to cytoplasmic proteins between cells [222].  In endothelium, cell junctions 
mainly include adherens junctions and tight junctions (Figure 32A) [223]. Endothelial 
cell to cell junctions not only mediate intercellular communication, but also regulate 
vascular permeability [224].  Furthermore, adherens junction may be also involved in 
vessel morphogenesis and stability [222]. Evidence showed that inflammatory 
molecules such TNF and IL-1 elevate vascular permeability by binding to specific 
receptors generating intracellular signals, which lead to the cytoskeletal reorganization 
and cell gap opening (reviewed in [225]). In obese individuals, ECs in OAT showed 
higher levels of inflammatory gene expression than SAT [37], but whether the 
endothelial cell to cell junction is affected is still unclear. A preliminary study was done 
in 3 patients; 1 from each group - MHO, PO and diabetic. Our data showed that ECs in 
OAT displayed significantly larger adherens junctions compared to SAT (Figure 
32B&C). In addition, the structure of cell junction may be compromised in OAT 
(Figure 32C). The wider endothelial junction and ‘de-structured’ junction in OAT may 
be due to the inflammation in this depot, which may facilitate macrophage infiltration 
into the endothelium and increase the risk of atherosclerosis.   
In this study, we also found a number of mitochondria in AT vasculature. Mitochondrial 
number and function are directly involved in the AT oxygenation. Data suggest oxygen 
consumption in mitochondria is down-regulated in obese individuals [38]. Thus, 
mitochondrial metabolic disorder may be a risk factor associated with AT dysfunction. 
But, due to the small sample size, the mitochondrial numbers could not be fully 
quantified in the study. This would be worth further investigation.  
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Figure 32 Junctional components in ECs and depot-specific difference in AT endothelial 
junction. 
 
 
 
 
 
 
 
In ECs, there are mainly two distinct junctional domains, adherens junctions and tight 
junctions (A, extracted from [223]) 
In a non-diabetic subject, arterioles in SAT (B) displayed significantly larger junctions 
compared with OAT (C). Furthermore, structural alterations in OAT was observed, 
which suggest the impairment of endothelial junction intactness (arrows).   
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6.14 Conclusion 
The interplay between the vasculature and AT is crucial to maintaining AT normal 
function and remodelling capacity. Preserved vascular NA sensitivity as well as low 
levels of local AT NA synthesis may play a key role to protect AT from tissue fibrosis, 
inflammation and hypoxia. This study demonstrated local chronically elevated NA in 
AT desensitized adrenergic regulation of vasoconstriction and increased vessel stiffness 
via elevating tissue fibrosis, perhaps consequently leading to a vascular hyporeactivity, 
which may be associated with AT dysfunction. Concomitantly angiogenesis was 
triggered, perhaps to compensate for the compromised vascular function, as observed in 
OAT and diabetes. Due to the vascular dysfunction, neovasculature, even at relatively 
normal or high levels, may not be adequate to reverse local hypoxia and inflammation 
but only facilitate the ‘unhealthy’ tissue expansion.  
The endothelium-derived adiponectin suggests that ECs per se may produce adiponectin, 
which is known to be protective against the initial stages of atherosclerosis. Higher 
levels of adiponectin in the arteries further explains its potential advantage in CABG, 
but the effect of endothelium-derived adiponectin and its intracellular pathway need to 
be further investigated.  
 
 
 
 
 
 
 
 
 
  154
 
 
 
 
 
 
 
 
 
 
Chapter 7 
References 
 
 
 
 
 
 
 
 
 
 
 
 
  155
1. Flegal, KM, Carroll, MD, Ogden, CL, and Curtin, LR, Prevalence and Trends in 
Obesity Among US Adults, 1999-2008. J Am Med Assoc, 2010. 303(3): p. 235-
241. 
2. WHO, Obesity and overweight. Fact sheet N°311, 2012. 
http://www.who.int/mediacentre/factsheets/fs311/en/. 
3. Alberti, KGMM, Eckel, RH, Grundy, SM, Zimmet, PZ, Cleeman, JI, Donato, 
KA, Fruchart, JC, James, WPT, Loria, CM, and Smith, SC, Harmonizing the 
Metabolic Syndrome A Joint Interim Statement of the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, 
and Blood Institute; American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International Association for the 
Study of Obesity. Circulation, 2009. 120(16): p. 1640-1645. 
4. Sowers, JR, Obesity as a cardiovascular risk factor. Am J Med, 2003. 115: p. 
37-41. 
5. Ross, R and Despres, JP, Abdominal Obesity, Insulin Resistance, and the 
Metabolic Syndrome: Contribution of Physical Activity/Exercise. Obesity, 2009. 
17: p. S1-S2. 
6. Calabro, P, Golia, E, Riegler, L, Palmieri, R, Maddaloni, V, D'Alessandro, R, 
Limongelli, G, Pacileo, G, Golino, P, Russo, M, and Calabro, R, Abdominal 
Obesity, Chronic Inflammation and the Cardiovascular Risk: Not All Fat Is 
Equal. Horiz Cancer Res, 2010. 41: p. 163-182. 
7. Primeau, V, Coderre, L, Karelis, AD, Brochu, M, Lavoie, ME, Messier, V, 
Sladek, R, and Rabasa-Lhoret, R, Characterizing the profile of obese patients 
who are metabolically healthy. Int J Obesity, 2011. 35(7): p. 971-981. 
8. Andres, R, Effect of Obesity on Total Mortality. Int J Obesity, 1980. 4(4): p. 
381-386. 
  156
9. Arsenault, BJ, Rana, JS, Lemieux, I, Despres, JP, Warehame, NJ, Kastelein, JJP, 
Boekholdt, SM, and Khaw, KT, Physical activity, the Framingham risk score 
and risk of coronary heart disease in men and women of the EPIC-Norfolk study. 
Atherosclerosis, 2010. 209(1): p. 261-265. 
10. Karelis, AD, Messier, V, Brochu, M, and Rabasa-Lhoret, R, Metabolically 
healthy but obese women: effect of an energy-restricted diet. Diabetologia, 2008. 
51(9): p. 1752-1754. 
11. Frayn, KN, Coppack, SW, Fielding, BA, and Humphreys, SM, Coordinated 
regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose 
tissue in vivo: implications for the control of fat storage and fat mobilization. 
Adv Enzyme Regul, 1995. 35: p. 163-178. 
12. Karastergiou, K and Mohamed-Ali, V, The autocrine and paracrine roles of 
adipokines. Mol Cell Endocrinol, 2010. 318(1-2): p. 69-78. 
13. Mohamed-Ali, V, Pinkney, JH, and Coppack, SW, Adipose tissue as an 
endocrine and paracrine organ. Int J Obes Relat Metab Disord, 1998. 22(12): p. 
1145-1158. 
14. Sethi, JK and Vidal-Puig, AJ, Thematic review series: Adipocyte biology - 
Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid 
Res, 2007. 48(6): p. 1253-1262. 
15. Snijder, MB, Dekker, JM, Visser, M, Bouter, LM, Stehouwer, CDA, Kostense, 
PJ, Yudkin, JS, Heine, RJ, Nijpels, G, and Seidell, JC, Associations of hip and 
thigh circumferences independent of waist circumference with the incidence of 
type 2 diabetes: the Hoorn Study. Am J Clin Nutr, 2003. 77(5): p. 1192-1197. 
16. Lissner, L, Bjorkelund, C, Heitmann, BL, Seidell, JC, and Bengtsson, C, Larger 
hip circumference independently predicts health and longevity in a Swedish 
female cohort. Obes Res, 2001. 9(10): p. 644-646. 
  157
17. Despres, JP and Lemieux, I, Abdominal obesity and metabolic syndrome. Nature, 
2006. 444(7121): p. 881-887. 
18. Bjorntorp, P, Hazards in Subgroups of Human Obesity. Eur J Clin Invest, 1984. 
14(4): p. 239-241. 
19. Bjorntorp, P, Obesity and the Risk of Cardiovascular-Disease. Ann Clin Res, 
1985. 17(1): p. 3-9. 
20. Fujioka, S, Matsuzawa, Y, Tokunaga, K, and Tarui, S, Contribution of intra-
abdominal fat accumulation to the impairment of glucose and lipid metabolism 
in human obesity. Metabolism, 1987. 36(1): p. 54-59. 
21. Despres, JP, Nadeau, A, Tremblay, A, Ferland, M, Moorjani, S, Lupien, PJ, 
Theriault, G, Pinault, S, and Bouchard, C, Role of Deep Abdominal Fat in the 
Association between Regional Adipose-Tissue Distribution and Glucose-
Tolerance in Obese Women. Diabetes, 1989. 38(3): p. 304-309. 
22. Pouliot, MC, Despres, JP, Nadeau, A, Moorjani, S, Prudhomme, D, Lupien, PJ, 
Tremblay, A, and Bouchard, C, Visceral Obesity in Men - Associations with 
Glucose-Tolerance, Plasma-Insulin, and Lipoprotein Levels. Diabetes, 1992. 
41(7): p. 826-834. 
23. Tran, TT, Yamamoto, Y, Gesta, S, and Kahn, CR, Beneficial effects of 
subcutaneous fat transplantation on metabolism. Cell Metab, 2008. 7(5): p. 410-
420. 
24. Kim, JY, De Wall, EV, Laplante, M, Azzara, A, Trujillo, ME, Hofmann, SM, 
Schraw, T, Durand, JL, Li, H, Li, G, Jelicks, LA, Mehler, MF, Hui, DY, 
Deshaies, Y, Shulman, GI, Schwartz, GJ, and Scherer, PE, Obesity-associated 
improvements in metabolic profile through expansion of adipose tissue. J Clin 
Invest, 2007. 117(9): p. 2621-2637. 
  158
25. Yang, X and Smith, U, Adipose tissue distribution and risk of metabolic disease: 
does thiazolidinedione-induced adipose tissue redistribution provide a clue to 
the answer? Diabetologia, 2007. 50(6): p. 1127-1139. 
26. Mohammed, BS, Cohen, S, Reeds, D, Young, VL, and Klein, S, Long-term 
effects of large-volume liposuction on metabolic risk factors for coronary heart 
disease. Obesity, 2008. 16(12): p. 2648-2651. 
27. Wajchenberg, BL, Subcutaneous and Visceral Adipose Tissue: Their Relation to 
the Metabolic Syndrome. Endocr Rev, 2000. 21(6): p. 697-738. 
28. Lee, M-J, Wu, Y, and Fried, SK, Adipose tissue heterogeneity: Implication of 
depot differences in adipose tissue for obesity complications. Mol Aspects Med, 
2013. 34(1): p. 1-11. 
29. Frayn, KN, Adipose tissue as a buffer for daily lipid flux. Diabetologia, 2002. 45: 
p. 1201-1210. 
30. Smith, J, Al-Amri, M, Dorairaj, P, and Sniderman, A, The adipocyte life cycle 
hypothesis. Clin Sci (Lond), 2006. 110(1): p. 1-9. 
31. Cao, Y, Angiogenesis as a therapeutic target for obesity and metabolic diseases. 
Chem Immunol Allergy, 2014. 99: p. 170-179. 
32. Hausman, DB, DiGirolamo, M, Bartness, TJ, Hausman, GJ, and Martin, RJ, The 
biology of white adipocyte proliferation. Obes Rev, 2001. 2(4): p. 239-254. 
33. Lundgren, M, Svensson, M, Lindmark, S, Renstrom, F, Ruge, T, and Eriksson, 
JW, Fat cell enlargement is an independent marker of insulin resistance and 
'hyperleptinaemia'. Diabetologia, 2007. 50(3): p. 625-633. 
34. Skurk, T, Alberti-Huber, C, Herder, C, and Hauner, H, Relationship between 
adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab, 
2007. 92(3): p. 1023-1033. 
  159
35. Tchernof, A, Belanger, C, Morisset, AS, Richard, C, Mailloux, J, Laberge, P, 
and Dupont, P, Regional differences in adipose tissue metabolism in women - 
Minor effect of obesity and body fat distribution. Diabetes, 2006. 55(5): p. 1353-
1360. 
36. Veilleux, A, Caron-Jobin, M, Noel, S, Laberge, PY, and Tchernof, A, Visceral 
adipocyte hypertrophy is associated with dyslipidemia independent of body 
composition and fat distribution in women. Diabetes, 2011. 60(5): p. 1504-1511. 
37. Villaret, A, Galitzky, J, Decaunes, P, Esteve, D, Marques, MA, Sengenes, C, 
Chiotasso, P, Tchkonia, T, Lafontan, M, Kirkland, JL, and Bouloumie, A, 
Adipose tissue endothelial cells from obese human subjects: differences among 
depots in angiogenic, metabolic, and inflammatory gene expression and cellular 
senescence. Diabetes, 2010. 59(11): p. 2755-2763. 
38. Goossens, GH, Bizzarri, A, Venteclef, N, Essers, Y, Cleutjens, JP, Konings, E, 
Jocken, JW, Cajlakovic, M, Ribitsch, V, Clement, K, and Blaak, EE, Increased 
adipose tissue oxygen tension in obese compared with lean men is accompanied 
by insulin resistance, impaired adipose tissue capillarization, and inflammation. 
Circulation, 2011. 124(1): p. 67-76. 
39. Sun, K, Kusminski, CM, and Scherer, PE, Adipose tissue remodeling and 
obesity. J Clin Invest, 2011. 121(6): p. 2094-2101. 
40. Ye, JP, Gao, ZG, Yin, J, and He, Q, Hypoxia is a potential risk factor for 
chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and 
dietary obese mice. Am J Physiol-Endoc M, 2007. 293(4): p. E1118-E1128. 
41. Pasarica, M, Sereda, OR, Redman, LM, Albarado, DC, Hymel, DT, Roan, LE, 
Rood, JC, Burk, DH, and Smith, SR, Reduced Adipose Tissue Oxygenation in 
Human Obesity Evidence for Rarefaction, Macrophage Chemotaxis, and 
  160
Inflammation Without an Angiogenic Response. Diabetes, 2009. 58(3): p. 718-
725. 
42. Cao, Y, Adipose tissue angiogenesis as a therapeutic target for obesity and 
metabolic diseases. Nat Rev Drug Discov, 2010. 9(2): p. 107-115. 
43. Nishimura, S, Manabe, I, Nagasaki, M, Hosoya, Y, Yamashita, H, Fujita, H, 
Ohsugi, M, Tobe, K, Kadowaki, T, Nagai, R, and Sugiura, S, Adipogenesis in 
obesity requires close interplay between differentiating adipocytes, strontal cells, 
and blood vessels. Diabetes, 2007. 56(6): p. 1517-1526. 
44. Hausman, GJ and Richardson, RL, Adipose tissue angiogenesis. J Anim Sci, 
2004. 82(3): p. 925-934. 
45. Crandall, DL, Busler, DE, McHendry-Rinde, B, Groeling, TM, and Kral, JG, 
Autocrine regulation of human preadipocyte migration by plasminogen 
activator inhibitor-1. J Clin Endocrinol Metab, 2000. 85(7): p. 2609-2614. 
46. Planat-Benard, V, Silvestre, JS, Cousin, B, Andre, M, Nibbelink, M, Tamarat, R, 
Clergue, M, Manneville, C, Saillan-Barreau, C, Duriez, M, Tedgui, A, Levy, B, 
Penicaud, L, and Casteilla, L, Plasticity of human adipose lineage cells toward 
endothelial cells - Physiological and therapeutic perspectives. Circulation, 2004. 
109: p. 656-663. 
47. Gupta, RK, Mepani, RJ, Kleiner, S, Lo, JC, Khandekar, MJ, Cohen, P, Frontini, 
A, Bhowmick, DC, Ye, L, Cinti, S, and Spiegelman, BM, Zfp423 expression 
identifies committed preadipocytes and localizes to adipose endothelial and 
perivascular cells. Cell Metab, 2012. 15(2): p. 230-239. 
48. Tugues, S, Koch, S, Gualandi, L, Li, XJ, and Claesson-Welsh, L, Vascular 
endothelial growth factors and receptors: Anti-angiogenic therapy in the 
treatment of cancer. Mol Aspects Med, 2011. 32(2): p. 88-111. 
  161
49. Hagberg, CE, Mehlem, A, Falkevall, A, Muhl, L, Fam, BC, Ortsater, H, Scotney, 
P, Nyqvist, D, Samen, E, Lu, L, Stone-Elander, S, Proietto, J, Andrikopoulos, S, 
Sjoholm, A, Nash, A, and Eriksson, U, Targeting VEGF-B as a novel treatment 
for insulin resistance and type 2 diabetes. Nature, 2012. 490(7420): p. 426-430. 
50. Shweiki, D, Itin, A, Soffer, D, and Keshet, E, Vascular Endothelial Growth-
Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis. 
Nature, 1992. 359(6398): p. 843-845. 
51. Elias, I, Franckhauser, S, Ferre, T, Vila, L, Tafuro, S, Munoz, S, Roca, C, 
Ramos, D, Pujol, A, Riu, E, Ruberte, J, and Bosch, F, Adipose Tissue 
Overexpression of Vascular Endothelial Growth Factor Protects Against Diet-
Induced Obesity and Insulin Resistance. Diabetes, 2012. 61(7): p. 1801-1813. 
52. Tinahones, F, Salas, J, Mayas, MD, Ruiz-Villalba, A, Macias-Gonzalez, M, 
Garrido-Sanchez, L, DeMora, M, Moreno-Santos, I, Bernal, R, Cardona, F, and 
El Bekay, R, VEGF gene expression in adult human thymus fat: a correlative 
study with hypoxic induced factor and cyclooxygenase-2. PLoS One, 2009. 4(12): 
p. e8213. 
53. Zhang, QX, Magovern, CJ, Mack, CA, Budenbender, KT, Ko, W, and Rosengart, 
TK, Vascular endothelial growth factor is the major angiogenic factor in 
omentum: Mechanism of the omentum-mediated angiogenesis. J Surg Res, 1997. 
67(2): p. 147-154. 
54. Pellet-Many, C, Frankel, P, Jia, H, and Zachary, I, Neuropilins: structure, 
function and role in disease. Biochem J, 2008. 411(2): p. 211-226. 
55. Herzog, Y, Kalcheim, C, Kahane, N, Reshef, R, and Neufeld, G, Differential 
expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev, 
2001. 109(1): p. 115-119. 
  162
56. Koch, S, Neuropilin signalling in angiogenesis. Biochem Soc Trans, 2012. 40(1): 
p. 20-25. 
57. Zachary, I, Neuropilins: role in signalling, angiogenesis and disease. Chem 
Immunol Allergy, 2014. 99: p. 37-70. 
58. Kawasaki, T, Kitsukawa, T, Bekku, Y, Matsuda, Y, Sanbo, M, Yagi, T, and 
Fujisawa, H, A requirement for neuropilin-1 in embryonic vessel formation. 
Development, 1999. 126(21): p. 4895-4902. 
59. Giordano, A, Cesari, P, Capparuccia, L, Castellucci, M, and Cinti, S, Sema3A 
and neuropilin-1 expression and distribution in rat white adipose tissue. J 
Neurocytol, 2003. 32(4): p. 345-352. 
60. Belaid, Z, Hubint, F, Humblet, C, Boniver, J, Nusgens, B, and Defresne, M, 
Differential expression of vascular endothelial growth factor and its receptors in 
hematopoietic and fatty bone marrow: evidence that neuropilin-1 is produced by 
fat cells. Haematologica, 2005. 90(3): p. 400-401. 
61. Cao, RH, Brakenhielm, E, Wahlestedt, C, Thyberg, J, and Cao, YH, Leptin 
induces vascular permeability and synergistically stimulates angiogenesis with 
FGF-2 and VEGF. P Natl Acad Sci USA, 2001. 98(11): p. 6390-6395. 
62. Sierra-Honigmann, MR, Nath, AK, Murakami, C, Garcia-Cardena, G, 
Papapetropoulos, A, Sessa, WC, Madge, LA, Schechner, JS, Schwabb, MB, 
Polverini, PJ, and Flores-Riveros, JR, Biological action of leptin as an 
angiogenic factor. Science, 1998. 281(5383): p. 1683-1686. 
63. Wood, IS, Stezhka, T, and Trayhurn, P, Modulation of adipokine production, 
glucose uptake and lactate release in human adipocytes by small changes in 
oxygen tension. Pflugers Archiv-European Journal of Physiology, 2011. 462(3): 
p. 469-477. 
  163
64. Lihn, AS, Pedersen, SB, and Richelsen, B, Adiponectin: action, regulation and 
association to insulin sensitivity. Obes Rev, 2005. 6(1): p. 13-21. 
65. Brakenhielm, E, Veitonmaki, N, Cao, R, Kihara, S, Matsuzawa, Y, Zhivotovsky, 
B, Funahashi, T, and Cao, Y, Adiponectin-induced antiangiogenesis and 
antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc 
Natl Acad Sci U S A, 2004. 101(8): p. 2476-2481. 
66. Mahadev, K, Wu, X, Donnelly, S, Ouedraogo, R, Eckhart, AD, and Goldstein, 
BJ, Adiponectin inhibits vascular endothelial growth factor-induced migration 
of human coronary artery endothelial cells. Cardiovasc Res, 2008. 78(2): p. 
376-384. 
67. Landskroner-Eiger, S, Qian, BZ, Muise, ES, Nawrocki, AR, Berger, JP, Fine, EJ, 
Koba, W, Deng, YF, Pollard, JW, and Scherer, PE, Proangiogenic Contribution 
of Adiponectin toward Mammary Tumor Growth In vivo. Clin Cancer Res, 2009. 
15(10): p. 3265-3276. 
68. Ouchi, N, Kobayashi, H, Kihara, S, Kumada, M, Sato, K, Inoue, T, Funahashi, T, 
and Walsh, K, Adiponectin stimulates angiogenesis by promoting cross-talk 
between AMP-activated protein kinase and Akt signaling in endothelial cells. J 
Biol Chem, 2004. 279(2): p. 1304-1309. 
69. Gealekman, O, Guseva, N, Hartigan, C, Apotheker, S, Gorgoglione, M, Gurav, 
K, Tran, KV, Straubhaar, J, Nicoloro, S, Czech, MP, Thompson, M, Perugini, 
RA, and Corvera, S, Depot-specific differences and insufficient subcutaneous 
adipose tissue angiogenesis in human obesity. Circulation, 2011. 123(2): p. 186-
194. 
70. Lemoine, AY, Ledoux, S, Queguiner, I, Calderari, S, Mechler, C, Msika, S, 
Corvol, P, and Larger, E, Link between Adipose Tissue Angiogenesis and Fat 
  164
Accumulation in Severely Obese Subjects. Journal of Clinical Endocrinology & 
Metabolism, 2012. 97(5): p. E775-E780. 
71. Levy, BI, Ambrosio, G, Pries, AR, and Struijker-Boudier, HA, Microcirculation 
in hypertension: a new target for treatment? Circulation, 2001. 104(6): p. 735-
740. 
72. Vicaut, E, Hypertension and the microcirculation: a brief overview of 
experimental studies. J Hypertens Suppl, 1992. 10(5): p. S59-68. 
73. de Jongh, RT, Serne, EH, Ijzerman, RG, de Vries, G, and Stehouwer, CDA, 
Impaired microvascular function in obesity - Implications for obesity-associated 
microangiopathy, hypertension, and insulin resistance. Circulation, 2004. 
109(21): p. 2529-2535. 
74. Greenstein, AS, Khavandi, K, Withers, SB, Sonoyama, K, Clancy, O, Jeziorska, 
M, Laing, I, Yates, AP, Pemberton, PW, Malik, RA, and Heagerty, AM, Local 
inflammation and hypoxia abolish the protective anticontractile properties of 
perivascular fat in obese patients. Circulation, 2009. 119(12): p. 1661-1670. 
75. Sobey, CG, Potassium channel function in vascular disease. Arterioscler 
Thromb Vasc Biol, 2001. 21(1): p. 28-38. 
76. Vane, JR, Anggard, EE, and Botting, RM, Regulatory functions of the vascular 
endothelium. N Engl J Med, 1990. 323(1): p. 27-36. 
77. Nacci, C, Tarquinio, M, and Montagnani, M, Molecular and clinical aspects of 
endothelial dysfunction in diabetes. Intern Emerg Med, 2009. 4(2): p. 107-116. 
78. Schiffrin, EL and Touyz, RM, Vascular biology of endothelin. J Cardiovasc 
Pharm, 1998. 32: p. S2-S13. 
79. Zhang, J, Yang, W, Hu, B, Wu, W, and Fallon, MB, Endothelin-1 activation of 
the endothelin B receptor modulates pulmonary endothelial CX3CL1 and 
  165
contributes to pulmonary angiogenesis in experimental hepatopulmonary 
syndrome. Am J Pathol, 2014. 184(6): p. 1706-1714. 
80. Caballero, AE, Endothelial dysfunction in obesity and insulin resistance: A road 
to diabetes and heart disease. Obes Res, 2003. 11(11): p. 1278-1289. 
81. Zeng, GY, Nystrom, FH, Ravichandran, LV, Cong, LN, Kirby, M, Mostowski, 
H, and Quon, MJ, Roles for insulin receptor, PI3-kinase, and Akt in insulin-
signaling pathways related to production of nitric oxide in human vascular 
endothelial cells. Circulation, 2000. 101(13): p. 1539-1545. 
82. Cardillo, C, Nambi, SS, Kilcoyne, CM, Choucair, WK, Katz, A, Quon, MJ, and 
Panza, JA, Insulin stimulates both endothelin and nitric oxide activity in the 
human forearm. Circulation, 1999. 100(8): p. 820-825. 
83. Clark, MG, Wallis, MG, Barrett, EJ, Vincent, MA, Richards, SM, Clerk, LH, 
and Rattigan, S, Blood flow and muscle metabolism: a focus on insulin action. 
Am J Physiol Endocrinol Metab, 2003. 284(2): p. E241-258. 
84. Lteif, A, Vaishnava, P, Baron, AD, and Mather, KJ, Endothelin limits insulin 
action in obese/insulin-resistant humans. Diabetes, 2007. 56(3): p. 728-734. 
85. Achike, FI, To, NH, Wang, H, and Kwan, CY, Obesity, metabolic syndrome, 
adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol 
Physiol, 2011. 38(1): p. 1-10. 
86. Vecchione, C, Maffei, A, Colella, S, Aretini, A, Poulet, R, Frati, G, Gentile, MT, 
Fratta, L, Trimarco, V, Trimarco, B, and Lembo, G, Leptin Effect on Endothelial 
Nitric Oxide Is Mediated Through Akt–Endothelial Nitric Oxide Synthase 
Phosphorylation Pathway. Diabetes, 2002. 51(1): p. 168-173. 
87. Cooke, JP and Oka, RK, Does Leptin Cause Vascular Disease? Circulation, 
2002. 106(15): p. 1904-1905. 
  166
88. Procopio, C, Andreozzi, F, Laratta, E, Cassese, A, Beguinot, F, Arturi, F, Hribal, 
ML, Perticone, F, and Sesti, G, Leptin-stimulated endothelial nitric-oxide 
synthase via an adenosine 5'-monophosphate-activated protein kinase/Akt 
signaling pathway is attenuated by interaction with C-reactive protein. 
Endocrinology, 2009. 150: p. 3584-3593. 
89. Bastard, JP, Maachi, M, Lagathu, C, Kim, MJ, Caron, M, Vidal, H, Capeau, J, 
and Feve, B, Recent advances in the relationship between obesity, inflammation, 
and insulin resistance. Eur Cytokine Netw, 2006. 17(1): p. 4-12. 
90. Fruhbeck, G, Pivotal role of nitric oxide in the control of blood pressure after 
leptin administration. Diabetes, 1999. 48(4): p. 903-908. 
91. Leung, YM and Kwan, CY, Dual vascular effects of leptin via endothelium: 
Hypothesis and perspective. Chinese J Physiol, 2008. 51(1): p. 1-6. 
92. Quehenberger, P, Exner, M, Sunder-Plassmann, R, Ruzicka, K, Bieglmayer, C, 
Endler, G, Muellner, C, Speiser, W, and Wagner, O, Leptin induces endothelin-1 
in endothelial cells in vitro. Circ Res, 2002. 90(6): p. 711-718. 
93. Loffreda, S, Yang, SQ, Lin, HZ, Karp, CL, Brengman, ML, Wang, DJ, Klein, 
AS, Bulkley, GB, Bao, C, Noble, PW, Lane, MD, and Diehl, AM, Leptin 
regulates proinflammatory immune responses. Faseb Journal, 1998. 12(1): p. 57-
65. 
94. Antoniades, C, Antonopoulos, AS, Tousoulis, D, and Stefanadis, C, Adiponectin: 
from obesity to cardiovascular disease. Obes Rev, 2009. 10(3): p. 269-279. 
95. Xi, W, Satoh, H, Kase, H, Suzuki, K, and Hattori, Y, Stimulated HSP90 binding 
to eNOS and activation of the PI3-Akt pathway contribute to globular 
adiponectin-induced NO production: Vasorelaxation in response to globular 
adiponectin. Biochem Bioph Res Co, 2005. 332(1): p. 200-205. 
  167
96. Fesus, G, Dubrovska, G, Gorzelniak, K, Kluge, R, Huang, Y, Luft, FC, and 
Gollasch, M, Adiponectin is a novel humoral vasodilator. Cardiovascular 
Research, 2007. 75(4): p. 719-727. 
97. Tan, KCB, Xu, A, Chow, WS, Lam, MCW, Ai, VHG, Tam, SCF, and Lam, 
KSL, Hypoadiponectinemia is associated with impaired endothelium-dependent 
vasodilation. Journal of Clinical Endocrinology & Metabolism, 2004. 89(2): p. 
765-769. 
98. Chudek, J and Wiecek, A, Adipose tissue, inflammation and endothelial 
dysfunction. Pharmacol Rep, 2006. 58 Suppl: p. 81-88. 
99. Ohkawa, F, Ikeda, U, Kawasaki, K, Kusano, E, Igarashi, M, and Shimada, K, 
Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J 
Physiol, 1994. 266(3 Pt 2): p. H898-902. 
100. Schrader, LI, Kinzenbaw, DA, Johnson, AW, Faraci, FM, and Didion, SP, IL-6 
deficiency protects against angiotensin II induced endothelial dysfunction and 
hypertrophy. Arterioscler Thromb Vasc Biol, 2007. 27(12): p. 2576-2581. 
101. Brian, JE, Jr. and Faraci, FM, Tumor necrosis factor-alpha-induced dilatation of 
cerebral arterioles. Stroke, 1998. 29(2): p. 509-515. 
102. Meijer, RI, Serne, EH, Smulders, YM, van Hinsbergh, VW, Yudkin, JS, and 
Eringa, EC, Perivascular adipose tissue and its role in type 2 diabetes and 
cardiovascular disease. Curr Diab Rep, 2011. 11(3): p. 211-217. 
103. Gu, P and Xu, A, Interplay between adipose tissue and blood vessels in obesity 
and vascular dysfunction. Rev Endocr Metab Disord, 2013. 14(1): p. 49-58. 
104. Lee, RMKW, Lu, C, Su, LY, and Gao, YJ, Endothelium-dependent relaxation 
factor released by perivascular adipose tissue. J Hypertens, 2009. 27(4): p. 782-
790. 
  168
105. Lohn, M, Dubrovska, G, Lauterbach, B, Luft, FC, Gollasch, M, and Sharma, 
AM, Periadventitial fat releases a vascular relaxing factor. Faseb Journal, 2002. 
16(9): p. 1057-1063. 
106. Gao, YJ, Lu, C, Su, LY, Sharma, AM, and Lee, RMKW, Modulation of vascular 
function by perivascular adipose tissue: the role of endothelium and hydrogen 
peroxide. Brit J Pharmacol, 2007. 151(3): p. 323-331. 
107. Eringa, EC, Bakker, W, and van Hinsbergh, VWM, Paracrine regulation of 
vascular tone, inflammation and insulin sensitivity by perivascular adipose 
tissue. Vasc Pharmacol, 2012. 56(5-6): p. 204-209. 
108. Yudkin, JS, Eringa, E, and Stehouwer, CDA, "Vasocrine" signalling from 
perivascular fat: a mechanism linking insulin resistance to vascular disease. 
Lancet, 2005. 365(9473): p. 1817-1820. 
109. Richelsen, B, Factors regulating the production of prostaglandin E2 and 
prostacyclin (prostaglandin I2) in rat and human adipocytes. Biochem J, 1987. 
247(2): p. 389-394. 
110. Traupe, T, Lang, M, Goettsch, W, Munter, K, Morawietz, H, Vetter, W, and 
Barton, M, Obesity increases prostanoid-mediated vasoconstriction and 
vascular thromboxane receptor gene expression. J Hypertens, 2002. 20(11): p. 
2239-2245. 
111. Traupe, T, D'Uscio, LV, Muenter, K, Morawietz, H, Vetter, W, and Barton, M, 
Effects of obesity on endothelium-dependent reactivity during acute nitric oxide 
synthase inhibition: modulatory role of endothelin. Clin Sci (Lond), 2002. 103 
Suppl 48: p. 13S-15S. 
112. Axelrod, L, Insulin, Prostaglandins, and the Pathogenesis of Hypertension. 
Diabetes, 1991. 40(10): p. 1223-1227. 
  169
113. Tobin, L, Simonsen, L, Galbo, H, and Bulow, J, Vascular and metabolic effects 
of adrenaline in adipose tissue in type 2 diabetes. Nutr Diabetes, 2012. 2: p. e46. 
114. Mohamed-Ali, V, Flower, L, Sethi, J, Hotamisligil, G, Gray, R, Humphries, SE, 
York, DA, and Pinkney, J, beta-Adrenergic regulation of IL-6 release from 
adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab, 2001. 
86(12): p. 5864-5869. 
115. Prieto, D, Physiological regulation of penile arteries and veins. Int J Impot Res, 
2008. 20(1): p. 17-29. 
116. Spraul, M, Ravussin, E, Fontvieille, AM, Rising, R, Larson, DE, and Anderson, 
EA, Reduced sympathetic nervous activity. A potential mechanism predisposing 
to body weight gain. J Clin Invest, 1993. 92(4): p. 1730-1735. 
117. Rumantir, MS, Vaz, M, Jennings, GL, Collier, G, Kaye, DM, Seals, DR, 
Wiesner, GH, Brunner-La Rocca, HP, and Esler, MD, Neural mechanisms in 
human obesity-related hypertension. J Hypertens, 1999. 17(8): p. 1125-1133. 
118. Vargovic, P, Ukropec, J, Laukova, M, Cleary, S, Manz, B, Pacak, K, and 
Kvetnansky, R, Adipocytes as a new source of catecholamine production. FEBS 
Lett, 2011. 585(14): p. 2279-2284. 
119. Tatemoto, K, Carlquist, M, and Mutt, V, Neuropeptide Y--a novel brain peptide 
with structural similarities to peptide YY and pancreatic polypeptide. Nature, 
1982. 296(5858): p. 659-660. 
120. Tang-Christensen, M, Vrang, N, Ortmann, S, Bidlingmaier, M, Horvath, TL, 
and Tschop, M, Central administration of ghrelin and agouti-related protein 
(83-132) increases food intake and decreases spontaneous locomotor activity in 
rats. Endocrinology, 2004. 145(10): p. 4645-4652. 
121. Lundberg, JM, Franco-Cereceda, A, Lacroix, JS, and Pernow, J, Neuropeptide Y 
and sympathetic neurotransmission. Ann N Y Acad Sci, 1990. 611: p. 166-174. 
  170
122. Pernow, J, Ohlen, A, Hokfelt, T, Nilsson, O, and Lundberg, JM, Neuropeptide Y: 
presence in perivascular noradrenergic neurons and vasoconstrictor effects on 
skeletal muscle blood vessels in experimental animals and man. Regul Pept, 
1987. 19(5-6): p. 313-324. 
123. Wahlestedt, C, Hakanson, R, Vaz, CA, and Zukowska-Grojec, Z, 
Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in 
vitro. Am J Physiol, 1990. 258(3 Pt 2): p. R736-742. 
124. Kalra, SP and Kalra, PS, NPY and cohorts in regulating appetite, obesity and 
metabolic syndrome: beneficial effects of gene therapy. Neuropeptides, 2004. 
38(4): p. 201-211. 
125. Sun, K, Tordjman, J, Clement, K, and Scherer, PE, Fibrosis and adipose tissue 
dysfunction. Cell Metab, 2013. 18(4): p. 470-477. 
126. Keophiphath, M, Achard, V, Henegar, C, Rouault, C, Clement, K, and Lacasa, D, 
Macrophage-secreted factors promote a profibrotic phenotype in human 
preadipocytes. Mol Endocrinol, 2009. 23(1): p. 11-24. 
127. Sun, K, Halberg, N, Khan, M, Magalang, UJ, and Scherer, PE, Selective 
inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue 
dysfunction. Mol Cell Biol, 2013. 33(5): p. 904-917. 
128. Divoux, A, Tordjman, J, Lacasa, D, Veyrie, N, Hugol, D, Aissat, A, Basdevant, 
A, Guerre-Millo, M, Poitou, C, Zucker, JD, Bedossa, P, and Clement, K, 
Fibrosis in human adipose tissue: composition, distribution, and link with lipid 
metabolism and fat mass loss. Diabetes, 2010. 59(11): p. 2817-2825. 
129. Khan, T, Muise, ES, Iyengar, P, Wang, ZV, Chandalia, M, Abate, N, Zhang, BB, 
Bonaldo, P, Chua, S, and Scherer, PE, Metabolic dysregulation and adipose 
tissue fibrosis: role of collagen VI. Mol Cell Biol, 2009. 29(6): p. 1575-1591. 
  171
130. Pasarica, M, Gowronska-Kozak, B, Burk, D, Remedios, I, Hymel, D, Gimble, J, 
Ravussin, E, Bray, GA, and Smith, SR, Adipose Tissue Collagen VI in Obesity. 
Journal of Clinical Endocrinology & Metabolism, 2009. 94(12): p. 5155-5162. 
131. Raines, EW, The extracellular matrix can regulate vascular cell migration, 
proliferation, and survival: relationships to vascular disease. Int J Exp Pathol, 
2000. 81(3): p. 173-182. 
132. Lan, TH, Huang, XQ, and Tan, HM, Vascular fibrosis in atherosclerosis. 
Cardiovasc Pathol, 2013. 22(5): p. 401-407. 
133. Oben, JA, Roskams, T, Yang, S, Lin, H, Sinelli, N, Li, Z, Torbenson, M, 
Thomas, SA, and Diehl, AM, Norepinephrine induces hepatic fibrogenesis in 
leptin deficient ob/ob mice. Biochem Biophys Res Commun, 2003. 308(2): p. 
284-292. 
134. Rassler, B, Marx, G, Schierle, K, and Zimmer, HG, Catecholamines Can Induce 
Pulmonary Remodeling in Rats. Cell Physiol and Biochem, 2012. 30(5): p. 
1134-1147. 
135. Zebekakis, PE, Nawrot, T, Thijs, L, Balkestein, EJ, van der Heijden-Spek, J, 
Van Bortel, LM, Struijker-Boudier, HA, Safar, ME, and Staessen, JA, Obesity is 
associated with increased arterial stiffness from adolescence until old age. J 
Hypertens, 2005. 23(10): p. 1839-1846. 
136. Giltay, EJ, Lambert, J, Elbers, JM, Gooren, LJ, Asscheman, H, and Stehouwer, 
CD, Arterial compliance and distensibility are modulated by body composition 
in both men and women but by insulin sensitivity only in women. Diabetologia, 
1999. 42(2): p. 214-221. 
137. Steinberg, HO, Chaker, H, Leaming, R, Johnson, A, Brechtel, G, and Baron, AD, 
Obesity/insulin resistance is associated with endothelial dysfunction. 
  172
Implications for the syndrome of insulin resistance. J Clin Invest, 1996. 97(11): 
p. 2601-2610. 
138. Grassi, G, Seravalle, G, Scopelliti, F, Dell'Oro, R, Fattori, L, Quarti-Trevano, F, 
Brambilla, G, Schiffrin, EL, and Mancia, G, Structural and functional 
alterations of subcutaneous small resistance arteries in severe human obesity. 
Obesity, 2010. 18(1): p. 92-98. 
139. Van Gaal, LF, Mertens, IL, and De Block, CE, Mechanisms linking obesity with 
cardiovascular disease. Nature, 2006. 444(7121): p. 875-880. 
140. Farb, MG, Ganley-Leal, L, Mott, M, Liang, Y, Ercan, B, Widlansky, ME, 
Bigornia, SJ, Fiscale, AJ, Apovian, CM, Carmine, B, Hess, DT, Vita, JA, and 
Gokce, N, Arteriolar Function in Visceral Adipose Tissue Is Impaired in Human 
Obesity. Arterioscler Thromb Vasc Biol, 2012. 32(2): p. 467-473. 
141. Georgescu, A, Popov, D, Constantin, A, Nemecz, M, Alexandru, N, Cochior, D, 
and Tudor, A, Dysfunction of human subcutaneous fat arterioles in obesity alone 
or obesity associated with Type 2 diabetes. Clin Sci (Lond), 2011. 120(10): p. 
463-472. 
142. Barton, M, Baretella, O, and Meyer, MR, Obesity and risk of vascular disease: 
importance of endothelium-dependent vasoconstriction. Br J Pharmacol, 2012. 
165(3): p. 591-602. 
143. Fried, M, Hainer, V, Basdevant, A, Buchwald, H, Deitel, M, Finer, N, Greve, 
JW, Horber, F, Mathus-Vliegen, E, Scopinaro, N, Steffen, R, Tsigos, C, Weiner, 
R, and Widhalm, K, Interdisciplinary European guidelines for surgery for 
severe (morbid) obesity. Obes Surg, 2007. 17(2): p. 260-270. 
144. Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF, and 
Turner, RC, Homeostasis model assessment: insulin resistance and beta-cell 
  173
function from fasting plasma glucose and insulin concentrations in man. 
Diabetologia, 1985. 28(7): p. 412-419. 
145. Hausman, GJ, Cytochemistry for lectins, actin, nucleotide tetrazolium 
reductases and several phosphatases in the porcine semitendinosus muscle: 
vascular development in young pigs. J Anim Sci, 1989. 67(5): p. 1375-1386. 
146. Matsumoto, S, Morikawa, K, and Yanagida, M, Light microscopic structure of 
DNA in solution studied by the 4',6-diamidino-2-phenylindole staining method. J 
Mol Biol, 1981. 152(2): p. 501-516. 
147. Dashwood, MR, Dooley, A, Xu, SW, Abraham, DJ, and Souza, DSR, Does 
periadventitial fat-derived nitric oxide play a role in improved saphenous vein 
graft patency in patients undergoing coronary artery bypass surgery? Journal of 
Vascular Research, 2007. 44: p. 175-181. 
148. Chomczynski, P and Sacchi, N, Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 1987. 
162(1): p. 156-159. 
149. Smith, PK, Krohn, RI, Hermanson, GT, Mallia, AK, Gartner, FH, Provenzano, 
MD, Fujimoto, EK, Goeke, NM, Olson, BJ, and Klenk, DC, Measurement of 
protein using bicinchoninic acid. Anal Biochem, 1985. 150(1): p. 76-85. 
150. Friedewald, WT, Levy, RI, and Fredrickson, DS, Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge. Clin Chem, 1972. 18(6): p. 499-502. 
151. Alvarez, GE, Beske, SD, Ballard, TP, and Davy, KP, Sympathetic neural 
activation in visceral obesity. Circulation, 2002. 106(20): p. 2533-2536. 
152. Straznicky, NE, Grima, MT, Sari, CI, Eikelis, N, Lambert, EA, Nestel, PJ, Esler, 
MD, Dixon, JB, Chopra, R, Tilbrook, AJ, Schlaich, MP, and Lambert, GW, 
Neuroadrenergic dysfunction along the diabetes continuum: a comparative 
  174
study in obese metabolic syndrome subjects. Diabetes, 2012. 61(10): p. 2506-
2516. 
153. Alvarez, GE, Ballard, TP, Beske, SD, and Davy, KP, Subcutaneous obesity is 
not associated with sympathetic neural activation. Am J Physiol Heart Circ 
Physiol, 2004. 287(1): p. H414-418. 
154. Bartness, TJ and Bamshad, M, Innervation of mammalian white adipose tissue: 
implications for the regulation of total body fat. Am J Physiol, 1998. 275(5 Pt 2): 
p. R1399-1411. 
155. Lambert, GW, Straznicky, NE, Lambert, EA, Dixon, JB, and Schlaich, MP, 
Sympathetic nervous activation in obesity and the metabolic syndrome--causes, 
consequences and therapeutic implications. Pharmacol Ther, 2010. 126(2): p. 
159-172. 
156. Rizzoni, D, De Ciuceis, C, Porteri, E, Semeraro, F, and Rosei, EA, Structural 
alterations in small resistance arteries in obesity. Basic Clin Pharmacol Toxicol, 
2012. 110(1): p. 56-62. 
157. Ball, N, Danks, JL, Dorudi, S, and Nasmyth, PA, Desensitization by 
noradrenaline of responses to stimulation of pre- and postsynaptic 
adrenoceptors. Br J Pharmacol, 1982. 76(1): p. 201-210. 
158. Abraham, GJ and Nasmyth, PA, Desensitization of the rat aortic strip to 
vasopressin by infusions of noradrenaline [proceedings]. Br J Pharmacol, 1976. 
57(3): p. 458P. 
159. Simonsen, L, Bulow, J, Astrup, A, Madsen, J, and Christensen, NJ, Diet-induced 
changes in subcutaneous adipose tissue blood flow in man: effect of beta-
adrenoceptor inhibition. Acta Physiol Scand, 1990. 139(2): p. 341-346. 
  175
160. Ruiz-Ortega, M, Rodriguez-Vita, J, Sanchez-Lopez, E, Carvajal, G, and Egido, J, 
TGF-beta signaling in vascular fibrosis. Cardiovasc Res, 2007. 74(2): p. 196-
206. 
161. Annes, JP, Munger, JS, and Rifkin, DB, Making sense of latent TGFbeta 
activation. J Cell Sci, 2003. 116(Pt 2): p. 217-224. 
162. Leask, A and Abraham, DJ, TGF-beta signaling and the fibrotic response. 
FASEB J, 2004. 18(7): p. 816-827. 
163. Santana, AB, de Souza Oliveira, TC, Bianconi, BL, Barauna, VG, Santos, EW, 
Alves, TP, Silva, JC, Fiorino, P, Borelli, P, Irigoyen, MC, Krieger, JE, and 
Lacchini, S, Effect of high-fat diet upon inflammatory markers and aortic 
stiffening in mice. Biomed Res Int, 2014. 2014: p. 914102. 
164. Pereira, S, Teixeira, L, Aguilar, E, Oliveira, M, Savassi-Rocha, A, Pelaez, JN, 
Capettini, L, Diniz, MT, Ferreira, A, and Alvarez-Leite, J, Modulation of 
adipose tissue inflammation by FOXP3+ Treg cells, IL-10, and TGF-beta in 
metabolically healthy class III obese individuals. Nutrition, 2014. 30(7-8): p. 
784-790. 
165. Aprahamian, TR, Elevated adiponectin expression promotes adipose tissue 
vascularity under conditions of diet-induced obesity. Metabolism, 2013. 
166. Niu, J, Wang, K, Zhelyabovska, O, Saad, Y, and Kolattukudy, PE, MCP-1-
induced protein promotes endothelial-like and angiogenic properties in human 
bone marrow monocytic cells. J Pharmacol Exp Ther, 2013. 
167. Costa, PZ and Soares, R, Neovascularization in diabetes and its complications. 
Unraveling the angiogenic paradox. Life Sci, 2013. 92(22): p. 1037-1045. 
168. Adham, SA and Coomber, BL, Glucose is a key regulator of VEGFR2/KDR in 
human epithelial ovarian carcinoma cells. Biochem Biophys Res Commun, 
2009. 390(1): p. 130-135. 
  176
169. Morita, Y, Maeda, K, Kondo, T, Ishii, H, Matsudaira, K, Okumura, N, 
Mitsuhashi, H, Shibata, R, Murohara, T, and on behalf of the Nagoya Acute 
Myocardial Infarction Study, G, Impact of Adiponectin and Leptin on Long-
Term Adverse Events in Japanese Patients With Acute Myocardial Infarction. 
Circ J, 2013. 
170. Cheng, KK, Lam, KS, Wang, Y, Huang, Y, Carling, D, Wu, D, Wong, C, and 
Xu, A, Adiponectin-induced endothelial nitric oxide synthase activation and 
nitric oxide production are mediated by APPL1 in endothelial cells, Diabetes, 
2007. p. 1387-1394. 
171. Perri, A, Vizza, D, Lofaro, D, Gigliotti, P, Leone, F, Papalia, T, and Bonofiglio, 
R, Adiponectin Is Expressed and Secreted by Tubular Epithelial Renal Cells. 
Nephrology Dialysis Transplantation, 2013. Epub ahead of print. 
172. Okamoto, Y, Arita, Y, Nishida, M, Muraguchi, M, Ouchi, N, Takahashi, M, 
Igura, T, Inui, Y, Kihara, S, Nakamura, T, Yamashita, S, Miyagawa, J, 
Funahashi, T, and Matsuzawa, Y, An adipocyte-derived plasma protein, 
adiponectin, adheres to injured vascular walls. Horm Metab Res, 2000. 32: p. 
47-50. 
173. Eringa, EC, Bakker, W, Smulders, YM, Serne, EH, Yudkin, JS, and Stehouwer, 
CD, Regulation of vascular function and insulin sensitivity by adipose tissue: 
focus on perivascular adipose tissue. Microcirculation, 2007. 14(4-5): p. 389-
402. 
174. Komura, N, Maeda, N, Mori, T, Kihara, S, Nakatsuji, H, Hirata, A, Tochino, Y, 
Funahashi, T, and Shimomura, I, Adiponectin protein exists in aortic endothelial 
cells. PLoS One, 2013. 8(8): p. e71271. 
175. Tschritter, O, Fritsche, A, Thamer, C, Haap, M, Shirkavand, F, Rahe, S, Staiger, 
H, Maerker, E, Haring, H, and Stumvoll, M, Plasma adiponectin concentrations 
  177
predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 2003. 
52(2): p. 239-243. 
176. Kadowaki, T, Yamauchi, T, Kubota, N, Hara, K, Ueki, K, and Tobe, K, 
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the 
metabolic syndrome. J Clin Invest, 2006. 116(7): p. 1784-1792. 
177. Souza, DS, Johansson, B, Bojo, L, Karlsson, R, Geijer, H, Filbey, D, Bodin, L, 
Arbeus, M, and Dashwood, MR, Harvesting the saphenous vein with 
surrounding tissue for CABG provides long-term graft patency comparable to 
the left internal thoracic artery: results of a randomized longitudinal trial. J 
Thorac Cardiovasc Surg, 2006. 132(2): p. 373-378. 
178. Sims, FH, A comparison of coronary and internal mammary arteries and 
implications of the results in the etiology of arteriosclerosis. Am Heart J, 1983. 
105(4): p. 560-566. 
179. Li, CJ, Sun, HW, Zhu, FL, Chen, L, Rong, YY, Zhang, Y, and Zhang, M, Local 
adiponectin treatment reduces atherosclerotic plaque size in rabbits. J 
Endocrinol, 2007. 193(1): p. 137-145. 
180. Bahadori, B, Neuer, E, Schumacher, M, Fruhwald, F, Eber, B, Klein, W, Topak, 
H, and Wascher, TC, Prevalence of coronary artery disease in obese versus lean 
men with angina pectoris and positive exercise stress test. Am J Cardiol, 1996. 
77(11): p. 1000-1001. 
181. Emdin, M, Gastaldelli, A, Muscelli, E, Macerata, A, Natali, A, Camastra, S, and 
Ferrannini, E, Hyperinsulinemia and autonomic nervous system dysfunction in 
obesity: effects of weight loss. Circulation, 2001. 103(4): p. 513-519. 
182. Goodpaster, BH, Wolfe, RR, and Kelley, DE, Effects of obesity on substrate 
utilization during exercise. Obes Res, 2002. 10(7): p. 575-584. 
  178
183. Bruce, CR, Mertz, VA, Heigenhauser, GJ, and Dyck, DJ, The stimulatory effect 
of globular adiponectin on insulin-stimulated glucose uptake and fatty acid 
oxidation is impaired in skeletal muscle from obese subjects. Diabetes, 2005. 
54(11): p. 3154-3160. 
184. Cannon, B, Nedergaard, J, Lundberg, JM, Hokfelt, T, Terenius, L, and Goldstein, 
M, 'Neuropeptide tyrosine' (NPY) is co-stored with noradrenaline in vascular 
but not in parenchymal sympathetic nerves of brown adipose tissue. Exp Cell 
Res, 1986. 164(2): p. 546-550. 
185. Bulow, J, Astrup, A, Christensen, NJ, and Kastrup, J, Blood flow in skin, 
subcutaneous adipose tissue and skeletal muscle in the forearm of normal man 
during an oral glucose load. Acta Physiol Scand, 1987. 130(4): p. 657-661. 
186. Dimitriadis, G, Lambadiari, V, Mitrou, P, Maratou, E, Boutati, E, Panagiotakos, 
DB, Economopoulos, T, and Raptis, SA, Impaired postprandial blood flow in 
adipose tissue may be an early marker of insulin resistance in type 2 diabetes. 
Diabetes Care, 2007. 30(12): p. 3128-3130. 
187. Flechtner-Mors, M, Jenkinson, CP, Alt, A, Biesalski, HK, Adler, G, and 
Ditschuneit, HH, Sympathetic regulation of glucose uptake by the alpha1-
adrenoceptor in human obesity. Obes Res, 2004. 12(4): p. 612-620. 
188. Boschmann, M, Krupp, G, Luft, FC, Klaus, S, and Jordan, J, In vivo response to 
alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res, 
2002. 10(6): p. 555-558. 
189. Lafontan, M, Barbe, P, Galitzky, J, Tavernier, G, Langin, D, Carpene, C, 
Bousquet-Melou, A, and Berlan, M, Adrenergic regulation of adipocyte 
metabolism. Hum Reprod, 1997. 12 Suppl 1: p. 6-20. 
  179
190. Sotornik, R, Brassard, P, Martin, E, Yale, P, Carpentier, AC, and Ardilouze, JL, 
Update on adipose tissue blood flow regulation. Am J Physiol Endocrinol Metab, 
2012. 302(10): p. E1157-1170. 
191. De Ciuceis, C, Porteri, E, Rizzoni, D, Corbellini, C, La Boria, E, Boari, GE, Pilu, 
A, Mittempergher, F, Di Betta, E, Casella, C, Nascimbeni, R, Rosei, CA, 
Ruggeri, G, Caimi, L, and Rosei, EA, Effects of weight loss on structural and 
functional alterations of subcutaneous small arteries in obese patients. 
Hypertension, 2011. 58(1): p. 29-36. 
192. Blaak, EE, van Baak, MA, Kemerink, GJ, Pakbiers, MT, Heidendal, GA, and 
Saris, WH, Beta-adrenergic stimulation and abdominal subcutaneous fat blood 
flow in lean, obese, and reduced-obese subjects. Metabolism, 1995. 44(2): p. 
183-187. 
193. Millet, L, Barbe, P, Lafontan, M, Berlan, M, and Galitzky, J, Catecholamine 
effects on lipolysis and blood flow in human abdominal and femoral adipose 
tissue. J Appl Physiol (1985), 1998. 85(1): p. 181-188. 
194. Patel, JN, Eisenhofer, G, Coppack, SW, and Miles, JM, Norepinephrine 
spillover in forearm and subcutaneous adipose tissue before and after eating. J 
Clin Endocrinol Metab, 1999. 84(8): p. 2815-2819. 
195. Vollenweider, P, Tappy, L, Randin, D, Schneiter, P, Jequier, E, Nicod, P, and 
Scherrer, U, Differential effects of hyperinsulinemia and carbohydrate 
metabolism on sympathetic nerve activity and muscle blood flow in humans. J 
Clin Invest, 1993. 92(1): p. 147-154. 
196. Gentile, CL, Orr, JS, Davy, BM, and Davy, KP, Modest weight gain is 
associated with sympathetic neural activation in nonobese humans. Am J 
Physiol Regul Integr Comp Physiol, 2007. 292(5): p. R1834-1838. 
  180
197. Chen, W, Sang, JY, Liu, DJ, Qin, J, Huo, YM, Xu, J, and Wu, ZY, 
Desensitization of G-protein-coupled receptors induces vascular 
hypocontractility in response to norepinephrine in the mesenteric arteries of 
cirrhotic patients and rats. Hepatobiliary Pancreat Dis Int, 2013. 12(3): p. 295-
304. 
198. Ferguson, SS, Evolving concepts in G protein-coupled receptor endocytosis: the 
role in receptor desensitization and signaling. Pharmacol Rev, 2001. 53(1): p. 1-
24. 
199. Gluszek, J, Ischaemic heart disease and hypertension in patients with chronic 
obstructive pulmonary disease and obstructive sleep apnoea. Pneumonol 
Alergol Pol, 2013. 81(6): p. 567-574. 
200. Fu, Y, Xiao, H, and Zhang, Y, Beta-adrenoceptor signaling pathways mediate 
cardiac pathological remodeling. Front Biosci (Elite Ed), 2012. 4: p. 1625-1637. 
201. Johnson, RJ, Gordon, KL, Suga, S, Duijvestijn, AM, Griffin, K, and Bidani, A, 
Renal Injury and Salt-Sensitive Hypertension After Exposure to Catecholamines. 
Hypertension, 1999. 34(1): p. 151-159. 
202. Reichenbach, DD and Benditt, EP, Catecholamines and cardiomyopathy: The 
pathogenesis and potential importance of myofibrillar degeneration. Human 
Pathol, 1970. 1(1): p. 125-150. 
203. Diez, J, Panizo, A, Gil, MJ, Monreal, I, Hernandez, M, and Pardo Mindan, J, 
Serum markers of collagen type I metabolism in spontaneously hypertensive rats: 
relation to myocardial fibrosis. Circulation, 1996. 93(5): p. 1026-1032. 
204. Laviades, C, Varo, N, Fernandez, J, Mayor, G, Gil, MJ, Monreal, I, and Diez, J, 
Abnormalities of the extracellular degradation of collagen type I in essential 
hypertension. Circulation, 1998. 98(6): p. 535-540. 
  181
205. Kato, H, Suzuki, H, Tajima, S, Ogata, Y, Tominaga, T, Sato, A, and Saruta, T, 
Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle 
cells. J Hypertens, 1991. 9(1): p. 17-22. 
206. Tharaux, PL, Chatziantoniou, C, Fakhouri, F, and Dussaule, JC, Angiotensin II 
activates collagen I gene through a mechanism involving the MAP/ER kinase 
pathway. Hypertension, 2000. 36(3): p. 330-336. 
207. Lin, HM, Lee, JH, Yadav, H, Kamaraju, AK, Liu, E, Zhigang, D, Vieira, A, Kim, 
SJ, Collins, H, Matschinsky, F, Harlan, DM, Roberts, AB, and Rane, SG, 
Transforming growth factor-beta/Smad3 signaling regulates insulin gene 
transcription and pancreatic islet beta-cell function. J Biol Chem, 2009. 284(18): 
p. 12246-12257. 
208. Tan, CK, Leuenberger, N, Tan, MJ, Yan, YW, Chen, Y, Kambadur, R, Wahli, 
W, and Tan, NS, Smad3 deficiency in mice protects against insulin resistance 
and obesity induced by a high-fat diet. Diabetes, 2011. 60(2): p. 464-476. 
209. Chen, YL, Wu, HW, and Jiang, MJ, Transforming growth factor-beta1 gene and 
protein expression associated with atherogenesis of cholesterol-fed rabbits. 
Histol Histopathol, 2000. 15(2): p. 421-428. 
210. Yang, YL, Guh, JY, Yang, ML, Lai, YH, Tsai, JH, Hung, WC, Chang, CC, and 
Chuang, LY, Interaction between high glucose and TGF-beta in cell cycle 
protein regulations in MDCK cells. J Am Soc Nephrol, 1998. 9(2): p. 182-193. 
211. Rutkowski, JM, Davis, KE, and Scherer, PE, Mechanisms of obesity and related 
pathologies: the macro- and microcirculation of adipose tissue. FEBS J, 2009. 
276(20): p. 5738-5746. 
212. Halberg, N, Khan, T, Trujillo, ME, Wernstedt-Asterholm, I, Attie, AD, 
Sherwani, S, Wang, ZV, Landskroner-Eiger, S, Dineen, S, Magalang, UJ, 
Brekken, RA, and Scherer, PE, Hypoxia-Inducible Factor 1 alpha Induces 
  182
Fibrosis and Insulin Resistance in White Adipose Tissue. Mol Cell Biol, 2009. 
29(16): p. 4467-4483. 
213. Park, J and Scherer, PE, Adipocyte-derived endotrophin promotes malignant 
tumor progression. J Clin Invest, 2012. 122(11): p. 4243-4256. 
214. Simons, M, Angiogenesis - Where do we stand now? Circulation, 2005. 111(12): 
p. 1556-1566. 
215. Heil, M, Eitenmuller, I, Schmitz-Rixen, T, and Schaper, W, Arteriogenesis 
versus angiogenesis: similarities and differences. Journal of Cellular and 
Molecular Medicine, 2006. 10(1): p. 45-55. 
216. Lu, XD, Ji, Y, Zhang, LQ, Zhang, YT, Zhang, SZ, An, Y, Liu, P, and Zheng, 
YW, Resistance to Obesity by Repression of VEGF Gene Expression through 
Induction of Brown-Like Adipocyte Differentiation. Endocrinology, 2012. 153(7): 
p. 3123-3132. 
217. Cabebe, E and Wakelee, H, Role of anti-angiogenesis agents in treating NSCLC: 
focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat 
Options Oncol, 2007. 8(1): p. 15-27. 
218. Aird, WC, Phenotypic heterogeneity of the endothelium: I. Structure, function, 
and mechanisms. Circ Res, 2007. 100(2): p. 158-173. 
219. Aird, WC, Phenotypic heterogeneity of the endothelium: II. Representative 
vascular beds. Circ Res, 2007. 100(2): p. 174-190. 
220. Scott, DW, Vallejo, MO, and Patel, RP, Heterogenic endothelial responses to 
inflammation: role for differential N-glycosylation and vascular bed of origin. J 
Am Heart Assoc, 2013. 2(4): p. e000263. 
221. Macho, P, Perez, R, Huidobro-Toro, JP, and Domenech, RJ, Neuropeptide Y 
(NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced 
coronary constriction. Eur J Pharmacol, 1989. 167(1): p. 67-74. 
  183
222. Dejana, E, Tournier-Lasserve, E, and Weinstein, BM, The control of vascular 
integrity by endothelial cell junctions: molecular basis and pathological 
implications. Dev Cell, 2009. 16(2): p. 209-221. 
223. Lampugnani, MG, Endothelial cell-to-cell junctions: adhesion and signaling in 
physiology and pathology. Cold Spring Harb Perspect Med, 2012. 2(10). 
224. Dejana, E, Endothelial adherens junctions: implications in the control of 
vascular permeability and angiogenesis. J Clin Invest, 1997. 100(11 Suppl): p. 
S7-10. 
225. Dejana, E, Corada, M, and Lampugnani, MG, Endothelial cell-to-cell junctions. 
FASEB J, 1995. 9(10): p. 910-918. 
 
 
